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1. Shared medical appointments: from promising clinical experiences 
to evidence-based care, a historical overview and ﬁ rst characterization
In 2006 the Neurology department of the Radboud University Medical Center Nijmegen 
(RadboudUMC), the Netherlands started offering shared medical appointments (SMAs) for 
patients with a chronic neuromuscular disorder and their partner or primary caregiver. In 
doing so, the department was among the first to pilot this care model in the Netherlands 
as initiated by the CBO, the Dutch Institute for Healthcare Improvement (1). Ed Noffsinger, 
one of the architects of the SMA concept, inspired medical teams to look differently at 
outpatient care and to combine individualised medicine with a supportive group approach 
that would allow more time to be spent on psychosocial aspects and self-management. 
Receiving and offering care in a group context rather than an individual patient setting 
potentially has advantages for both patients and physicians, fostering staff availability 
and reducing the healthcare burden. See Box 1.1 for characteristics of an SMA.
Box 1.1 Characteristics of a shared medical appointment
During an SMA 5–12 patients and their spouses or principal informal caregivers are seen 
during a 90–120 minute outpatient appointment. An SMA generally substitutes individual 
follow-up visits, with the consulting physician remaining responsible for each patient’s 
treatment plan, addressing the same topics (s)he tends to address during regular individual 
visits. The physician simultaneously addresses the medical needs and questions of each 
patient and partner and formulates a disease management plan. Necessary prescriptions, 
referrals, and chart notes are taken care of during or directly after the SMA. Usually a group 
facilitator serves to monitor and (time-)manage the process, promote between-patients 
interactions and propose psychosocial subjects for discussion. Participants typically share 
a common medical concern. If privacy sensitive physical examinations are necessary, they 
are conducted in a private examination room directly after the SMA. 
How could shared medical appointments work for patients? 
Apart from having more time with their consulting physician, an SMA provides the 
participants with the opportunity to exchange knowledge and experiences with fellow 
patients and their respective care partners. SMAs could contribute to optimising self 
management capacities of chronic patients by influencing coping styles, communication 
and self-efficacy (2-4). Self-efficacy is defined as how much confidence one has in being 
able to execute specific behavior. The degree of self efficacy predicts actual change in 
behavior and is often used to evaluate self management interventions (5-8). The following 
sources of information for self-efficacy made us hypothesize that participants of an SMA 
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could yield higher self-efficacy scores than those attending an individual appointment. 
Through both observation of others and experiencing support and expectations of others 
SMA-participants could be strengthened in their confidence to execute a specific task 
or behaviour themselves. Another interesting aspect is the fact that patients outnumber 
healthcare providers; seeing patients with similar conditions together as a group helps 
level out the patient-physician relationship. 
What’s in it for the healthcare professional?
From the perspective of the healthcare professionals, SMAs allow them to spend more 
time with their patients while leaving sufficient time to address psychosocial aspects. 
Group consultations, moreover, make quality of care less dependent on patient-clinician 
time. SMAs compel physicians to be transparent in their communications in the company 
of multiple patients, while they need to share their role as experts with expert patients. 
The responsibility for disease management thus shifts from physician to patient, which 
is in line with the newly proposed definition of health, i.e. the ability to adapt and 
self-manage in the face of social, physical and emotional challenges (9). Additionally, 
seeing 5–12 patients with the same diagnosis together offers resident physicians ‘live 
education’, enabling them to expand their knowledge of the specific disease within a 
relatively short time span, while the SMAs may prompt new research topics. Together, 
this will promote expertise as well as job satisfaction (2, 10, 11). 
Mechanisms which contribute to healthcare efﬁ ciency goals
Besides possibilities to improve quality of care, SMAs can contribute to achieving 
healthcare efficiency goals. If scheduled and delivered properly, SMAs enable physicians 
to see more patients within a similar timeframe otherwise dedicated to single patients, 
while the sharing of information amongst peers and the resultant improvement of self-
management skills may decrease the use of healthcare resources (12, 13). 
Potential downsides of seeing a group of patients simultaneously
Offering individualised healthcare in the presence of fellow patients does have potential 
downsides as well. For instance, how does one protect the privacy of the participants? 
Do patients and care partners really feel free to ask all the questions on their mind? 
How about time management? How does one distribute time fairly among participants, 
especially when one participant has a lot to ask or communicate? And what about 
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physical examinations? Also, inviting and persuading patients and their care partner to 
participate in an innovative care model takes time and effort, as does learning how to 
execute an SMA effectively.
Still, despite the limited scientific underpinning of SMAs in the international literature 
(1, 14), at the time of the start of our research project, the aforementioned pilot study 
yielded promising results in terms of positive experiences for both patients and 
professionals. To answer some of the questions posed above and to contribute to the 
body of knowledge on SMAs in general and their effectiveness for chronic neuromuscular 
patients in particular, we next conducted a systematic review of the literature and set 
up a randomised controlled trial.
2. Where do SMAs originate from and what is the scope of practical 
application and scientiﬁ c research?
SMAs originate from the chronic care model. During the mid-90s both Scott and 
Noffsinger developed a group visit model based on their experiences as a patient 
and health professional (3, 12). The past fifteen years have seen an increasing body of 
studies on group visits, most of which were executed in the United States, but since their 
introduction in the Netherlands in 2005, the interest of Dutch physicians and scientists 
in SMAs has expanded rapidly. The CBO has had well over 50 multidisciplinary teams 
trained in the use of SMAs as part of their medical practice and four RCTs across different 
universities of the Netherlands evaluate their effectiveness in different patient groups 
(2, 15-18). At the launch of our research project, the scientific evidence for group visits 
for neurological patients comprised a single RCT for paediatric headache patients (19). 
Worldwide, the diversity in group visit models currently being implemented in clinical 
practice is large. Adaptations to meet the needs of specific patient groups and attending 
health professionals may, understandably, be necessary, but the resulting clinical 
heterogeneity does complicate scientific evaluation. To facilitate research into the 
effectiveness of SMAs, in Chapter 5 of this thesis we propose a conceptual framework 
to capture the different SMA formats.
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3. Towards better care for chronic neuromuscular patients and their 
partners
Various crucial factors in the care of and research on chronic neuromuscular disorders 
prompted us to study the effects of SMAs in this extensive patient group. First and 
foremost, most of these typically progressive disorders have a large impact on the 
patients’ lives as well as that of their partner and family, most specifically in terms of 
quality of life. And they constitute a considerable healthcare burden in terms of both 
time and costs, while no curative treatments are currently available for this group of 
diseases, making optimal supportive care indispensable (17, 20, 21). Second, many 
consulting neurologists and allied health professionals find it difficult to fulfil the complex 
needs of their patients in the usually brief, problem-focused one-to-one visits that leave 
little room for the patients’ and partners’ psychosocial needs and their education and 
empowerment. Third, a research agenda drafted by neuromuscular patients and health 
professionals stated that, above and beyond fundamental research, research on the 
quality of life and effective treatment of symptoms needs to be given more priority (22). 
And finally, in the same context, while the randomised controlled trial still is the gold 
standard for the determination of effectiveness, the large diversity of neuromuscular 
diseases and their unfamiliarity with the public at large results in too small a number of 
larger-scale RCTs being funded (23, 24).
4. Aim and outline of the thesis
The aim of the studies presented in this thesis was to evaluate and compare the clinical 
effectiveness and cost-effectiveness of shared medical appointments (SMAs) with that 
of regular, individual outpatient visits in patients suffering from a chronic, progressive 
neuromuscular disorder and their (informal care) partners. To this end, we conducted 
an RCT including 249 patients and 149 care partners with a follow-up of six months. 
Part I, Chapter 2, of this dissertation describes the rationale and study protocol of 
our RCT of an SMA versus usual care (17). We designed the trial such that we were 
able to compare a single SMA with a typical annual one-on-one visit to our neurology 
clinic. Having adopted quality of life (QoL) as the primary outcome measure, we used 
validated generic questionnaires that were available at the time to assess respective 
QoL levels, the most well-known of which were the SF-36 and EQ-5D (25-27). Although 
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generic QoL measures facilitate the comparison with other studies, they do not allow 
the detection of changes in specific muscle symptoms. To help us do so, we translated 
the Individualised Neuromuscular Quality of Life (INQoL) questionnaire into Dutch and 
performed a validation study, which is described in Part II, Chapter 3 (28). Part III, 
Chapter 4, details the clinical results of our RCT comparing a single SMA with a single 
annual one-to-one visit. 
While healthcare expenditures continue to rise worldwide, we are of the opinion that, 
before implementing an alternative care model on a wider scale, a thorough analysis of 
the costs and effects of the intervention is imperative. In Chapter 5 the results of our cost-
effectiveness analysis are presented. A systematic evaluation of a complex intervention 
like an SMA across patient groups requires a well-defined framework, which was lacking 
at the time we devised the studies described in this thesis. Knowledge of the working 
mechanisms of SMAs was scarce, while we deemed a systematic review of the available 
evidence vital. Part IV, Chapter 6, hence features a Cochrane systematic review of all 
randomised trials on SMAs for all physical illnesses that had become available since the 
start date of literature databases up until 2015.
Finally, in Part V, Chapter 7, the results of the various studies presented in this thesis 
and their implications are discussed in context and directions for future research and 
clinical practice described.
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ABSTRACT
Background
Shared medical appointments are a series of one-to-one doctor-patient contacts, in 
presence of a group of 6–10 fellow patients. This group visits substitute the annual con-
trol visits of patients with the neurologist. The same items attended to in a one-to- one 
appointment are addressed. The possible advantages of a shared medical appointment 
could be an added value to the present management of neuromuscular patients. The 
currently problem-focused one-to-one out-patient visits often leave little time for the 
patient’s psychosocial needs, patient education, and patient empowerment. 
Methods/design
A randomized, prospective controlled study (RCT) with a follow up of 6 months will be 
conducted to evaluate the clinical and cost-effectiveness of shared medical appointments 
compared to usual care for 300 neuromuscular patients and their partners at the Radboud 
University Medical Center (RadboudUMC). Every included patient will be randomly al-
located to one of the two study arms. This study has been reviewed and approved by 
the medical ethics committee of the region Arnhem-Nijmegen, the Netherlands. The 
primary outcome measure is quality of life as measured by the EQ-5D, SF-36 and the 
Individualized neuromuscular Quality of Life Questionnaire. The primary analysis will be 
an intention-to-treat analysis on the area under the curve of the quality of life scores. A 
linear mixed model will be used with random factor group and fixed factors treatment, 
baseline score and type of neuromuscular disease. For the economic evaluation an 
incremental cost-effectiveness analysis will be conducted from a societal perspective, 
relating differences in costs to difference in health outcome. Results are expected in 2012.
Discussion
This study will be the first randomized controlled trial which evaluates the effect of 
shared medical appointments versus usual care for neuromuscular patients. This will 
enable to determine if there is additional value of shared medical appointments to the 
current therapeutical spectrum. When this study shows that group visits produce the 
alleged benefits, this may help to increase the acceptance of this innovative and creative 
way of using one of the most precious resources in health care more efficiently: time. 
Trial registration
Dutch Trial Register www.trialregister.nl NTR1412.
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BACKGROUND
Introduction
As of January 2006, the department of neurology at the RadboudUMC has started 
offering shared medical appointments (SMAs) or group visits to patients with a 
neuromuscular disease. This novel approach of delivering outpatient care is now being 
compared with usual care during a randomized controlled trial with 300 patients and 
their partners. The focus in this trial is on health outcomes and costs.
Motive
Most neuromuscular diseases are chronic progressive diseases necessitating periodic 
specialized care. Because of the progressive nature of the disease, existing symptoms 
aggravate over time and new symptoms may develop over time, requiring adjustment 
of management, and giving rise to new questions on the part of the patient and his 
or her partner. In the absence of definitive cures for chronic neuromuscular diseases, 
the improvement of quality of life, patient- and partner satisfaction with care, self 
management and functional capacity become key objectives of care. Currently, these 
patients attend the out-patient clinic at regular intervals (usually annually), where they 
are seen in one-to-one patient- physician encounters. It is difficult, however, to fulfill the 
complex needs of neuromuscular patients in these brief, problem-focused out-patient 
visits which leave little time for the patient’s psychosocial needs, patient education, and 
patient empowerment. The possible advantages of an SMA could be an answer to these 
questions. Our hypotheses are that shared medical appointments show 1) the same effect 
on the development of the disease as individual appointments 2) an improvement of 
self-efficacy as opposed to individual appointments, therefore resulting in an improved 
quality of life 3) better use of resource utilization and 4) a positive effect on self efficacy 
and quality of life of the partner as well as on the relationship (1-6).
What is a shared medical appointment?
During an SMA, 6–10 patients and their partners are seen simultaneously by a physician 
who is supported by a group mentor. SMAs are a series of one-to-one doctor-patient 
contacts, in presence of a group fellow patients. A group visit takes 1.5–2 hours and 
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substitutes the annual control visit of the patients. The same items the neurologist attends 
to in a one to one appointment are addressed. The physician has more time to give 
information and patients and partners can ask questions to- and learn from their fellow 
patients. The group mentor facilitates the group process, fosters interaction between 
patients and manages time. SMAs should not be confused with group education or 
peer support groups. As opposed to a group visit, these meetings do not substitute 
for the periodic consultation with the clinician (7, 8).
Experience with shared medical appointments in patients with diabetes, heart failure, 
bone marrow transplantation and chronically ill older patients have been reported (9-
14). Evidence of group visits for neurological patients is at this moment at the level of 
a feasibility trial for patients with Parkinson disease (15). 
METHODS/DESIGN
A randomized, prospective controlled study (RCT) with a follow up of 6 months will be 
conducted to evaluate the clinical and cost-effectiveness of shared medical appointments 
compared to usual care for neuromuscular patients. The trial flow of the proposed subject 
enrolment and randomization procedures are shown in Figure 2.1. 
Study population
The aim is to include 270 evaluable patients with one of the following chronic neuromus-
cular diseases: 
• Myotonic Dystrophy type 1. Genetically determined (classic and juvenile 
type) (16);
• McArdles disease, Glycogen Storage Disease Type V. Biochemically and 
genetically determined;
• Facioscapulohumeral Muscular Dystrophy (FSHD). Genetically determined;
• Chronic progressive external ophthalmoplegia (CPEO). As defined by 
Emery (17);
• Oculopharyngeal Muscular Dystrophy (OPMD). Genetically determined;
• Inclusion body myositis (IBM). As defined by Badrising and Verschuuren 
(18, 19);
23
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• Non-dystrophic myotonias. These skeletal muscle channelopathies include 
two main groups: the chloride and sodium channelopathies (20);
• Myositis: Dermatomyositis and Polymyositis (21);
• Polyneuropathy: CMT1 and HNPP (22).
Figure 2.1 Flowchart of trial design.
Screening and recruitment
Inclusion and 
randomization
Baseline measurements:
Intervention group:
shared medical 
appointment
Control group:
Individual outpatient 
appointment
T1 questionnaires
T2 questionnaires
T1 questionnaires
T2 questionnaires
T=pre
T=0
T=3
T=2
T=1
CRAMP database
T3 questionnaires T3 questionnaires
Questionnaires:
Use of care
General health (SF-36, 
EQ-5D, INQOL)
Self efficacy, social 
support, relationship
Questionnaires:
General health (SF-36, 
EQ-5D, INQOL)
Self efficacy, social 
support, relationship
Satisfaction
Questionnaires:
Use of care
General health (SF-36, 
EQ-5D, INQOL)
Self efficacy, social 
support, relationship
Satisfaction
1 week
3 months
3 months
Questionnaires:
Use of care
General health (SF-36, 
EQ-5D, INQOL)
Self efficacy, social 
support, relationship
Satisfaction
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The partners of these patients will also be included. All patients will be identified 
by CRAMP, a neuromuscular database containing data from over 4500 patients with 
neuromuscular disease attending the outpatient clinic of the Radboud University Medical 
Center (RadboudUMC) (23). From this database, patients who meet the inclusion criteria 
(Table 2.1) will be contacted by telephone by the primary investigator (FS) to inform 
them about the study and ask permission to send information and informed consent 
forms. If the patient decides not to participate in the study, the reason will be asked 
and documented. If written consent forms are not returned within 3 weeks, patients will 
receive a reminder phone call. After written informed consent is obtained, patients and 
their partners are randomized to one of the two study arms. Reasons for drop-out will be 
asked and documented.
Table 2.1 Inclusion and exclusion criteria
Inclusion criteria 
1. Registered in CRAMP database with one of the following neuromuscular diseases: 
• Myotonic Dystrophy type 1. Genetically proven (classic and juvenile type);
• McArdles disease, Glycogen Storage Disease Type V. Biochemically and genetically 
proven;
• Facioscapulohumeral Muscular Dystrophy (FSHD). Genetically determined;
• Chronic progressive external ophthalmoplegia (CPEO). As defined by Emery; 
• Oculopharyngeal Muscular Dystrophy (OPMD). Genetically determined;
• Inclusion body myositis (IBM). As defined by Badrising and Verschuuren;
• Non-dystrophic myotonias. These skeletal muscle channelopathies include two 
main groups: the chloride and sodium channelopathies;
• Myositis: Dermatomyositis and Polymyositis;
• Polyneuropathy: CMT1 & HNPP.
2. Age >18 years.
3. Patients and their partners are control patients in care at the department of neurology 
RadboudUMC.
Exclusion criteria
1. Patients or partners with severe hearing problems.
2. Patients or partners who cannot speak, read or understand the Dutch language well.
3. Patients and their partner who have had a control visit with a neurologist at the 
neurology department of the RadboudUMC less than 6 months ago.
Ethical approval and registration
This study has been reviewed and approved by the medical ethics committee of the 
region Arnhem-Nijmegen, the Netherlands (reference CMO nr. 2008/224) and has been 
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registered in the NTR (Dutch Trial Registration nr. NTR1412). Patients and their partners 
receive verbal and written information about the study and written informed consent will 
be obtained before randomization.
Randomization and blinding
Concealed randomization will be performed through computer-generated randomization 
software. Every included patient will be randomly allocated to one of the two study arms 
by the computer. The method of simple randomization is applied. In view of the nature 
of the interventions, blinding of the participants, participating neurologists and primary 
researcher is not possible. The statistician who conducts the analysis of the data will, 
however, be blinded for the patient groups. 
Interventions
Care as usual: individual outpatient appointment
Patients and partners who are randomized to the control group will have their regular 
control visit with one of the participating neuromuscular neurologists at the outpatient 
neurology department of the RadboudUMC. This one on one control visit substitutes 
the regular annual control visit the patients pay to the neurology department. The 
same items that are normally attended to during the control visit, are attended to by 
the neurologist. All physical examinations, prescriptions and referrals are conducted as 
deemed appropriate, and documented in the patient record. The regular one on one 
control visit takes 30 minutes. 
Intervention: shared medical appointment
Patients and partners who are randomized to the intervention arm of the study will be 
invited to an SMA of 1.5–2 hours with one of the participating neuromuscular neurologists 
and a group mentor at the outpatient neurology department of the RadboudUMC. The 
same neurologists execute the individual appointments and the SMAs.
The group mentor starts with a short introduction to explain the rationale and procedure 
of the SMA. Patients and their partners are then asked to sign a privacy form, which is 
kept in the patient record in order to emphasize confidentiality. The neurologist next 
addresses the first patient (and partner), discusses the patient’s medical needs and 
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questions, after which they jointly formulate a disease management plan and medication 
regimen aimed at improving quality of life. If applicable, the group mentor asks if fellow 
patients or partners have comparable experiences or questions they want to share with 
the group or the neurologist. The neurologist subsequently concludes the consultation 
with the first patient and completes the chart notes. Sequentially, the neurologist consults 
the other patients and their partners. The group mentor verifies whether all questions 
have been satisfactorily addressed and, if so, concludes the SMA. If privacy sensitive 
physical examinations are necessary, they are conducted in a private examination room 
directly after the SMA. SMAs are interactive and the neurologist as well as fellow patients 
and partners may provide information. Agenda setting is driven by the questions of the 
participants. Necessary prescriptions, referrals, and chart notes are taken care of during 
or directly after the SMA.
Compliance and attrition
When participants indicate that they wish to discontinue their participation in the study, 
reasons will be documented.
Outcomes
Outcome measures for patients are listed in Table 2.2a. The primary outcome measure 
is quality of life (daily activity limitations, pain, mood, fatigue, social activities) as 
measured by the EQ-5D, SF-36 and the Individualized neuromuscular Quality of Life 
Questionnaire (INQoL). For the SF-36 and EQ 5 D, normative scores are available based 
on the Dutch population. For the INQoL, no Dutch version was available. With granted 
authorization from the authors, a translation into the Dutch language was made (24-27). 
Secondary outcome measures are 1) Use of health care resources (use of health care 
services, medication, compliance with medication, use of assistance with daily activities) 
Questions from the Client Service Receipt Inventory (CSRI) are used to record service 
utilization (28). 2) Self efficacy (how much confidence one has in being able to execute 
specific behaviour), as measured by the Self Efficacy questionnaire from Schwarzer (29). 
This is a 10-item psychometric scale that is designed to assess self-beliefs to cope with 
a variety of difficult demands in life. Also, a questionnaire to measure self efficacy of 
patients with neuromuscular disease was developed by the research group. 3) The need 
for social support was assessed by using the subscale emotional support of the Dutch 
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questionnaire SSLD (Sociale Steun Lijst-Discrepanties) from Sanderman and van Sonderen 
(30). 4) Satisfaction with relationship was measured by asking the participants to rate 
their relationship on a 1/10 scale and to rate their relationship on a VAS scale, ranging 
from the worst possible relationship to the best possible relationship (31). 5) Satisfaction 
with and aspects of the visit, as measured by The QUality Of care Through the patient’s 
Eyes (QUOTE) questionnaire (32). The severity of the disease as measured through the 
Rankin-scale is assessed during the shared medical appointments and through reviewing 
Table 2.2a Outcome measures and instrumentation patients
Instruments T0 T1 T2 T3
Primary outcome measures 
Quality of life EQ-5D, SF-36, INQOL √ √ √ √
Secondary outcome measures
Demographic statistics √
Severity of the disease Rankin Scale √
Use of care resources and 
medicine
Client Service Receipt Inventory 
(CSRI)
√ √ √
Self efficacy SE questionnaire from Schwarzer, 
SE NMD
√ √ √ √
Social support SSLD (Sociale Steun Lijst-
Discrepanties) 
√ √ √ √
Satisfaction with relationship √ √ √ √
Satisfaction with the 
appointment
QUality Of care Through the 
patient’s Eyes (QUOTE)
√ √ √
Table 2.2b Outcome measures and instrumentation partners
Instruments T0 T1 T2 T3
Primary outcome measures 
Quality of life EQ-5D √ √ √ √
Secondary outcome measures
Demographic statistics √
Self efficacy SE questionnaire from Schwarzer √ √ √ √
Social support SSLD (Sociale Steun Lijst-
Discrepanties) 
√ √ √ √
Satisfaction with relationship √ √ √ √
Satisfaction with the 
appointment
QUality Of care Through the 
patient’s Eyes (QUOTE)
√ √ √
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the chart notes for individual appointments by the participating neurologists or primary 
researcher (33, 34). 
Outcome measures for partners are listed in Table 2.2b. Among partners of patients, 
quality of life (EQ-5D) (24-27), self efficacy (SE questionnaire by Schwarzer (29)), the need 
for social support (subscale emotional support of the Dutch questionnaire SSLD (30), 
satisfaction with the relationship (VAS scale and 1–10 reporting) (31) , objective burden 
of care and satisfaction with and aspects of the visit (QUOTE questionnaire, (32)) will be 
measured. Ojective burden of care is measured by asking after the amount of time a 
partner spends on caring for the partner and on doing household tasks in order to be 
able to relieve or support their partner with the chronic disease; time spent on delivering 
care for the chronically ill partner is the main predictor for the impact of the disease on 
the life of the partner (35).  
Economic evaluation
Cost effectiveness will be assessed from a societal perspective. Direct neuromuscular 
disease-related costs, health care costs, including costs of outpatient care, physical-, 
speech- and occupational therapy, additional visits to other health care providers 
(GPs, specialist care, etc.), district nursing, receipt of aids and adaptations, prescription 
medication, professional home care and hospitalization will be included, as well as non-
health care costs such as costs for paid and unpaid help. For unit cost prices, standard rates 
will be adopted from the national guideline (36) or real cost prices (e.g., for medication) will 
be obtained through the website of the Dutch Health Care Insurance Board (CVZ, www.
medicijnkosten.nl). For shared medical appointments, a cost price will be calculated on 
the basis of available standard rates and real expenditures. The price year will be 2009, 
the currency Euros, and in view of the timescale of the study, costs and health benefits 
will not be discounted. Utilization of itemized resources over the trial period will be self-
recorded by patients with a modified version of the Client Service Receipt Inventory (CSRI) 
(28). Costs per patient will be calculated by multiplying resource volumes by unit costs.
Outcome measures will be obtained through standardized questionnaires, who patients 
and partners fill out at home at the start of the study period (T0), 1 week (T1), 3 months 
(T2) and 6 months after the intervention (T3). See Figure 2.1 and Table 2.2a and 2.2b. At 
the first measurements (T0) demographic data will be obtained.  
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STATISTICAL ANALYSIS
Sample size
On the basis of the literature (37, 38) group visits may be expected to lead to a clinically 
relevant improvement in quality of life of 5 points on the total SF-36 score. Assuming a 
standard deviation of 12 (39), 92 patients need to be enrolled in both groups to achieve 
a statistical power of 80% (alpha = 0.05, two-sided). Taking into account non-evaluable 
patients, to adjust for imbalances and to be able to do subgroup analysis on age, sex, 
gender and severity, 135 patients will be enrolled in both groups. In order to be able 
to evaluate 270 patients, the aim is to include 300 patients.
Analysis of outcome measures
300 neuromuscular patients and if applicable their partners will be included in the study. 
The primary analysis will be an intention-to-treat analysis on the area under the curve 
of the quality of life scores (average response during 6 months). A linear mixed model 
will be used with random factor group and fixed factors treatment, baseline score and 
type of neuromuscular disease. Other outcome parameters will be evaluated in a similar 
way and additional per protocol analyses will be carried out.
For the analyses SPSS version 17 statistical software will be used. A p-value of 0.05 
will be considered statistically significant. Missing data will be imputed using multiple 
imputation techniques. 
Economic evaluation 
An incremental cost-effectiveness analysis will be conducted from a societal perspective, 
relating differences in costs to difference in health outcome as measured by the Euroqol-
5D, an instrument to evaluate different health states. Bootstrapping will be used for 
pair-wise comparisons in direct health care costs, direct non-health care costs, total 
direct costs, total indirect costs, and total costs between the two groups. Confidence 
intervals will be obtained by conventional re-sampling methods (bootstrapping). The 
cost effectiveness analysis will provide information on the marginal costs and effects 
of shared medical appointments relative to conventional one-to-one outpatient visits 
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through the calculation of an incremental cost effectiveness ratio. Ratios will include the 
primary outcome of the trial, i.e., quality of life and two secondary outcome parameters; 
functional activities, and self-efficacy. Cost acceptability curves will be calculated showing 
the probability that a shared medical appointment is cost effective at specified ceiling 
ratios. In situations where there is no significant difference in effects, the use of cost-
minimization analysis will be used for the reporting of cost differences only. Sensitivity 
analyses will be conducted, exploring the sensitivity of the conclusions to various sources 
of uncertainty, including sampling variation (e.g., differences in self-efficacy and functional 
abilities in both groups) and point-estimates (e.g., unit cost prices of major cost drivers).
DISCUSSION
To the best of our knowledge, this study will be the first randomized controlled trial which 
evaluates the effect of shared medical appointments versus usual care for neuromuscular 
patients. Evidence shows that shared medical appointments can have substantial added 
value, deriving not only from sharing a health care professional’s time, but also from 
sharing mutual experiences, particularly for patients with a chronic disease (2, 3, 40). 
In the literature, group visits have been shown to result in fewer hospitalizations and 
emergency visits, increased patient satisfaction and increased self-efficacy as compared 
to usual one-to-one outpatient visits in elderly, chronically ill patients (9). In patients 
with diabetes, a randomized controlled trial demonstrated an increased frequency of 
preventive procedures among patients attending group visits, resulting in a better 
general health status as measured by the SF-36 (3). Sadur et al. (1999) demonstrated 
greater satisfaction with diabetes care, greater self-efficacy, better glycemic control, and 
lower service utilization among patients with diabetes who were randomly allocated to 
group visits as compared to counterparts who were allocated to usual care.
This study has several strengths. Firstly, shared medical appointments will be compared 
with usual care in a randomized design. This will enable to determine if there is 
additional value of shared medical appointments to the current management spectrum. 
Secondly, this study involves measuring effect of a treatment on partners of patients 
with a neuromuscular disease. Studies from Baanders et al. (2007) and Timman (2010) 
show that living with a chronically ill person, specifically with a neuromuscular disorder, 
has an impact on the partner’s life that goes beyond the consequences of care giving, 
for example consequences on personal life strain, social relations, financial burden, 
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and intrinsic rewards (35). And that marital satisfaction is a strong predictor of better 
wellbeing, both for patients and, even more so, for partners (31). Thirdly, this study aims 
to determine the cost effectiveness of shared medical appointments as compared to 
care as usual. In current healthcare time is a scarce good. Efficiency goals are on top of 
every healthcare managers’ list. When introducing a new way of delivering care, such 
as shared medical appointments, this preferably is just as or even more efficient than 
care as usual. Therefore it is important to take cost effectiveness of the intervention into 
account in this study. A limitation of this study can be the fact that it is a single center 
study. This may influence the transferability of the research results to other hospitals. Due 
to pragmatic and financial reasons the follow up time is limited to 6 months. For patients 
with neuromuscular disorders annual control visits are offered, this limits the number of 
shared medical appointments a patient receives during the study to one. Possibly the 
effect of group visits increases when attended several times. With this study design it 
is not possible to show this effect. A reflection of practice in this study, that could be a 
possible limitation, is inclusion of different patient groups. Although patients all have a 
chronic neuromuscular disease, possible differences in effects between patient groups 
could be difficult to show with this study design. 
In conclusion, this study will provide greater insight in the (cost) effectiveness of shared 
medical appointments for neuromuscular patients. The concept of group visits or shared 
medical appointments is a typical example of organizing the delivery of health care in 
a different way, in an attempt to improve patient outcome within the limits of available 
resources. Many attempts at increasing efficiency of health care consist of reducing the 
amount of time health care professionals spend on specific activities. Such attempts 
risk, however, to jeopardize the quality of care (41). When our study shows that group 
visits produce the alleged benefits, this may help to increase the acceptance of this 
innovative and creative way of using one of the most precious resources in health care 
more efficiently: time. 
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ABSTRACT
Introduction
In this paper, the translation and psychometric evaluation of the Dutch Individualized 
Neuromuscular Quality of Life questionnaire are described. 
Methods
Backward and forward translation of the questionnaire was executed and psychometric 
properties were assessed on the basis of reliability and validity.
Results
In this study 206 patients were included. Reliability analyses resulted in Cronbach’s 
alpha values above 0.70 for all sub-domains. Known group validity showed a significant 
correlation between INQoL scores and severity as well as age for the majority of sub-
domains. Item-total correlation for overall QoL was satisfactory. Concurrent validity with 
SF-36 and EQ-5D was good (range Spearman correlation coefficients: -0.43 to -0.76).
Conclusion
This study resulted in a questionnaire which is appropiate for use in the Dutch speaking 
population to measure quality of life of patients with a wide variety of neuromuscular 
disorders. This confirms and extends data obtained in the United Kingdom, US, Italy 
and Serbia. 
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INTRODUCTION
Measuring quality of life (QoL) for patients with a neuromuscular disorder (NMD) is 
important in identifying specific areas at which to direct interventions that might help 
retain QoL despite illness progression (1, 2). NMDs show a wide variety of symptoms, 
often with a large impact on multiple aspects of daily living, for which no curative 
treatments are currently available (3-5). In contrast to generic QoL measurement 
instruments, disease specific questionnaires allow for detecting differences or changes 
in specific NMD symptoms such as locking or weakness of the muscles or body 
image. This minimizes the questionnaire burden on patients and clinicians caused 
by irrelevant or potentially intrusive items and therefore facilitates their use in daily 
clinical practice as well as research (6). The Individualized Neuromuscular Quality of 
Life (INQoL) questionnaire is a disease-specific quality of life questionnaire for patients 
with a neuromuscular disorder, developed by Rose et al. in 2007 (7). The psychometric 
properties of the INQoL have been tested and shown valid, reliable and to some extent 
responsive (7-9). The INQoL was translated and validated for the population of the UK, 
USA, Italy and Serbia (7-10). In this paper, the translation and psychometric evaluation of 
the Dutch INQoL questionnaire for patients with an NMD are described. Psychometric 
properties were assessed on the basis of reliability and validity (known-group validity, 
item-total correlation and concurrent validation). In addition we performed the same 
analyses for a small group of polyneuropathy patients, as corresponding symptoms like 
fatigue, muscle weakness and the impact on QoL led us to evaluate applicability of the 
questionnaire for this patient group.  
METHODS
INQoL questionnaire
The INQoL is constructed of four main domains, divided into 12 sub-domains. Each 
sub-domain is composed of questions varying from 3 to 14 items, with responses given 
on a 7-point Likert scale. Raw data are converted to a score from 0–100 for every sub-
domain, a higher score indicating a greater impact on QoL. The four main domains of 
the INQoL include symptoms (sub-domains weakness, locking, pain and fatigue); life 
domains (sub-domains activities, independence, social relationships, emotions and 
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body image); treatment effects (sub-domains perceived treatment effects and expected 
treatment effects) and overall QoL, an aggregation of parts of the five sub-domains 
(activities, independence, social relationships, emotions and body image). The four 
main domains are considered to properly reflect the QoL of patients with an NMD (7).
Cultural translation
Backward and forward translation of the questionnaire was executed independently by 
two neurologists (CH, NV). Differences were resolved by consensus. Remaining questions 
were submitted to the original author (MR) in order to assure conceptual equivalence 
with the original questionnaire.
Psychometric evaluation
Psychometric properties of the Dutch INQoL questionnaire were evaluated using data 
collected from a randomised controlled trial (RCT) on shared medical appointments 
for patients with an NMD. The RCT and the subsequent use of the data for this study 
were reviewed and approved by the local medical ethics committee (reference CMO 
nr. 2008/224) and registered with the NTR (Dutch Trial Registration nr. NTR1412) (11). 
Reliability was assessed by measuring the relationship (Cronbach’s alpha) of the items 
within each of the 12 sub-domains. The internal consistency among items addressing 
the same underlying domains should be higher than Alpha value 0.70 (12). Spearman 
correlation coefficient and interclass correlation (single measures) were computed to 
assess the relation between the questions of each domain (13). 
Validity was assessed through known-group validity, item-total correlation and concurrent 
validity. Known-group validity aimed to compare the INQoL scores with demographic 
or disease related factors which are known from previous research to have a significant 
correlation with the INQoL. Earlier studies showed that age and severity of disease are 
negatively correlated with the INQoL scores (2, 8). Age was divided in three groups: 18-
35, 36-65 and 66-80 years. Severity of the disease was assessed through the Modified 
Rankin Scale (MRS), ranging from 0 – no symptoms – to 5 – severe disability; bedridden, 
incontinent and requiring constant nursing care and attention (14). Means and standard 
deviations of the INQoL scores for the sub-groups were analysed. P-values <0.05 were 
considered statistically significant for known-group validity. Item-total correlation was 
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determined by the correlation between the individual items (activities, independence, 
social relationships, emotions and body image) and overall QoL. The corresponding item 
was omitted in the total score. Correlation coefficients should be between 0.20 and 0.90 
in order to indicate sufficient item-total correlation (12). Concurrent validity was measured 
by the association of the 12 INQoL sub-domains with the corresponding SF-36 and 
EQ-5D questions and expressed in terms of Spearman correlation coefficients (15, 16).
Subjects and data collection
Patients were recruited from the department of neurology of the Radboud University 
Medical Center (RadboudUMC) and identified as NMD patients through the Dutch neuro-
muscular database CRAMP (17). Patients had to be aged 18 years and above and literate 
in the Dutch language. In view of the RCT intervention on shared medical appointments, 
patients with hearing problems and patients who attended the outpatient clinic less than 
six months ago were excluded (11). Of the eligible patients 70% accepted to participate 
in the RCT. Data were collected through a self-administered questionnaire-booklet which 
contained – besides the Dutch INQoL questionnaire – the following questionnaires: EQ-5D, 
SF-36, General self-efficacy, social support subscale from the Dutch Social Support 
List-Discrepancies, QUality Of care Through the patient’s Eyes, and satisfaction with 
the marital relationship. The questionnaires were filled out at home. Non-responders 
at two weeks were contacted by phone to remind them to complete the questionnaire. 
SPSS version 18 was used for statistical analyses.   
RESULTS
Cultural translation
A noteworthy adjustment resolved by discussion with the original author (MR) concerned 
the English word for locking which implies myotonia. In Dutch, this is not a common lay 
term, therefore this was translated as: “Do you notice that your muscles have difficulties 
relaxing after sustained contraction?“. A final version of the Dutch INQoL questionnaire 
has been deposited with the MAPI Research Institute Website and inquiries regarding 
its use can be obtained from www.mapi-trust.org. 
Chapter 3
44
Patient characteristics
In total, 206 patients with one of the following NMDs were included in the study: 
Myotonic dystrophy (MD), McArdles disease, Facioscapulohumeral muscular dystrophy 
(FSHD), chronic progressive external ophthalmoplegia (CPEO), Oculopharyngeal 
muscular dystrophy (OPMD), Inclusion body myositis (IBM), Non-dystrophic myotonias 
and Myositis. See Table 3.1 for patient characteristics. Myotonic dystrophy was the 
largest patient group (N=75) and chronic progressive external ophthalmoplegia (CPEO) 
the smallest (N=5). Slightly more than half of the patients were male (54%) and the 
mean age was 51 years with a range of 18–79. Most patients reported having a slight 
disability and although unable to carry out previous activities were still able to look after 
themselves without assistance (score 2 on MRS) (N=63). 29 patients with polyneuropathy 
also completed the INQoL and their results are described separately.
Table 3.1 Patient characteristics
Variable
Men (N) (%) 111 (54)
Age (years), Mean (SD) 51 (14.6)
Diagnosis (N)
Myotonic Dystrophy 75 
McArdles disease 8 
Facioscapulohumeral Muscular Dystrophy 46 
Chronic progressive external ophthalmoplegia 5
Oculopharyngeal Muscular Dystrophy 22
Inclusion body myositis 9
Non-dystrophic myotonias: chloride and sodium channelopathies 21
Myositis: Dermatomyositis and Polymyositis 19
Missing 1
Rankin Scale (N)
No symptoms (0) 9
No significant disability (1) 27
Slight disability (2) 63
Moderate disability (3) 31
Moderate severe disability (4) 56
Severe disability (5) 2
Missing 18
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Reliability 
Table 3.2 shows that all internal consistency values revealed a Cronbach’s alpha above 
0.70, ranging from 0.721 (relationships) to 0.903 (fatigue). The correlation coefficients 
ranged from 0.797 (body image) to 0.331 (relationships). All inter-class correlation 
coefficients were above 0.400, ranging from 0.478 (expected treatment effects) to 0.792 
(body image), except for the sub-domains relationships (0.224).
Table 3.2 Reliability as measured through item internal consistency (Cronbach’s alpha)
INQoL sub-domains
Number 
of items
Correlation 
coefficient 
95% 
confidence 
interval 
min–max
ICC
(single 
measures)
Cronbach’s 
alpha 
Muscle weakness 3 0.729 0.646–0.844 0.717 0.884
Locking 3 0.700 0.586–0.778 0.693 0.871
Muscle pain 3 0.719 0.629–0.819 0.704 0.877
Fatigue 3 0.757 0.714–0.789 0.756 0.903
Activities 4 0.551 0.359–0.716 0.549 0.829
Independence 2 0.712 0.712–0.712 0.712 0.832
Relationships 9 0.331 0.025–0.745 0.224 0.721
Emotions 5 0.545 0.443–0.667 0.524 0.846
Body image 2 0.797 0.797–0.797 0.792 0.884
Perceived treatment effects 3 0.597 0.431–0.706 0.599 0.818
Expected treatment effects 4 0.478 0.283–0.706 0.478 0.785
Validity
Known group validation
Figure 3.1 summarizes the relation between severity of disease (MRS) and INQoL sub-
domains. The MRS showed a significantly higher INQoL score for more severely disabled 
patients for 8 of the 10 sub-domains (p<0.03). Age significantly correlated with INQoL 
score for 4 of the 10 sub-domains (p<0.03) (data not shown). 
Item-total correlation
In Table 3.3, the correlation between the calculated domain overall QoL and the 
individual items contributing to this score, is presented. Although some items correlated 
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Figure 3.1 Known group validity; INQoL subdomains vs severity of disease as measured by 
the Modiﬁ ed Rankin Scale (MRS).
Mean values. MRS 0: No symptoms (n=9); MRS 1: No significant disability (n=27); MRS 2: Slight disability (n=63); MRS 3: 
Moderate disability (n=31); MRS 4: Moderate severe disability (n=56); MRS 5: Severe disability (n=2).
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only poorly, overall QoL correlated quite well with each of its component items. 
Correlation coefficients were 0.400 or higher for all sub-domains with overall QoL, 
ranging from 0.448 (activity) to 0.533 (independence).
Concurrent validation
The data in Table 3.4 show the correlation between the INQoL and the SF-36 
questionnaire. The Spearman correlation coefficient ranged from -0.453 (emotions 
vs. emotional well being) to -0.769 (Activities vs. Physical functioning). The concurrent 
validation analysis for the EQ-5D VAS score and the EQ-5D index score compared to 
the INQoL overall QoL score resulted in Spearman correlation coefficients of -0.472 
and -0.4 respectively (data not shown).
Table 3.3 Item-total correlation overall QoL correlation coefﬁ cients
Overall 
QoL Activity Independence Relationships Emotions
Body 
image
Overall QoL - 0.448 0.533 0.468 0.469 0.495
Activity 0.448 - 0.742 0.412 0.279 0.521
Independence 0.533 0.742 - 0.413 0.240 0.570
Relationships 0.468 0.412 0.413 - 0.336 0.313
Emotions 0.469 0.279 0.240 0.336 - 0.279
Body image 0.495 0.521 0.570 0.313 0.279 -
Table 3.4 Concurrent validity; correlation between selected INQoL domains and SF-36 items. 
Spearman correlation coefﬁ cient.
INQoL SF-36 Spearman correlation
Pain Pain -0.686
Fatigue Energy/fatigue/emotions -0.686
Independence Social functioning -0.510
Overall QoL General Health -0.453
Activities Physical functioning -0.769
Emotions Emotional well being -0.453
Relationships Social functioning -0.504
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Psychometric properties of INQoL for patients with polyneuropathy
For the 29 polyneuropathy patients various scores on reliability and validity measures 
were lower than for the group of NMD patients. For reliability the subscales of emotions 
and body image resulted in Cronbach’s alphas of <0.70. Known group validation showed 
a relationship between MRS scores and four INQoL sub-domains (p<0.05) and no 
significant relationship for age groups and INQoL sub-domains. Item total correlation 
showed correlation coefficients between 0.305 and 0.743 for overall QoL. Spearman 
correlation coefficients for the relation between the INQoL and the SF-36 were <0.300 
for the subscores overall QoL, emotions and relationships. Both EQ-5D scores showed 
a corellation of <0.300 with the INQoL overall QoL scores as well.
DISCUSSION
Main ﬁ ndings
The results of this study show that the translation of the INQoL questionnaire resulted 
in a Dutch-language questionnaire with adequate psychometric properties for patients 
with a neuromuscular disorder. Reliability, known group validity, item-total correlation and 
concurrent validation were good. The questionnaire is appropiate for use in the Dutch 
speaking population to measure quality of life of patients with diverse neuromuscular 
disorders. This confirms and extends data obtained in the United Kingdom, US, Italy 
and Serbia (7-10).
For the 29 polyneuropathy patients overall scores on reliability and validity measures 
were lower than for the group of NMD patients. The generally lower scores on the 
psychometric measures cannot be explained entirely by differences in symptoms 
between patients with NMD or polyneuropathy. The sample size for polyneuropathy 
patients was small and so definitive conclusions cannot be made. However tentatively, 
we suggest that that in order to measure quality of life in patients with polyneuropathy, 
the INQoL questionnaire should be modified using data from a larger sample size 
or that the use of a previous developed specific HRQoL questionnaire for peripheral 
neuropathy be considered (6, 18).
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Strengths and limitations
A major strength of our study was the broad range of the study population, including 
nine different diagnoses, reflecting the variation that is seen among patients with a 
neuromuscular disorder. As such, our data on the psychometric properties of the INQoL 
may be considered applicable to the broad range of patients that are encountered in 
clinical practice. A limitation is that our study design did not allow for the assessment 
of a test-retest reliability of the INQoL. 
Implications and future research
The assessment of quality of life patients with a neuromuscular disorder can help identify 
domains that are affected most by the disease in individual patients. Such findings may 
help to guide clinical management decisions, and may be used to evaluate the impact 
of treatments. The INQoL questionnaire is an easy to administer, self-rating scale with 
an acceptable burden on patients and satisfactory psychometric properties. It can be 
used both, in daily clinical practice as well as for research objectives. The availability of 
quantitative data on minimal clinical significant differences of the INQoL questionnaire 
would be imperative to make optimal use of this instrument. Responsiveness and 
test-retest analyses should be performed in future research to further strengthen the 
validation of the Dutch-language INQoL questionnaire. 
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ABSTRACT
Objective
To systematically study the effects of shared medical appointments (SMAs) as compared 
with individual appointments for patients with a chronic neuromuscular disorder (NMD) 
and their partners. 
Methods
In this randomized controlled trial with a follow-up of 6 months, we included patients 
with a chronic neuromuscular disorder and their partners. Participants were randomly 
allocated to an SMA or an individual outpatient appointment. The primary outcome 
measure was patients’ health-related quality of life (HRQoL) (SF-36). Secondary outcome 
measures included: self-efficacy, social support, patient and partner satisfaction with 
the appointment and time available per patient.
Results
272 patients and 149 partners were included. HRQoL showed greater improvement in 
patients who had attended an SMA (MD 2.8 points, 95% CI 0.0 to 5.7, p=0.05). Secon-
dary outcomes showed small improvements in the control group for satisfaction with the 
appointment (p=0.01). Neurologists spent less time per patient during the SMAs; mean 
16 minutes (range 11–30) versus 25 minutes for individual appointments (range 20–30).
Conclusions
This study provides evidence that SMAs can improve aspects of QoL of patients with a 
chronic neuromuscular disorder. This could result in an alternative for individual appoint-
ments improving both effectiveness and efficiency. Further research to optimize SMAs 
and to identify critical success factors seems warranted. These data extend evidence 
on SMAs for neurological patients. 
Classification of evidence
This study provides Class III evidence that for patients with chronic neuromuscular dis-
orders shared medical appointments improve QoL as compared to individual medical 
appointments.  
Trial registration
Dutch Trial Register www.trialregister.nl NTR1412.
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INTRODUCTION
Healthcare faces the challenge of finding an optimal balance between quality of care 
and time available per patient, prompting hospitals and physicians to look for alternative 
care options. Specifically for patients with a chronic neuromuscular disorder it is difficult 
to fulfil their complex needs during a conventional individual appointment. Moreover 
because in absence of cure, main treatment goals focus at optimising quality of life and 
improving self management. Accumulating evidence suggests an association between 
shared medical appointments (SMAs) and improving patient reported outcome measures 
for various common, mostly chronic, diseases (1-4). Feasibility of SMAs has recently 
been reported in Parkinson Disease (3), however the evidence for effectiveness of SMAs 
compared with individual appointments for patients with Parkinson disease or other 
neurological diseases has not been conclusive.
During an SMA, also known as group visit, a physician sees multiple patients simultane-
ously, combining individualised medical patient care with peer-support and self-
management education. This gives patients and partners the opportunity to not only 
share a healthcare professionals’ time, but also share mutual experiences (5-7). In 
addition, the continuity and repetition offered during a series of multiple SMAs, as 
described in most previous randomized studies, may at least partly account for the 
observed outcomes (8). A series of SMAs is, however, not always feasible nor desirable 
for most groups of neurological patients.
With the present randomized controlled trial we therefore wished to evaluate whether 
already a single SMA would yield beneficial effects on quality of life relative to an 
individual appointment for chronic neuromuscular patients and their partners. 
METHODS
Study design
Methods have been described in accordance with the CONSORT 2010 statement and have 
been reported in detail elsewhere (9, 10). In brief, we conducted an RCT with a follow-up 
of six months and randomized participants to either an SMA or an individual appointment 
with one of the two participating neurologists (BvE, GD) at the outpatient clinic of the 
neurology department of the Radboud University Medical Center (RadboudUMC). 
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The primary research question for this study was to evaluate whether a single SMA 
improves HRQoL for patients with chronic neuromuscular disorders as compared to 
individual medical appointments.
The secondary research questions were whether a single SMA improves Individualized 
Neuromuscular Quality of Life, self-efficacy, social support, and satisfaction with care 
for chronic neuromuscular patients and QoL, self-efficacy and satisfaction with care for 
the patients’ partners.
This study provides Class III evidence that for patients with chronic neuromuscular 
disorders a shared medical appointment improves QoL as compared to an individual 
medical appointment.
This trial was approved by the regional medical ethics committee and written informed 
consent had been obtained from all participants, including partners. The trial was 
registered with the Dutch Trial Register under the number NTR1412.
Participants
Patients identified through CRAMP (Computer Registry of All Myopathies and Polyneu-
ropathies), the Dutch neuromuscular database, were recruited between March 2009 
and March 2011 (11). Eligible patients were invited to participate together with their 
partners. Patients were eligible when they were diagnosed with one of the selected 
chronic neuromuscular disorders (see Table 4.1), were over 18 years of age, currently 
in the care of our department and had not seen their neurologist six months prior to 
study commencement. Exclusion criteria were severe hearing problems or insufficient 
command of the Dutch language (10).
Randomization
Concealed randomization (1:1) balanced by diagnosis was performed through computer-
generated randomization software. In view of the nature of the intervention, physicians 
and participants could not be blinded to group assignment. The statistician who 
conducted the analyses was blinded for treatment allocation. 
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Table 4.1 Baseline participant characteristics for the two study groups. Data are numbers (%) 
unless stated otherwise.
Shared medical 
appointment (SMA)
Individual 
appointment 
Variable
Patient
(123)
Partner
(66)
Patient
(112)
Partner
(58)
Age, mean (standard deviation) 50 (13.5) 54 (2.9) 52 (13.3) 56 (11.6)
Men 63( 51.2) - 62 (55.4) -
Relationship 86 (70.5) - 79 (72.5) -
Diagnoses
Myotonic Dystrophy type 1 45 (36.6) 25 (37.9) 30 (26.8) 12 (20.7)
Facioscapulohumeral Muscular Dystrophy 24 (19.5) 14 (21.2) 23 (20.5) 11 (19.0)
Non-dystrophic myotonias: chloride and 
sodium channelopathies
9 (7.3) 4 (6.1) 12 (10.7) 6 (10.3)
Myositis: Dermatomyositis and 
Polymyositis 
7 (5.7) 3 (4.5) 12 (10.7) 7 (12.1)
Polyneuropathy 14 (11.4) 6 (9.1) 15 (13.4) 6 (10.3)
Inclusion body myositis 4 (3.3) 3 (4.5) 5(4.5) 4 (6.9)
Chronic progressive external 
ophthalmoplegia
4 (3.3) 1 (1.5) 1 (0.9) 1 (1.7)
McArdle’s disease 5 (4.1) 3 (4.5) 3 (2.7) 2 (3.4)
Oculopharyngeal Muscular Dystrophy 11 (8.9) 7 (10.6) 11 (9.8) 9 (15.5)
Modified Rankin scale
(higher scores indicate more severe symptoms)
0 4 (3.4) - 8 (8.2) -
1 19 (16.0) - 13 (13.4) -
2 39 (32.8) - 35 (36.1) -
3 21 (17.6) - 14 (14.4) -
4 34 (28.6) - 27 (27.8) -
5 2 (1.7) - 0 (0) -
Level of education
Low 28 (23.1) 15 (25.4) 25 (22.9) 13 (26.0)
Medium 58 (47.9) 25 (42.4) 55 (50.5) 23 (46.0)
High 35 (28.9) 19 (32.2) 29 (26.6) 14 (28.0)
Employment status
Studying / in training 2 (1.7) 0 (0.0) 2 (1.9) 0 (0.0)
Paid work 42 (36.5) 35 (60.3) 33 (31.1) 22 (43.1)
Housework / volunteer work 8 (7.0) 4(6.9) 7 (6.6) 7 (13.7)
Searching for a job 2 (1.7) 0 (0) 1 (0.9) 2 (3.9)
(Partially) medically retired 36 (31.3) 2(3.4) 37 (34.9) 3 (5.9)
Retired 25 (21.7) 17 (29.3) 26 (24.5) 17 (33.3)
Attended SMA before 28 (23.0) 16 (27.1) 16 (14.5) 11 (21.6)
Membership of the Dutch patient 
association for muscle diseases 
71 (58.2) 18 (31.0) 51 (46.4) 9 (18.0)
Appointment with own neurologist 20 (16.3) 11 (16.7) 34 (30.6) 23 (39.7)
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Intervention
Patients and partners randomized to the SMA group of the study were invited to attend 
an SMA of 1.5–2 hours in lieu of their annual appointment. During the SMA one of two 
neurologists (either BvE or GD) saw 5–8 patients with the same diagnosis and their 
partners simultaneously, addressing the same topics that are commonly covered during 
an individual appointment. The neurologist was supported by a group mentor who 
facilitated the group process by fostering interaction between patients and partners 
and by managing time. Both neurologists and the group mentor had received training 
in conducting SMAs prior to the study. Patients (and their partners) randomized to the 
control group were seen individually by one of the neurologists during their regular 
annual 20–30 minute appointment in which the customary topics were addressed. In 
both conditions patients were not necessarily seen by their regular consulting physician. 
For both intervention groups care was tailored to the needs of the patients and their 
partners. Prescriptions, referrals and medical record keeping were as usual.
Outcomes
The primary outcome measure was health-related quality of life (HRQoL) as measured 
by the SF-36 (12). The secondary outcome measures were: 1) HRQoL as measured by 
the EQ-5D generating two indices: the descriptive profile was used to calculate a single 
summary EQ-5D index score and an overall self-rated health status as measured by the 
Visual Analogue Scale (VAS) (13, 14); 2) the Individualized Neuromuscular Quality of Life 
questionnaire (INQoL) (15, 16); 3) the Generalized Self-Efficacy scale (GSE) by Schwarzer 
where the respondents rate the confidence they have in being able to perform specific 
behaviours (17); 4) the emotional support subscale of the Dutch Social Support List-
Discrepancies questionnaire (SSL-D) (18); 5) QUality Of care Through the patient’s Eyes 
(QUOTE) inventory consisting of questions on communication, treatment, symptoms 
and medication (19); 6) satisfaction with the appointment as rated on a 5-point scale; 
7) satisfaction with the marital relationship as rated on a 10-point scale and a VAS (20). 
Potential differences in impact between the SMA and the individual appointments on 
the patients’ partners were evaluated by: 1) the EQ-5D; 2) the GSE; 3) the QUOTE; 
4) satisfaction with the appointment (5-point scale); 5) satisfaction with the marital 
relationship (10-point scale and VAS), and 6) burden of care, in terms of how many hours 
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per week the respondent spends on caring for and relieving the partner of household 
tasks (21).
All outcome measures were obtained through standardised self-reported questionnaires. 
Patients and partners received these by mail at home four weeks before and one, twelve, 
and twenty-four weeks after the intervention. Severity of neuromuscular disorders was 
clinician-rated (BvE, GD) using the Modified Rankin Scale (22, 23). 
Because of the type of intervention, we did not expect to see a change in incidence 
of adverse events, and thus information about adverse events was not collected 
systematically.
Statistical analysis
A sample size calculation showed that 92 patients per group were needed to demonstrate 
an improvement of 5 points on the SF-36 (12). Assuming a standard deviation of 12, 
a power of 80%, a two-sided alpha of 0.05, and taking into account loss to follow-up, 
135 patients had to be enrolled in both groups. Statistical analyses were performed 
using SPSS software, version 18. Descriptive statistics were used to present baseline 
characteristics. For the primary analyses, we used a Toeplitz covariance model to 
conduct separate repeated measures analyses (24).We included time, treatment, and 
the interaction between time and treatment as fixed factors in the linear mixed model. In 
addition, we added the baseline values of the dependent variables as possible significant 
covariates to the model and corrected for variables that demonstrated an imbalance at 
baseline (7). When the interaction factor did not show significant results, it was discarded 
from the model. Residual plots from the mixed models were examined to assess model 
assumptions. All linear mixed model analyses were performed on all participants, 
including those with incomplete datasets. Two-tailed analyses were performed with a 
p-value of 0.05. Similar analyses were conducted to determine differences in secondary 
outcome measures.  
RESULTS
A total of 880 patients was assessed for eligibility (see Figure 4.1: Patient flowchart), 
286 of whom did not meet the inclusion criteria, leaving 594 eligible patients who were 
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Figure 4.1 Patient ﬂ owchart.
CRAMP, Computer Registry of All Myopathies and Polyneuropathies.
Patients included and 
randomized (n=272)
Allocated to intervention 
group:
shared medical 
appointment (n=143)
Received allocated 
intervention (n=128)
Did not receive 
allocated intervention 
(n=15):
Deceased (n=1)
Too ill and time
investment (n=7)
Unknown reason(n=7)
Allocated to control 
group:
individual appointment 
(n=129)
Received allocated 
intervention (n=122)
Did not receive 
allocated intervention 
for unknown reason 
(n=7)
Lost to follow up (n=2)
Deceased(n=2)
Lost to follow up 
(n=5)
No show (n=3)
Other (n=2)
Excluded (n=608)
Not meeting inclusion 
criteria (n=286)
-Could not be contacted 
(n=99)
-Declined to participate 
(n=220)
-Other reasons (n=6)
Lost to follow up (n=6)
Deceased (n=1)
Too ill (n=3)
Other (n=2)
CRAMP database:
Assessed for eligibility 
(n=880)
invited by telephone and subsequent information letter to participate in the study 
together with their partner, if relevant. Of these, 99 patients were not traceable, while 
220 patients declined to participate, of whom 17.7% refused participation in an SMA, 
while 29% reported practical barriers and 3.2% too low energy levels, with 50% declining 
for various other reasons. In total, 272 patients and 149 partners were included in the 
study and 23 SMAs and 122 individual appointments were conducted.
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Patients and partners in the two groups were similar at baseline with respect to most 
variables (see Table 4.1). In the SMA group slightly more patients were diagnosed with 
Myotonic Dystrophy type 1 and fewer patients were seen by their own neurologist. 
These differences were corrected for in the statistical analyses. 
Modeled data (Table 4.2) showed a beneficial effect of SMAs on the primary outcome 
health-related quality of life as measured by two SF-36 subscales: for general health 
the mean difference between groups was 2.8 irrespective of follow up time (p=0.05), 
for social functioning an interaction was found between treatment and time (p=0.03), 
indicating that SMAs and individual appointments had a different impact on this aspect 
of the quality of the lives of the patients over time. The other SF-36 subscales showed 
no significant trends.
Secondary outcomes for patients showed higher values for quality of life as measured by the 
INQoL fatigue scale in the SMA group relative to the control group, with different treatment 
effects across time points resulting from the interaction between time and treatment (p=0.03).
Satisfaction of patients with the appointment was lower in the SMA group, with QUOTE 
scores being lower by 0.2 points and ratings on the 5-point scale by 0.4 points (p=0.01 
and p=0.001, respectively). Perceived social support scores were 1.1 points higher in 
the individual appointment group (p=0.004). Remaining secondary outcome measures 
for patients showed no significant differences between intervention groups (see 
Supplementary material Table e4.1).  
The data for the patients’ partners showed no between-group differences, except for 
satisfaction with the appointment, where the scores for the SMA group were 0.3 points 
lower on the QUOTE (p=0.01) and 0.4 points lower on the 5-point scale (p=0.001) (see 
Supplementary material Table e4.2). 
With a mean of 16 minutes (range 11–30), the neurologists spent less time per patient 
during the SMAs as the individual appointments lasted on average 25 minutes (range 
20–30). In less than 8% of the patients individual attention was needed after the SMA. This 
did not significantly influence the total time spent per patient in the intervention group.
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DISCUSSION
The main finding of this RCT is that a single SMA resulted in a modest beneficial effect on 
self-reported health-related quality of life (SF-36) compared to individual appointments 
in chronic neuromuscular patients. Even though on average considerably less time was 
spent per patient by the neurologist during the SMAs. Secondary outcome measures 
confirmed improvement of HRQoL on a disease specific scale (INQoL), although patient 
and partner satisfaction with the appointment was slightly lower in the SMA group. Based 
on these results we posit that even single SMAs have the potential to improve both 
effectiveness and efficiency of the care for chronic neuromuscular patients, offering a 
viable alternative for individual outpatient appointments. Further research to optimize 
SMAs and to identify critical success factors seems warranted before SMAs can be more 
widely implemented in this and other groups of neurological patients. These data extend 
evidence on SMAs for neurological patients.
The most conspicuous difference with earlier randomised SMA studies is that we 
compared single SMAs with single individual appointments, whereas all previous 
studies but one evaluated a series of SMAs, in which it was consistently suggested 
that effectiveness was related to the number of SMAs patients attended (1, 2, 5, 7, 25, 
26). However, our study shows that even a single SMA is able to improve aspects of 
HRQoL. The one study that also evaluated a single SMA found no such benefits (27). This 
difference in results may be due to the fact that communication was more unidirectional 
in nature in Abram’s study, while during our SMAs we adopted a patient-driven agenda 
and actively encouraged patients and their partners to share their experiences. Arguably, 
it may be the sharing and learning from the experiences of fellow patients and peer 
support that accounts for the effectiveness of the SMA model, regardless of the effects 
of the repetitiveness and continuity of a succession of SMAs. In contrast to previous 
reports (4, 5, 28) we found that patients (and partners) were slightly less satisfied with 
the SMA than those receiving individual care. This result, too, might be related to the 
fact that attending multiple successive SMAs give participants the opportunity to build 
a relationship with peers and to acquaint themselves with the new care model over time. 
Finally, previous studies found the burden of care for the partners of chronic patients 
to be substantial and recommended tailoring healthcare to the needs of both patients 
and partners (20, 21, 29-33). To our knowledge, ours is the first RCT to evaluate the 
differential effects of an SMA and an individual appointment in the patients’ partners (8).
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Our study design was robust in that we were able to include a sizeable sample of 
patients and their partners in a randomized trial. We, moreover, prevented bias due 
to inter-physician variation by having two neurologists deliver both the experimental 
intervention and usual care. Additionally, the wide range of neuromuscular disorders is 
reflective of clinical practice and improves the generalisability of our results. Also, refusal 
rates did not differ between intervention groups. With this design we were able to align 
the intervention to usual care and to reliably compare the effects of single SMAs to the 
effects of individual appointments. 
In addition to limitations such as limited generalisability due to a single centre design, 
possible influences of multiple outcome testing due to the subscales of the SF-36 and 
the inability to blind participants and physicians, two specific aspects of our study warrant 
further discussion. Firstly, among patients who were invited to participate in the study, 
25% declined because they refused to being allocated to an SMA, suggesting that the 
participants that did agree to the randomization were probably motivated to meet with 
and learn from peers on how to cope with a chronic condition. Secondly, although the 
effect sizes of the improvements on our two HRQoL primary outcome measures (SF-36) 
were similar to those obtained in previous SMA studies (1, 34), they did not reach the 
minimally clinically important difference of 5 points (12, 35). The modesty of the effects 
may be attributable to the progressive nature of chronic neuromuscular disorders.
Future research should focus on which determinants, under which circumstances, 
account for the effectiveness of SMAs. Among such determinants are the information 
exchange among fellow patients, peer support, and the sharing of experiences as well 
as the increased time to inform patients and attend to psychosocial aspects. Another 
research question meriting consideration is the effect SMAs have on physicians and 
nurses in terms of job satisfaction. Finally, weighing the costs and effects of our SMA 
intervention completely will require further empirical data on the use of care resources. 
An important implication of our study is that we showed a wider applicability of the 
SMA model to patients whose intervals between successive appointments to the clinic 
may be lengthy. This supports applicability to other neurological diseases provided that 
possibilities to improve patient satisfaction are further explored.   
Although modestly, the single SMAs in this study improved HRQoL, thus potentially 
offering chronic neuromuscular patients and their partners as well as consulting 
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neurologists an alternative care option, albeit that further refinements are needed before 
SMAs can be more widely implemented in this and other groups of neurological patients.
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ABSTRACT
Objective
To assess whether shared medical appointments (SMAs) for neuromuscular patients 
represent a way of using clinicians’ time efficiently without compromising quality of 
care for patients. 
Methods
Patients with a chronic NMD (N=272) were randomly allocated to either an SMA or a 
regular individual annual appointment, and followed up for a period of six months. Data 
on resource utilization and quality of life (EQ-5D) were collected prospectively, using 
a healthcare perspective. Incremental costs and changes in quality-adjusted life years 
(QALYs) were computed using a probabilistic decision model. Factors critical to the 
incremental cost-effectiveness of SMAs were explored in sensitivity analyses.
Results
No substantial differences between SMAs and individual visits in terms of costs per 
QALY were found (incremental cost-effectiveness ratio = €-960,-; 95% CI: €-34.600,-; 
€+36.800,-). Sensitivity analyses showed that the cost-effectiveness ratio was particularly 
sensitive to SMA group size and proportion of patients seeing their treating neurologist.
Conclusions
Cost-effectiveness of SMAs did not show a significant difference with that of individual 
appointments based on data from our RCT. On the other hand we were able to show 
that a minimum of six patients per SMA and 75% of patients attending their treating 
neurologist are specific conditions under which SMAs qualify as a cost-effective alter-
native. This implies that SMAs may be a means to increase productivity of the physician 
without compromising quality of care. 
Classification of evidence
This study provides Class III evidence that SMAs are not significantly more cost-effective 
than individual appointments for patients with NMDs. The study lacks the precision to 
exclude important differences in the cost effectiveness between SMAs and individual 
appointments.  
Trial registration
Dutch Trial Register www.trialregister.nl NTR1412.
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INTRODUCTION
Time is a precious resource in the context of patient care (1). Patients hope to find 
attentive concern on the part of the clinician. On the other hand, in the interest of cost 
control, less rather than more time per patient is available. The fact that productivity 
gains in healthcare do not match those in other areas is an important factor, contributing 
to the rise in healthcare costs (2). The resulting increase in time pressure is not always 
experienced in the same way. Clinicians who became patients realized how time can 
be experienced quite differently (3). Recognizing these developments in our own 
department, we wondered whether shared medical appointments (where multiple 
patients and their partners with the same diagnosis are seen by the neurologist at the 
same time) might help to resolve this problem. In a way, this creates more clinician-
time for the patient, although not exclusively for him individually. Also, the patient may 
benefit from knowledge and experiences of other patients contributing to a decrease 
in resource utilization (4, 5). To be sure, there is a trade-off here, since some patients 
may prefer not to discuss certain issues in the presence of others. We evaluated this 
approach in a randomized controlled trial (6). In this complementary paper, we report 
the results on resource use and quality of life. In a decision analytic model, we explored 
under which conditions SMAs for this patient population might qualify as an efficient 
and effective option. 
METHODS
Ethical approval
This randomized controlled trial (RCT) was approved by the regional medical ethics 
committee and written informed consent was obtained from all participants. The trial 
is registered with the Dutch Trial Register under the number NTR1412.
Study design
The present study comprises an economic evaluation from the healthcare perspective 
and was conducted in parallel with an RCT. The methods and results pertaining to the 
clinical effectiveness of the RCT have been described in detail elsewhere (6, 7). In brief, 
we conducted an RCT with a 6-month follow-up where NMD patients were randomized 
Chapter 5
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to either an SMA or an individual appointment with one of the two participating 
neuromuscular neurologists (BvE, GD) at the outpatient clinic of the neurology 
department of the Radboud University Medical Center (RadboudUMC). 
The primary research question for this study was to evaluate whether a single SMA is 
more cost-effective for patients with chronic neuromuscular disorders as compared to 
individual medical appointments.
The secondary research questions were to analyze under which conditions SMAs for 
NMD patients qualify as an efficient and effective alternative to individual appointments 
and what effect SMAs have on the productivity of participating neurologists
This study will provide Class III evidence whether SMAs are more cost-effective than 
individual appointments for patients with NMDs.
Participants
Patients were identified through CRAMP (Computer Registry of All Myopathies and 
Polyneuropathies), the Dutch database of patients with neuromuscular disease, and 
recruited between March 2009 and March 2011 (8). Patients were eligible when they 
were diagnosed with one of the selected chronic NMDs (see Table 5.1), over 18 years 
of age, currently in the care of our department, and had not seen their neurologist six 
months prior to study commencement. Patients were recruited from the practice of the 
study-neurologists (BvE, GD) as well as from colleague -neurologists of our department. 
Exclusion criteria were severe hearing problems or insufficient command of the Dutch 
language (7). Eligible patients were invited to participate together with their partners 
or chief informal caregiver.
Randomization
Patient randomization (1:1) was computer-generated (by dedicated software), concealed, 
and balanced for diagnoses. Due to the nature of the intervention, physicians and 
participants could not be blinded to group assignment, but the statistician who 
conducted the analyses was blinded for treatment allocation. 
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Table 5.1 Baseline participant characteristics for the two study groups
Shared medical 
appointment 
(N=123)
Individual 
appointment 
(N=112)
Age, mean (SD) 50 (13.5) 52 (13.3)
Men 63 (51.2) 62 (55.4)
Partner relationship 86 (70.5) 79 (72.5)
Diagnoses
Myotonic dystrophy type 1 45 (36.6) 30 (26.8)
Facioscapulohumeral muscular dystrophy 24 (19.5) 23 (20.5)
Non-dystrophic myotonias: chloride and sodium 
channelopathies
9 (7.3) 12 (10.7)
Myositis: dermatomyositis and polymyositis 7 (5.7) 12 (10.7)
Polyneuropathy 14 (11.4) 15 (13.4)
Inclusion body myositis 4 (3.3) 5 (4.5)
Chronic progressive external ophthalmoplegia 4 (3.3) 1 (0.9)
McArdle’s disease 5 (4.1) 3 (2.7)
Oculopharyngeal muscular dystrophy 11 (8.9) 11 (9.8)
Modified Rankin scale (higher scores indicate more 
severe symptoms)
0 4 (3.4) 8 (8.2)
1 19 (16.0) 13 (13.4)
2 39 (32.8) 35 (36.1)
3 21 (17.6) 14 (14.4)
4 34 (28.6) 27 (27.8)
5 2 (1.7) 0 (0)
Employment status
Studying / in training 2 (1.7) 2 (1.9)
Paid work 42 (36.5) 33 (31.1)
Housework / volunteer work 8 (7.0) 7 (6.6)
Seeking work 2 (1.7) 1 (0.9)
(Partially) medically retired 36 (31.3) 37 (34.9)
Retired 25 (21.7) 26 (24.5)
Self reported comorbidity 85 (70.2) 65 (60.2)
Cardiac symptoms 19 (15.8) 16 (15.2)
Depression 11 (9.2) 3 (2.9)
Eye/stare symptoms 20 (16.7) 14 (13.3)
Gastroenterological disease 28 (23.2) 20 (19.0)
Pain 24 (20.0) 15 (14.3)
Thyroid sympoms 6 (5.0) 2 (1.9)
Appointment with treating neurologist 20 (16.3) 34 (30.6)
EQ5D index, median (interquartile range) 0.78 (0.65–0.81) 0.78 (0.65–0.81)
Data are numbers (%) unless stated otherwise.
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Intervention
Patient and partners randomized to the SMA group were invited to attend an 
SMA of 1.5–2 hours as a substitute for their regular annual visit. During an SMA 
one of two specialist neurologists (either BvE or GD) saw 5–8 patients with the 
same diagnosis and their partners simultaneously, addressing the same topics that 
are commonly covered during the yearly follow-up appointment. The neurologist 
was supported by a group mentor who facilitated the group process by fostering 
interaction between patients and partners and by managing time. Both neurologists 
and the group mentor had received training in conducting SMAs prior to the study. 
Participants randomized to the control group were seen individually by one of the 
participating neurologists (BvE or GD) during their regular annual 20-to-30-minute 
appointment. For both intervention groups care was tailored to the needs of the patients 
and their partners. Prescriptions, referrals, and medical record keeping were as usual. 
Outcome measures
Utilities were evaluated by the EuroQol EQ-5D index scale for patients, a standardized 
instrument designed to determine health-related quality of life in terms of quality-
adjusted life years (QALYs) (9). To measure the use of resources, the following items 
from the Client Service Receipt Inventory (CSRI) (10) were included: visits to a general 
practitioner, medical specialist, physiotherapist, occupational therapist, psychologist, 
psychiatrist, and social worker; hospital admissions; medication; home care and domestic 
help.
Outcome measures were obtained through self-reported questionnaires unless stated 
otherwise. Participants received these by mail at home four weeks before and one, 
12, and 24 weeks after the intervention. Severity of disease according to the Modified 
Rankin Scale was established by the physicians during the appointments.  
Valuation of the cost items 
Costs were calculated by multiplying volumes of resources by the cost price per resource 
unit (Table 5.2). Cost prices were based on the Dutch guidelines for economic evaluation 
in healthcare unless stated otherwise (11). Domestic help was quantified in hours worked, 
adopting national average hourly wage rates for domestic cleaners. All prices were 
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converted to the year 2011 by means of the Dutch consumer price index and expressed 
in euros (at which time 1 euro was equivalent to British £ 0.85 and US $ 1.31) (12).
Intervention costs
Since no unit cost price was available for SMAs, we calculated SMA cost price on 
the basis of the actual time spent by the consultant neurologist and group mentor (a 
specialist nurse or equivalent). Cost prices of the health professionals’ time were based 
on the Dutch guidelines for economic evaluation in healthcare and converted to 2011 
corresponding with the valuation of the cost items (11). No adjustments were made for 
the number of patients per SMA since this did not affect its organization or duration.
Statistical analysis 
Descriptive statistics were used to generate baseline participant characteristics. 
Participant data were included for analysis when at least the baseline and one effect 
measurement was available. Remaining missing patient data on the volumes of resources 
used and QALYs were imputed with multiple imputation techniques (13). Imputation 
was executed five times and the weighted means of cost variables and effects over 
the follow-up time were calculated. QALYs were calculated from baseline to follow-up 
(6-month periods) using the area-under-the-curve method, and compared with a t-test. 
Analyses were conducted on the basis of the intention-to-treat principle A p-value of 
<0.05 was regarded as significant and SPSS was used to conduct the analyses of total 
costs and QALYs.
Probabilistic decision model
To compare the cost-effectiveness of an SMA with an individual appointment a probabilistic 
decision model was developed. The model consisted of two main branches, SMA and 
individual appointment, each allowing for the probability that a patient was seen by his 
own neurologist, or not (see Figure 5.1 for a schematic figure of the model structure). 
Model parameters for expected costs (in Euros) and effects (in QALYs) as well as number 
of patients per SMA were extracted from the results of our RCT for both treatment groups 
(Table 5.3). The incremental cost-effectiveness ratio (ICER) was calculated and represented 
visually as an ICE scatter plot showing pairs of incremental cost and effectiveness values 
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from N = 1000 iterations. The probability that an SMA is cost-effective was calculated using 
a willingness-to-pay of €80,000.00 per QALY, a threshold suggested by the Council for 
Public Health and Health Care of The Netherlands (14). The impact of model parameters 
on the ICER were explored in one-way and two-way sensitivity analyses. TreeAge Pro and 
Microsoft Excel were used to conduct the decision modeling.  
Table 5.3 Input parameters of the probabilistic decision model
Parameter Expected value SD 95% CI Source
Probability of attending 
treating neurologist
SMA 0.75 0.04 0.67–0.83 Clinical experience
Individual appointment 0.90 0.03 0.83–0.95 Clinical experience
Number of patients per SMA 3–9 (8) 1 6–10 Empirical data
Total costs resources used (€)
SMA
Treating neurologist €365,- (367) 356 11–1330 Empirical data
Other neurologist €828,- (810) 1057 2–3655 Empirical data
Individual appointment
Treating neurologist €419,- (378) 616 0–2245 Empirical data
Other neurologist €1198,- (1142) 1876 0–6397 Empirical data
Effectiveness (QALY)
SMA
Treating neurologist 0.67 0.18 0.29–0.96 Empirical data
Other neurologist 0.70 0.18 0.30–0.97 Empirical data
Individual appointment
Treating neurologist 0.73 0.18 0.30–0.98 Empirical data
Other neurologist 0.74 0.15 0.38–0.97 Empirical data
Figure 5.1 Schematic ﬁ gure of the probabilistic decision model.
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Shared medical
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RESULTS
Participants
In total, 272 patients were included in the study of whom 143 were randomly assigned 
to the SMA group and 129 to the individual appointment group. Of 37 patients less than 
two measurements were available, resulting in a total of 235 datasets for analysis. The 
patients in the two groups were similar at baseline with respect to most variables (Table 
5.1). In the SMA group slightly more patients were diagnosed with Myotonic dystrophy 
type 1, fewer patients were seen by their treating neurologist and slightly more patients 
reported comorbidity. These differences were corrected for in the statistical analyses. 
Outcome
Volumes of resource use, unit cost prices, and average costs for both groups are 
presented in Table 5.2. The pooled average costs of resources cumulated over the 
6-month follow-up period was €1,317.44 (range €104.50–€8,846.16) per patient for the 
SMA group and €1,646.89 (range €131.71–€16,221.05) for the individual appointment 
group. The mean QALYs over the 6-month follow-up period for the SMA group was 
0.69 (SE 0.14) and for the individual appointment group 0.74 (SE 0.16). 
Monte Carlo modeling 
A Monte Carlo simulation resulted in an incremental loss of 0.05 QALYs and a 
€48,- reduction in costs for the 6-month follow-up period for the SMA/individual 
appointment contrast. In other words, for 1 QALY lost, healthcare could gain €960 
per patient when SMAs would be implemented (ICER = €-960,- ; 95% CI: €-34,600,-; 
€36,800,-). The probability that SMAs are more cost-effective than individual visits was 
39% at a willingness-to-pay (WTP) of €80,000,- (Figure 5.2).
Sensitivity analysis
Costs appeared significantly influenced by the number of patients per SMA and the 
proportion of patients seen by their treating neurologist. One-way sensitivity analysis 
of number of patients per SMA vs expected costs resulted in a threshold value of 6.2 
89
Cost effectiveness of SMAs for neuromuscular patients
5
patients (Figure 5.3). Two-way sensitivity analyses of number of patients and probability 
of being seen by treating neurologist showed that group visits can be more cost-effective 
than individual visits provided that SMA groups comprise more than six patients and 
that 75% of the patients is seen by their treating neurologist (figure not shown).
Productivity
With a mean of 16 minutes (range 11–30), the neurologists spent less time per patient 
during the SMAs given that the individual appointments lasted on average 25 minutes 
(range 20–30), as based on the actual attendance rates during the study period. Less than 
Figure 5.2 Incremental cost-effectiveness scatterplot of shared vs individual medical 
appointments.
The ICE scatter plot includes a single set of points representing pairs of incremental cost and 
effectiveness values from the simulation results (N=1000) relative to a baseline. The slope 
intersecting the x axis is the willingness-to-pay (WTP) threshold of €80,000. In addition to the 
WTP line, a 95% confidence ellipse is drawn in the ICE scatter plot. The graph can be divided 
into four quadrants: south-east; SMAs are less costly and more effective (SMAs dominate), south-
west; SMAs are less costly and less effective, north-west: SMAs are more costly and less effective 
(individual appointments dominate), north-east: SMAs are more costly and more effective. The 
probability of SMAs being considered more cost-effective than individual appointments was 39% 
at a willingness-to-pay (WTP) of €80,000.
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8% of the patients required individual attention in addition to the SMA, which proportion 
did not significantly influence the total time spent per patient in the intervention group.
DISCUSSION
Using data from our RCT in chronic neuromuscular patients in a Monte Carlo 
simulation, we did not find any substantial significant differences between single SMAs 
and single conventional individual visits in terms of costs per QALYs. On the other 
hand, sensitivity analyses showed that a single SMA was more cost-effective than an 
individual appointment when a group size of more than six patients was maintained 
and 75% of these patients was seen by their treating neurologist. We have shown 
that if abovementioned prerequisites are met, SMAs have the possibility to improve 
productivity for this specific population without compromising quality of care. Shared 
appointments are quite different in nature from one-on-one visits and require a different 
approach and mind-set from both the attending consultant and the patient, but as they 
Figure 5.3 One-way sensitivity analyses of the costs for SMA group size.
Probability of being seen by the treating neurologist in the SMA group: 0.75; Probability of being seen by treating 
neurologist in the individual group: 0.90. Threshold value of €628.60 at 6.2 patients.
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provide patients an opportunity to share their knowledge and experiences as well as 
more time with their clinician, they may be more rewarding for both the patient and 
health professionals involved. However, we are well aware that such advantages are 
currently largely speculative and need to be explored and substantiated in future studies.
Although several studies have reported a decline in resource utilization associated with 
SMAs, our findings suggest that no such savings should be expected for the SMAs 
we evaluated during a 6-month follow up. This may be attributed to our distinctive 
diagnosis groups; the previous studies included patients with more common diseases 
like diabetes and heart failure (4, 5, 15). Attending a 90-minute group appointment with 
a neuromuscular neurologist and six to eight peers could provide patients with a rare 
neuromuscular disease with a wider variety of information and expertise, inducing more, 
instead of less, initial referrals. This is illustrated by the fact that resource utilization was 
significantly higher for patients who normally attend a general neurologist and during 
the study were seen by a specialized neuromuscular neurologist. Possibly underutilization 
of care is the case for several patients with a rare neuromuscular disease and SMAs 
could make specialist care available to more patients. A potential decrease of resource 
utilization should be assessed in the light of less complications in the longer term. 
We also offered the fact that we compared single SMAs with single individual appointments 
as an alternative explanation in our previous paper; most other studies evaluated series of 
SMAs (6, 16-18). Resource use might decrease after attending multiple SMAs, while patients 
gain knowledge over time and most referrals are being made during the first appointment.
Finally, although several authors emphasized that maintaining a sufficient SMA group 
size is important for both efficiency and interaction purposes, none have evaluated its 
impact (17, 19). With our study we have shown that the cost-effectiveness of SMAs for 
NMD outpatients is particularly sensitive to SMA group size and to the proportion of 
patients seeing their treating neurologist. 
We performed an economic evaluation alongside a sizeable RCT, which robust design 
enabled us to align the intervention to usual care and to reliably compare the cost-
effectiveness of a single SMA to that of an individual appointment (6). The wide range 
of neuromuscular disorders included in our cohort is reflective of clinical practice and 
enhances the generalisability of our results. Additionally, all missing volumes of resource 
use were imputed using multiple imputation techniques, which has been shown to be a 
reliable method for missing cost data (20). Then again, opting for a societal point of view 
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for this economic evaluation may have strengthened the results, although we conjectured 
that the effects would be negligible. When interpreting the results it is important to 
take into account that patients attending an SMA together could influence each other. 
This could result in clustering effects and overrate the effect of the SMAs. Also the self-
reported comorbidity rates at baseline were slightly higher in the SMA group. Correcting 
for this slight unbalance in the analysis did not affect the resource utilization in the two 
groups. Another limitation is the study period; the six months follow-up may have been 
too short a period to unveil differences in costs, as it is plausible to assume that the 
number of referrals for the patients attending SMAs will drop after the initial group visit. 
On a broad scale, controlled studies comparing the economic benefits of healthcare 
innovations that promote self-management skills in patients with a neuromuscular 
disorder are limited and additional RCTs with longer follow-up periods are needed to 
determine their long-term cost-effectiveness. More specific, the potential effect of SMAs 
on resource utilization could be higher for patients for whom curative treatment options 
are available alongside symptomatic treatment. This would be an interesting question 
for further studies in this area. Follow-up research should also investigate which (groups 
of) patients benefit most from SMAs and which variables, besides group size and the 
proportion of patients seeing their own neurologist, influence cost-effectiveness most.
Although we were unable to detect consistent significant differences in terms of costs 
per QALY between an SMA and an individual appointment for chronic neuromuscular 
patients within the scope of our investigations, our data did provide evidence suggesting 
that in this population the economic impact of SMAs depends on group size and the 
proportion of patients being seen by their own neurologist.
These, conditions will concurrently help increase the productivity of the consulting 
physician without compromising quality of care. This adds important data to our earlier 
results on the effectiveness of SMAs for neuromuscular patients (6). Especially for 
rare chronic diseases such as NMDs, group visits could make high-quality outpatient 
care from a specialist neurologist available for more patients while at the same time 
empowering these patients and their partners or informal caregivers by reinforcing their 
self-management skills. However, before SMAs can be more widely implemented, long-
term effects on the costs and possible working mechanisms will need to be systematically 
explored and substantiated further.
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AbstrAct
background
A group medical appointment (GMA) is a series of one-to-one patient-clinician contacts 
in the presence of several fellow patients. 
Objectives
To assess the effects of GMAs relative to individual visits in patients with a primary physical 
illness in terms of health-related quality of life (HRQOL), physical health, psychological 
health, self-efficacy and self-management and patient evaluation of care.
search methods
We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, 
PsycINFO, ProQuest, Science Citation index, clinicaltrials.gov and ISRCTN from their 
start date to July 2015. The reference lists of included trials were searched for additional 
studies.
selection criteria
All identified published and unpublished randomised controlled trials and cluster-
randomised trials comparing GMAs with one-to-one appointments for patients with a 
primary physical illness were included. GMAs were reviewed when they were intended 
as a substitute for individual visits with a clinician. We excluded studies that evaluated 
group therapy, support groups or group educational programmes. 
Data collection and analysis
Two review authors independently screened citations for inclusion and extracted data. 
The authors of included studies were contacted to locate unpublished data. We synthe-
sised the findings using meta-analysis where possible as well as narrative synthesis. We 
assessed the risk of bias of individual studies and considered the impact of the quality of 
the overall evidence on the strength of the results. Representatives of advocacy groups 
of people with a physical illness advised on various aspects of the review.  
Main results
We included 22 studies involving a total of 6,436 adult participants with diabetes, a 
chronical illness, a neurological condition, cancer, or hypertension, pregnant women 
and people with hearing aids. Two studies were excluded from the analysis due to high 
risk of bias. The quality of evidence was rated as low for all outcomes and very low 
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6for physical health (HBA1C%). The main reasons for the low quality of evidence were 
unexplained statistical heterogeneity among studies for the three primary outcome 
measures and unclear or incomplete data for the three secondary outcome measures.
We found that general HRQOL and diabetes-specific QOL, the first primary outcome 
measures, may improve or improve slightly by attending GMAs as compared to one-
to-one appointments. The results on physical health, the second primary outcome 
measure, of which HBA1C reduction in participants with diabetes was the most clinically 
relevant for this review, are inconclusive mainly due to their high level of inconsistency.
For the secondary outcome measures, i.e. self-efficacy and self-management, psy-
chological health and patient evaluation of care, our review of the results showed that 
attending GMAs has little or no effect above and beyond individual patient visits. The 
incomplete outcome data may have prevented differences between the intervention 
types from emerging. The analyses did show a trend towards a positive effect on self-
efficacy when GMAs have a group facilitator. None of the included studies described 
serious adverse effects.
Our analyses of three additional patient-reported and three economic outcome measu-
res demonstrated that GMAs have little additional effect on skills acquisition and social 
support relative to that found for individual visits, while the effects on patient knowledge 
are uncertain. As to economic effects, he number of emergency department visits 
decreased, but the effect on the number of hospital admissions and healthcare costs 
remained uncertain.
Authors’ conclusions
Although group medical appointments appear to improve quality of life to some 
extent relative to the levels reported for individual doctor visits and while no harms 
are reported, there is insufficient evidence to unreservedly recommend implementing 
GMAs in patients with a (chronic) physical illness. Taking a broad perspective on the 
effectiveness of GMAs, we evaluated a large variety of interventions, diagnostic groups 
and outcome variables. Except for the benefit of using a group facilitator, we were 
unable to identify characteristics that contributed to GMA success, mostly due to the 
low quality of evidence for all main outcomes. Conclusions and recommendations may 
change if future research improves the quality of evidence and results are more robust 
in diverse clinical treatment settings.
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table 6.1 Summary of findings
Group medical appointments compared with one-to-one appointments for patients with a 
physical illness
Patient or population: Patients with a physical illness
Settings: Ambulant care
Intervention: Group medical appointment
Comparison: One-to-one appointment
Outcomes
Effect of 
intervention
No of 
participants 
(studies)
Quality 
of the 
evidence 
(GrADE) comments
General Health-
Related Quality 
of Life
at end of study
The mean score 
in the intervention 
group was 0.04 
standard deviations 
higher (-0.12 lower 
to 0.21 higher) 1
565
(3 studies)
⊕⊕⊝⊝ 
low2
Larger effect sizes 
are expected with 
higher intervention 
intensity and longer 
follow-up times. This 
explains statistical 
heterogeneity.
Diabetes-specific 
quality of life 
(DQoL/Mod)
at end of study
DQol may improve 
by attending 
group medical 
appointments
compared with 
individual medical 
appointments3
877
(4 studies)
⊕⊕⊝⊝ 
low4
Physical outcome 
HBA1C%
at end of study
It is uncertain 
whether attending 
GMAs is effective in 
decreasing HbA1C 
compared with 
individual medical 
appointments5
1,474
(8 studies)
⊕⊕⊕⊝ 
very low6
Self-efficacy and 
self-management
at end of study
The mean score 
in the intervention 
group was 0.32 
standard deviations 
higher (0.08 to 0.56 
higher)7
273
(2 studies)
⊕⊕⊝⊝ 
low8
Presence of a group 
facilitator during 
GMAs may improve 
patients’ self-efficacy 
slightly. This partly 
explains statistical 
heterogeneity.
Psychological 
health
at end of study
(Higher scores 
indicating poorer 
psychological 
health)
The mean score 
in the intervention 
group was 
0.08 standard 
deviations lower 
(indicating better 
psychological 
health) (-0.17 lower 
to 0.02 higher)9
1,611
(6 studies)
⊕⊕⊝⊝ 
low 10
Worsening of 
psychological 
health for study of 
Dorsey explained 
by depression 
as symptom of 
Parkinson's disease. 
This explains statistical 
heterogeneity.
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table 6.1 Continued
Outcomes
Effect of 
intervention
No of 
participants 
(studies)
Quality 
of the 
evidence 
(GrADE) comments
Patient-
evaluation of 
care
at end of study
The mean score 
in the intervention 
group was 0.32 
standard deviations 
higher (0.16 to 
0.49)11
1,406
(6 studies)
⊕⊕⊝⊝
low12
Difference in cultural 
and social values 
might have resulted 
in highly positive 
evaluations with very 
little variation in data 
for the single study 
executed in a non-
western country. This 
explains statistical 
heterogeneity.
Adverse effects No serious adverse 
events were 
reported
CI: Confidence interval; MD: Mean Difference; SMD: Standardised Mean Difference
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect 
and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and 
is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1. Two studies did not describe results (Collins 2013; Visser 2015). Three studies could not be pooled, of which two 
showed a beneficial effect and one study no evidence of effect. The results of (Beck 1997) could not be pooled as 
they were dichotomous and (Seesing 2014) described results of a linear mixed model.
2. Quality of evidence rated as low due to explained heterogeneity and risk of reporting bias
3. Pooling of the results was not possible due to high statistical heterogeneity, but all studies described beneficial effects
4. Quality of evidence rated as low due to imprecision problems and unexplained heterogeneity
5. Pooling of the results was not possible due to high statistical heterogeneity. Six studies described substantial 
beneficial effects and three studies no evidence of effect.
6. Quality of evidence was rated as very low due to unexplained statistical heterogeneity and a high level of inconsistency
7. Remaining three studies showed no evidence of effect. Results (Seesing 2014) could not be pooled due linear mixed 
model analysis. Results of Coleman 2001 and Ickovics 2007 were excluded as they differed from the included studies 
in not describing whether a group facilitator was present or not.
8. Quality of evidence was rated as low as there was risk of bias due to lack of outcome blinding and unclear completeness 
of outcome data as well as explained statistical heterogeneity
9. Seesing 2014 could not be included in the pooled results due to linear mixed model results; the study described 
no evidence of effect. Dorsey 2011 was excluded from the meta-analysis as depression is one of the non-motor 
symptoms of Parkinson's disease, which can explain the much larger effect size for this study.
10. Quality of evidence was rated as low. Risk of bias occurred due to unclear or lack of completeness of outcome data 
and unclear blinding of outcome data, together with some imprecision problems and explained heterogeneity
11. The four studies not included in the pooled results described inconsistent results. From negative (Seesing 2014) 
to minimal difference (Anderson 2013) to favourable effects (Beck 1997; Jafari 2010). Beck and Anderson used 
dichotomous scales and could therefore not be pooled with the other studies. Seesing used a linear mixed model 
analysis without end-of-study mean differences. The Jafari study was the only study to be executed in a non-Western 
country and therefore excluded from the meta-analysis. Difference in cultural and social values might have resulted 
in highly positive patient-reported evaluations with very little variation in data.
12. Quality of evidence was rated as low. The main risks of bias were the unclear completeness of outcome data and 
unclear blinding for outcome data, with lack of consistency occurring as well.
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PLAiN LANGuAGE suMMAry 
Effects of group medical appointments for patients with a physical illness
Background
Traditionally, people consult their clinician on a one-to-one basis. For those that have a 
long-term illness, the ability to successfully manage their own health is very important. 
Here, group medical appointments (GMAs) may be an effective alternative for individual 
appointments. GMAs offer one-to-one patient-clinician contacts as well as interactions 
with a group of fellow-patients.
Review question
We compared the evidence on the effects of GMAs with the results of one-to-one 
patient-clinician appointments, looking at health-status, well-being and how patients 
evaluate the quality of care.
Results
We identified 22 studies that evaluated a wide variety of features of different types 
of GMAs that included participants that had diabetes, a neurological disease, cancer, 
high blood pressure, chronic illness, or women that were pregnant and people using 
hearing-aids. 
Compared to the results for patients having attended individual visits, we found that 
health-related quality of life (HRQOL) and quality of life for people with diabetes may 
improve slightly by attending GMAs. Looking at a specific indicator of physical health 
for people with diabetes (HBA1C%), the beneficial effects of GMAs were not clear 
because some studies found considerable effects while others found no effects. Overall, 
the quality of the evidence was rated as low. Importantly, none of the studies found 
evidence of harm or unwanted effects
Our review also showed that group visits have little or no additional effect on the 
participants’ self-management abilities, their psychological health or their ratings of 
the care they received, although GMAs that were supported by a group facilitator did 
appear to improve the participants’ self-management skills.
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We evaluated three other patient-reported and three economic outcomes. We found that 
GMAs had little effect on patients’ skills acquisition and quality of social support, while 
effects on patient knowledge were uncertain. The number of visits to hospital emergency 
departments did decrease, but the effects on the number of hospital admissions and 
healthcare costs were uncertain.
Conclusion
Based on our review of the results, we conclude that as an alternative to individual visits, 
group medical appointments may improve a participant’s quality of life to some degree. 
While no harms are reported, due to the inconsistency in the outcomes the evidence of 
the benefits of GMAs is insufficient to unreservedly recommend group visits for people 
with a (chronic) physical illness or other patient groups. Future research may change the 
results and thus this recommendation.
bAckGrOuND 
Since Hippocrates’ times, patients and clinicians have been meeting on a one-to-one 
basis. It is unclear, however, whether such one-to-one appointments are the most 
effective and efficient way of informing patients about their health status and improving 
their ability to manage their own health and illness. Group medical appointments 
(GMAs) may be a valid alternative for patients with a primary (chronic or non-chronic) 
physical illness to help improve both their health status and well-being while making 
better use of one of the most precious resources in health care: time. In recent decades, 
patients have participated in GMAs in various healthcare organisations in the US and 
other Western countries. This paper describes the results of a systematic analysis of 
the effects of GMAs in diverse outpatient care settings. For the purpose of this review, 
the term ‘outpatient care’ is used to cover a range of ambulatory care modes and 
includes care services delivered in primary care, specialty clinics and hospital outpatient 
settings.
Description of the condition 
GMAs are currently being offered to people with a wide array of primary physical 
illnesses, from children and adults with diabetes to patients recovering from bone marrow 
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transplantation (Sadur 1999; Meehan 2006; Edelman 2010; Rijswijk 2010). Most of the 
people attending GMAs have a chronic condition needing continuous management, 
although GMAs are also offered to individuals with a non-chronic physical illness such 
as a total hip or knee replacement. The focus of this review will be on GMAs for people 
with a primary physical illness, chronic or non-chronic. As some may also have mental 
health issues, these will be addressed during the GMA, particularly when they influence 
the course or management of the physical condition, but studies that focus solely on 
mental illness are not included in this review.
Description of the intervention 
A GMA is a series of one-to-one patient-clinician contacts in the presence of at least two 
other voluntarily attending fellow patients and their partners/carers, where the clinician is 
generally supported by a group facilitator. A GMA typically lasts 1 to 2 hours and serves 
as a substitute for the clinician’s individual appointments with the attending patients at 
a primary care or specialty clinic, or in a hospital outpatient setting. The items that the 
clinician attends to during the GMA are largely the same as those addressed during an 
individual visit. Patients and carers can ask the clinician and fellow patients and their 
carers questions and all parties can learn from each other’s knowledge and experiences. 
In this review, the term carers is used to refer to the accompanying spouses, partners, 
parents, adult children or other family members or friends who are closely involved in 
the patient’s life. Since during a GMA the clinician does not need to repeat information 
that is relevant for all participants, the time saved can be spent on the patients’ medical 
or psychosocial needs, patient/carer education, and patient empowerment.
Distinction between GMAs and other group meetings
GMAs are not to be confused with other group meetings for patients, such as group 
therapy, group education or peer support groups. Although their working mechanisms 
can be similar to those of GMAs, the focus of these group sessions is not primarily on 
medical issues. Whereas a GMA serves as a full substitute for a traditional consultation 
with the clinician, the scope of the other types of group meetings is often limited to 
one or two aspects, such as education, support or psychotherapy (Noffsinger 2009; 
Zantinge 2009; Edelman 2010). Thus, GMAs primarily focus on the management of the 
participants’ physical condition with associated psychosocial aspects coming second, 
while group therapy or peer support groups primarily focus on emotional, psychological 
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or social matters. Moreover, the agenda in GMAs is set by the patient’s individual 
questions, while the agenda in group education is pre-specified and clinician-led.
Conceptual framework
There is large diversity in the design of GMAs, as well as the types of patients and 
clinicians involved in them, posing key challenges for reviewers. To provide a consistent 
approach to describing and evaluating the different types of GMAs, we have developed 
a conceptual framework that describes three core GMA dimensions, which we will 
elucidate next.
conceptual framework for GMAs
Design Patient group team
Number of GMAs offered Continuity versus non-continuity Type of clinician
Time between successive GMAs Heterogeneous versus 
homogeneous
Presence of group 
facilitator
Duration of GMA Chronic versus non-chronic Training of team
Number of patients per GMA Children, adults, older adults
Design
GMA design has four determining components: the total number of GMAs provided 
(typically around 8 with a broad range from 1 to 36), the interval between successive 
GMAs (e.g. a month, 6 months, a year), the number of patients per GMA (6 to 10 in most 
cases) and GMA duration (typically 2 hours with a range of 1 to 3.5 hours). Differences 
in these features could, hypothetically, account for differences in effects on outcomes.
The effects on patients attending GMAs of longer duration or multiple GMAs may be 
reinforced due to patients having received repeated information. Attending successive 
GMAs may put participants more at ease as they become accustomed to the care 
model and the other participants, which could improve satisfaction and outcomes. 
The number of participants may also influence outcomes. Edelman 2010 suggested 
five to ten patients as the ideal group size. Fewer participants may negatively affect 
the interaction and information exchange, while more participants might compromise 
the attention paid to individual needs. The time between successive GMAs may also 
be relevant. It is conceivable that the longer the period between successive GMAs, 
the lower their effectiveness may be. After six or 12 months, for instance, patients may 
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have to make a new start in the group and may have forgotten information provided 
in the previous appointment(s).
Types of patient groups
As to patient groups, participant continuity or non-continuity is a factor of interest, as 
are group homogeneity or heterogeneity and whether patients have a chronic or an 
acute illness and whether they are of similar or different ages.
Non-continuity GMAs are stand-alone group visits with different participants attending 
each appointment, although groups are usually homogeneous (patients with similar 
diagnoses). Non-continuity GMAs can comprise drop-in groups where no scheduling is 
necessary in advance (the so-called Drop In Group Medical Appointments (DIGMAs)) or 
GMAs that are scheduled for specific groups. GMAs are usually diagnosis- or population-
specific while DIGMAs, depending on their design, can consist of homogeneous or 
heterogeneous patient groups, where a different group of patients can ‘drop and join in’ 
each day or week depending on their medical needs (Pennachio 2003; Noffsinger 2003).
In case of continuity GMAs, the same cohort of patients is offered a series of group visits 
scheduled during a given period (Pennachio 2003; Trilling 1999). Attending successive 
GMAs together with the same group of patients may create a safe atmosphere in which 
participants will feel free to ask and respond to questions. In heterogeneous groups, the 
participants will have different diagnoses and might hence learn less from each other 
than participants in homogeneous patient groups. It is likely that groups of patients 
with chronic illnesses will respond differently to GMAs than groups of patients with non-
chronic illnesses. The unexpected relapses and recoveries so characteristic of chronic 
diseases may imply a higher need for peer support in this population, reinforcing the 
effect of this aspect of GMAs. Conversely, as in non-chronic diseases peer support may 
be less (well) organised (e.g. by patient advocacy groups), the benefit of peer support 
provided during GMAs may be larger in non-chronic populations.
As patients of all ages can participate in a GMA, we will consider the results for the 
following age groups: children (<18 years), adults (18–65 years) and older adults (>65 
years). Depending on the practices of the treatment facility, the partners or carers of the 
patients may be invited to also attend the GMA, where their attendance is assumed to 
foster the positive effects of GMAs (e.g. by helping the patient retain new information).
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Team
The third key dimension of GMAs is the professional(s) conducting the GMA. We will 
consider the attending clinician, the presence /absence of a group facilitator and 
the training of the GMA provider(s). A GMA team typically consists of a clinician, a 
group mentor or facilitator and sometimes an administrator (Noffsinger 2009), where 
the clinician is a health professional whose consultations with individual patients are 
substituted by the GMAs. Clinicians can be a physician, physician assistant, specialised 
nurse, nurse practitioner or a paramedical professional. Usually, GMAs are provided 
by one clinician, but more than one may attend. A group mentor or facilitator is often 
added to facilitate the group process by fostering interactions between the health 
professional(s) and individual patients and exchanges among participants, and by 
managing time. A group facilitator may thus promote GMA course and outcomes. 
Among other professionals, this role can be fulfilled by a psychologist, a behaviourist or 
a specialised nurse who is acquainted with group processes. Some GMAs are specifically 
designed to be conducted without a group mentor. The education and training of team 
members can range from targeted GMA training to ‘learning by doing’ depending 
on their backgrounds. A team explicitly trained in conducting GMAs, for example by 
acquiring additional techniques in (group) interviewing and group management, may 
boost GMA effectiveness.
Description of control intervention
The effects of GMAs are compared to usual care defined as (regular) one-to-one patient-
clinician appointments. GMA studies that include additional care such as telephone 
follow-up or home visits alongside GMAs have been excluded from this review. 
How the intervention might work 
Interest in GMAs derives from the motivation of healthcare consumers and providers 
to continuously search for the most effective and efficient way to receive and deliver 
optimal care. The effects of GMAs can be assessed at three different levels, that of the 
patients and their carers, their clinicians and at the cost level.
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Patients and carers
In the literature, compared to usual one-to-one outpatient appointments, GMAs have 
been reported to result in fewer hospitalisations and emergency visits, increased patient 
satisfaction and self-efficacy in chronically-ill older patients (>60 years) and improved self-
efficacy and general health status in adult patients with diabetes (Sadur 1999; Wagner 
2001; Scott 2004). In the latter group, a randomised controlled trial (RCT) demonstrated 
more frequent preventive procedures among patients attending GMAs, resulting in a 
better general health status (Scott 2004). Sadur 1999 found greater patient satisfaction 
with diabetes care, greater self-efficacy, better glycaemic control, and lower service 
utilisation among diabetic patients who were randomly allocated to GMAs rather than 
usual care.
There is evidence to demonstrate that GMAs have substantial added value that not 
only derives from the patients having a health professional’s attention but also from 
sharing mutual experiences, particularly for patients with a chronic disease (Sadur 
1999; Wagner 2001; Scott 2004; Edelman 2010). GMAs are thought to help improve 
self-management skills and quality of life by augmenting the patients’ self-efficacy. The 
quality of life of chronically-ill people is influenced strongly by their self-management 
capacity. Optimal self-management entails that people take responsibility for their own 
health and well-being and are capable of managing any long-term illness (Lorig 2003). 
One way to gauge a patient’s self-management abilities is to assess self-efficacy, i.e. 
his/her confidence in being able to successfully perform a specific health-related task 
or behaviour (Bandura 1997). Self-efficacy can be raised by increased knowledge, social 
support and successful personal experiences or from those of others to whom one can 
relate (Bandura 1997; Bodenheimer 2002; Bandura 2004; Sol 2005). These attributes 
are more readily available during a GMA than during one-to-one appointments. Any 
positive effects of GMAs may thus be mediated by improved self-efficacy derived from 
increased social support and learning about successful experiences from the other GMA 
participants.
During GMAs, information from fellow patients can be just as or even more relevant 
than information provided by the attending professionals (Tattersall 2002). Peers with 
real-life experiences are strong advocates and living examples of the impact and pros 
and cons of a treatment or lifestyle change. Patients and carers acting as experts on 
their own disease and daily life can thus be a valuable support for their peers during 
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group visits. Finally, patients have more time with their consulting clinician and receive 
more and different information about their disease and symptoms in a GMA setting 
(Zantinge 2009).
GMAs have potential disadvantages or may have adverse effects. When offering medical 
care in a group setting, the foremost challenge is to secure patient privacy while still 
enabling all participants to talk freely about their problems. How both privacy and safety 
can best be safeguarded partly depends on a country’s legislation and the policy of 
the healthcare provider. Always, patients need to be informed correctly and in advance 
about what to expect and to give their informed consent for their medical details to 
be discussed in the group. Furthermore, both patients and their carers need to declare 
that they will not share information about other patients with third parties. Participation 
in GMAs is always voluntary and one-to one visits with their clinician need to be made 
available at all times, especially since patients may not always feel free to raise all issues 
relevant to the management of their condition during a GMA (e.g. requests for certain 
medications or matters relating to sensitive information like sexuality or fertility). Patients 
may also perceive that too little attention has been paid to their individual needs, while 
the 1-to-2-hour investment imposes a larger burden on their schedules than the 10 to 
30 minutes an individual visit usually takes. Here, people holding down a full-time job 
are likely to be more reluctant to opt for GMAs. 
Clinicians
Several advantages for clinicians have been described. Clinicians state that GMAs 
allow them more time to provide the patients with information while still leaving time 
to address any psychosocial aspects of their disease(s) (Zantinge 2009; Rijswijk 2010). 
The time gained from not having to repeat the same information to all patients may 
be used to stimulate the exchange of experiences among patients and to elaborate on 
specific aspects of a disease. Clinicians report that they learn from their patients during 
a GMA, can pay more attention to psychological and social aspects of the disease, have 
the opportunity and advantage to see a group of patients with the same disease in one 
visit and see their patients interact with other patients, which can prompt them to ask 
critical questions (Zantinge 2009). Clinicians who conducted GMAs also report a high 
level of job satisfaction (Zantinge 2009; Blumenfeld 2003).
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Not all clinicians will be equipped to conduct GMAs. The health professional has to have 
a basic interest in offering health care in a group setting and will have to have or develop 
specific skills in order to be able to effectively conduct a GMA. Usually, training to gain 
skills in group facilitation is necessary (Beck 1997; Blumenfeld 2003; Zantinge 2009).
Costs
There are two perspectives to improving efficiency by GMAs:
1. having patients use fewer care resources
2. reducing the cost price per outpatient visit.
Cost-effectiveness studies show variable results (Jaber 2006). Although there is some 
evidence of reduced resource use by patients having attended a GMA, for instance in 
terms of lowered emergency department use, fewer hospital admissions and visits to 
medical specialists (Sadur 1999; Coleman 2001; Clancy 2008), there is no consistent 
evidence of cost savings, which may also vary for the different reimbursement systems 
in use (Scott 2004; Trento 2008). The cost price of a GMA depends on the number of 
patients attending, the time scheduled for one-to-one visits with individual patients of 
the same group, the number of health professionals conducting the GMAs, and national 
reimbursement systems. If GMAs enable clinicians to see more patients within the same 
timeframe of one-to-one appointments and GMA costs are adequately reimbursed, the 
care model would make more efficient use of valuable clinician time. However, the initial 
training of clinicians and group mentors in GMA delivery may constitute a considerable 
cost and time investment. Offering a series of GMAs to patients who would otherwise 
use fewer one-to-one visits may also increase health costs. Moreover, from a societal 
point of view, if patients attend more 1-to-2-hour GMAs than they would individual 
10-to-30-minute visits, they have less time for work and other social activities, adding 
to the social burden.
Why it is important to do this review 
Group medical appointments are designed to be an effective and efficient way of 
delivering healthcare to patients with a physical illness. This review aims to systematically 
evaluate the outcomes of GMAs and to understand their overall effectiveness as a tool 
to provide ongoing care for patients with a physical illness, be they chronic or acute.
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A number of Cochrane reviews that include GMAs as one of the interventions studied 
contain management options for specific problems, for example interventions to improve 
medication adherence (Haynes 2008) or patients’ trust in doctors (McKinstry 2008). Two 
reviews focus on the effects of GMAs for a specific condition (Gagnon 2007; Homer 
2012) and two other reviews summarise the effects of GMAs for various patient groups 
(Jaber 2006; Edelman 2012). Jaber’s is a qualitative review, the search strategy was 
limited to PubMed and MEDLINE, while it included both observational and randomised 
trials and was executed seven years ago. Although more extensive and more recent, 
Edelman’s review was limited to studies in the English language, adult patients (>18 
years) with chronic conditions, and evaluations of a series of at least two GMAs. The 
current review differs from these existing Cochrane and non-Cochrane reviews in that 
we aim to evaluate the effectiveness of the GMA model irrespective of the participants’ 
physical condition and age or the number of GMAs provided.
ObjEctiVEs 
To assess the effects of GMAs on the health status and well-being of patients with a 
primary physical illness as compared to one-to-one patient-clinician appointments.
MEtHODs 
criteria for considering studies for this review 
Types of studies 
Randomised controlled trials (RCTs) including cluster RCTs.
Types of participants 
All patients with a primary physical illness, including newly-diagnosed patients.
Physical illness is defined as a chronic somatic condition or a non-chronic physical health 
problem such as infertility, excluding medical emergencies requiring acute medical 
attention. We included both children and adults receiving care from a primary care 
clinic, specialty clinic or hospital outpatient clinic (in this review denoted as ‘outpatient 
care’). Patients attended group medical appointments (GMAs) alone or together with a 
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carer defined as someone closely involved in the patient’s life such as spouses/partners, 
parents, adult children or other family members or friends. Studies that solely targeted 
carers of patients were excluded. Studies that evaluated GMAs exclusively including 
patients were not analysed separately from those that reported on GMAs with patient-
carer dyads. At all times, the main purpose of the GMA was patient care.
Newly-diagnosed patients and those with more long-standing illnesses who were familiar 
with their condition could either be seen in separate (series of) GMAs or in the same 
(series of) GMAs. Although all had a primary physical illness, patients could also have 
mental health issues, but studies focusing solely on mental illnesses were not reviewed.
Types of interventions 
A group medical appointment (GMA) was defined as (a series of) one-to-one patient-
clinician contacts in the presence of at least two other voluntarily attending patients 
with a physical illness – and, when appropriate, their carers – aimed at making better 
use of the patients’ knowledge and experience, the clinicians’ time and expertise, and 
the interactions among all parties present, and intended as a substitute for one-to-one 
appointments with a particular clinician (Jaber 2006; Noffsinger 2009). Each GMA needs to 
have at least two patients participating, but typically five to 15 patients will be attending.
Since a GMA is intended as a complete substitute for a one-to-one visit with a clinician 
and focuses primarily on the current health status of the patient, we excluded studies 
that solely reported on group psychotherapy, (parent) support groups, group self-
management or group educational programmes. 
The control intervention was (one or more) one-to-one patient-clinician appointments. 
Studies that included additional care such as telephone follow up or home visits alongside 
GMAs were not included in this review.
Types of outcome measures 
Outcomes needed to be related to patients and carers, health professionals and health 
organisations including government and health insurance companies. The type of 
outcome measure was not used as an inclusion criterion during the selection of the 
studies. We prioritised the outcomes for our review as follows:
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Primary outcomes
Primary patient-related outcomes reflecting changes to patient and/or carer health and 
well-being overall, captured by measures in the following two outcome categories:
Health-related quality of life
Health-related quality of life of patients/carers (generic as well as specific), measured 
through Patient Reported Outcome Measures (PROMS).
Physical health
Physical health of the patient, as evaluated by a health professional or laboratory or 
physiological markers (e.g. blood pressure, glycated haemoglobin).
Secondary outcomes
Patient and/or carer
•	 Psychological health, as assessed by measures such as depression or anxiety scores.
•	 Self-efficacy defined as the confidence patient has in one’s ability to reach a specified 
goal.
•	 Skills acquisition and health behaviour, including self-care skills and symptom control 
skills.
•	 Health behaviour in terms of treatment adherence and adherence to a recommended 
lifestyle.
•	 Knowledge such as knowledge of the condition and the treatment and management 
options.
•	 Support defined as practical or social support.
•	 Evaluation of care, where patients rate the patient-clinician interactions, give their 
perception of and satisfaction with the quality of care provided.
•	 Adverse effects: Did patients give permission for their medical or private information 
to be discussed in the group? Did patients feel free to raise all issues relevant to 
their physical and psychological health? Was the time investment on group visits a 
burden to patients’ schedules?
Health professionals
•	 Job satisfaction
•	 Knowledge and understanding of patient problems.
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Health economic outcomes
•	 Costs of care, cost price of intervention, time spent per patient, and costs from a 
societal perspective, such as employment rates, (school or work) absenteeism through 
sickness and medical expenses.
Service use
•	 Number and length of hospital admissions, emergency department visits, primary 
care visits.
To select outcomes within each outcome category, where more than one per study is 
reported, we adopted the following procedure: the outcomes reported in each trial 
were listed, without considering either the effect size or its statistical significance. These 
outcomes were considered independently by two review authors, using discussion to 
reach consensus and the decision which outcome measure had the most clinical relevance 
and was thus to be included in the analyses. Where this approach was not suitable, 
we selected one outcome per category per study by ranking the effect estimates and 
selecting the median effect estimate. In cases of an even number of outcomes, the 
outcome whose effect estimate is ranked n/2, where n is the number of outcomes, will 
be selected.
search methods for identification of studies 
Electronic searches 
We searched the following databases:
•	 Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane 
Library)
•	 MEDLINE (OvidSP)
•	 PsycINFO (OvidSP)
•	 EMBASE (OvidSP)
•	 Proquest
The MEDLINE search strategy is presented in Appendix 6.1. This search strategy was 
tailored to the other databases. All databases were searched from their start date to 
July 2015.
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Searching other resources 
The Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of 
Effects, and the NHS HTA database on The Cochrane Library were searched, as well as 
conference proceedings, dissertation abstracts, and ProQuest Theses & Dissertations to 
identify grey literature. The reference lists of included trials were searched for additional 
studies. The Science Citation Index was searched for publications citing the included 
studies as well as the following clinical trials registries: clinicaltrials.gov and the ISRCTN. 
The authors of included studies were contacted to locate any unpublished data. There 
was no language restriction.
Data collection and analysis 
Selection of studies 
Two authors (FS and WZ) screened all titles and abstracts identified by the search. All 
citations that were thought to meet the inclusion criteria by one of the screeners were 
retrieved in full text. Full texts of selected studies were reviewed independently to decide 
which articles fulfilled the inclusion criteria. If the same study was described in multiple 
publications, the data were compared to determine whether the study was eligible for 
inclusion. Any disagreement was resolved by discussion and consensus between the 
two authors. Potentially relevant studies excluded following examination of the full-text 
version are listed in Table 6.2, with the reason for exclusion given. 
Data extraction and management 
Two review authors (FS and WZ) independently extracted the data using a data extraction 
form based on the template developed by the Cochrane Consumers and Communication 
Review Group, which included the following components:
Methods
We extracted data about the study design, participant recruitment methods and the 
inclusion and exclusion criteria for participants, verified whether informed consent was 
obtained, whether ethical approval was described, and listed information on study 
funding, statistical methods used and consumer involvement. We assessed the risk of 
bias of the included studies, which is described below (see Assessment of risk of bias 
in included studies).
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Participant characteristics
From each study we recorded the following information on GMA participants: description 
of patients and carers, number of participants and their ages, gender, ethnicity, 
geographic location, primary health problem or diagnosis and the treatment received. 
We recorded the following information on the study: healthcare setting (hospital 
outpatient clinic, primary care clinic, speciality care clinic, community health service), 
type of healthcare system, type of reimbursement system.
Intervention
We used the conceptual framework (see Description of the intervention) for extraction 
of the details of the intervention, which includes the following domains:
1. GMA design, in terms of the duration and number of GMAs offered to the patient, 
the interval between successive GMAs, and the number of patients participating, 
as well as the possibility of attending a one-to-one appointment immediately after 
the GMA, and physical examinations conducted during the GMA.
2. Patients attending the GMA, in terms of participant continuity or non-continuity 
including drop-in groups or scheduled GMAs, heterogeneous or homogeneous 
patient groups, chronic versus non-chronic diseases including patients’ diagnoses 
and their ages, and attendance of carers (number and relationship to the patient).
3. Team, in terms of the number of clinicians present, their professional characteristics, 
whose clinician’s appointment is substituted, the presence of a group mentor/
facilitator or other attending clinicians or assistants and their role(s), GMA 
competence/experience, and type of GMA training received.
Outcomes
We listed all primary and secondary outcomes reported in each included study and 
described how they were assessed. We reported on the timing and length of follow-up in 
Table 6.3. Our analyses were confined to those outcomes selected a priori as described 
in Types of outcome measures.
Results
Results are reported per selected outcome measure for each intervention and control 
group. Both dichotomous and continuous outcomes are reported separately.
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Assessment of risk of bias in included studies 
We assessed and report on the methodological risk of bias of included individual 
RCTs in accordance with the Cochrane Handbook (Higgins 2011) and the guidelines 
of the Cochrane Consumers and Communication Review Group (Ryan 2011), which 
recommended the explicit reporting of the following individual elements for RCTs: 
random sequence generation; allocation concealment; blinding (participants, personnel); 
blinding (outcome assessment); completeness of outcome data; selective outcome 
reporting. For cluster RCTs we additionally assessed recruitment bias and loss of clusters. 
Other sources of bias included baseline imbalances for both individual and cluster RCTs 
and comparability with individually randomised trials for cluster RCTs. In all cases, two 
authors (FS and WZ) independently assessed the risk of bias of included studies, with 
any disagreements being resolved by discussion and consensus, resulting in a rating 
of high, unclear or low risk of bias for each domain.
Studies were deemed to be at the highest risk of bias when they received scores of 
high or unclear risk of bias on the sequence generation, allocation concealment and 
completeness of outcome data domains. Completeness of outcome data was rated as 
‘at low risk of bias’ when there were complete data for 75% or more of the participants, 
as ‘unclear’ if completeness of data could not be determined, and ‘at high risk of bias’ 
when 75% or more of the data were not complete.
We contacted study authors for additional information about the included studies or for 
clarification of the study methods as required. We incorporated the results of the ‘Risk of 
bias’ assessment into the review through standard tables, systematic narrative description 
and commentary about each of the elements, leading to an overall assessment of the 
risk of bias of all included studies and a judgement about the internal validity of the 
review’s results.
Measures of treatment effect 
We used relative risks (RR) and 95% confidence intervals (CI) to compare dichotomous 
outcomes between groups. Continuous data from the same scale are compared by mean 
differences (MD) and 95% CI, and continuous data from different scales by standardised 
mean differences (SMD).
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unit of analysis issues 
In case of individual randomised controlled trials the unit of analysis was determined as 
individual patients with physical illness. The analysis must take into account the level at 
which randomisation occurred. If we identified included studies using a cluster-randomised 
design, but where inference is intended at the level of the individual, they were analysed 
with intra-cluster correlations (ICCs) being taken into account. Estimates of the ICCs were 
obtained from contacting authors or imputed using external estimates. If this was not 
possible, we report effect estimates and annotated ‘unit of analysis error’ (Horvat 2011).
If the cluster-randomised trials were analysed correctly, we used the adjusted Mantel-
Haenszel test as described by Donner and Klar (Donner 2002) to combine the results of the 
individually randomised controlled trials with the results of the cluster-randomised trials.
If case studies compared more than two intervention groups, all relevant experimental 
intervention groups were pooled into a single group and all relevant control intervention 
groups pooled into a single control group (Higgins 2011).
Dealing with missing data 
When possible, we used the results from intention-to-treat analyses. We contacted the 
trial authors in case of missing summary data. For the remaining missing outcome or 
summary data we imputed missing data where possible and report any assumptions 
in our review, using sensitivity analyses to evaluate the effects of any imputed data on 
pooled effect estimates. In case of missing summary data, we report the levels of loss 
to follow-up and assess this as a source of potential bias, and discuss the potential 
implications of its absence from the meta-analysis.
Assessment of heterogeneity 
In our protocol paper we described that, in the case of meta-analyses, we would first 
be assessing clinical heterogeneity and then the statistical heterogeneity. This, however, 
resulted in a very small number of studies deemed sufficiently homogeneous to pool 
results. The main objective of our review was to evaluate GMA effectiveness irrespective 
of type of patient group and intervention. In order to draw meaningful conclusions in 
line with this objective we therefore decided to assess the interventions of all studies 
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as sufficiently similar to pool results. For each of the included outcomes suitable for 
meta-analysis, statistical heterogeneity was assessed by visual inspection of the forest 
plots and by examining the Chi2 test for heterogeneity. Statistical heterogeneity was 
quantified using the I2 statistic. An I2 value of 50% or more was considered to represent 
substantial levels of heterogeneity (Higgins 2011a). After determining statistical 
heterogeneity, we narratively explored the reasons for heterogeneity by evaluating 
the following characteristics of the study or the intervention: population, number and 
duration of sessions, the presence of a group facilitator and the timing of outcome 
assessments. We used narrative exploring if subgroup analyses were not possible due 
to the relatively small number of studies included in the meta-analyses.
Assessment of reporting biases 
If ten or more studies were included in the meta-analysis, reporting biases (such as 
publication bias) were investigated using funnel plots. Funnel plot asymmetry was 
assessed visually and by formal tests. For continuous outcomes we used the test 
proposed by Egger 1997, and for dichotomous outcomes the test proposed by Harbord 
2006. When asymmetry was detected in any of these tests or suggested by the visual 
inspection, we contacted study authors asking them to provide missing outcome data. 
If this was not possible, and the missing data were likely to introduce serious bias, we 
explored the impact of including these studies in the overall assessment of results by 
conducting a sensitivity analysis.
Data synthesis 
We combined data across studies quantitatively in a meta-analysis only if it was appro-
priate to do so. Due to the anticipated variability in the populations and interventions 
reported on, we used a random-effects model for the meta-analysis. If meta-analysis was 
possible (i.e. there were at least two studies that were sufficiently similar), we pooled 
effect measures (relative risks, mean differences or standardised mean differences) 
and calculated 95% confidence intervals to assess the effects of GMA visits relative to 
usual care. We describe the findings in the review text while considering the potential 
impact of bias and the degree of heterogeneity and their possible sources. The results 
are presented for subgroups, if appropriate (see Subgroup analysis and investigation 
of heterogeneity).
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If we were unable to conduct a meta-analysis, we conducted a narrative synthesis of 
the results. In our narrative synthesis, for the comparison ‘GMA versus care as usual’, 
we report: the median effect size across all comparisons, the median effect size across 
comparisons without unit of analysis errors, and the number of comparisons showing 
statistically significant effects. In the narrative synthesis and in any statistical synthesis 
we synthesised 1) according to the different types of interventions (grouping similar 
interventions together), 2) according to the types of outcomes, and 3) according to the 
strength of evidence by using the GRADE guidelines. In accordance with the GRADE 
guidelines we downgraded a starting rating of ‘high quality’ evidence for RCTs by one 
level for serious concerns (or by two levels for very serious concerns) about risk of bias, 
inconsistency, indirectness, imprecision or publication bias.
summary of findings table
We specified the following outcomes for inclusion in Table 6.1:
•	 Health-related quality of life
•	 Diabetes-specific HRQOL
•	 Physical outcomes
•	 Self-efficacy and self-management
•	 Psychological health
•	 Patient evaluation of care
•	 Adverse events
Additionally, we compared the effects of GMAs with one-to-one appointments on 
skills acquisition and health behaviour, patient knowledge, social support, emergency 
department visits, hospital admissions, and costs of healthcare use.
subgroup analysis and investigation of heterogeneity 
As the number of studies included in the meta-analyses was too small, we were not able 
to run subgroup analyses to explore reasons for statistical heterogeneity. Reasons for 
heterogeneity were thus explored narratively, as described in the section Assessment of 
heterogeneity.
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sensitivity analysis 
We conducted sensitivity analyses based on the ‘risk of bias’ assessment. Studies with 
the highest risk of bias were to be removed from the analysis for a sensitivity analysis if 
the number of included studies was sufficiently large. Studies with a high risk of bias were 
defined as trials being scored as having high or unclear risk on sequence generation, 
allocation concealment and completeness of outcome data domains of the ‘risk of bias’ 
tool. The effects of any imputed data on pooled effect estimates were also investigated 
through sensitivity analyses, if necessary.
Ensuring consumer relevance
For this review, consumer relevance was ensured by drawing on the list of consumer-
focused outcomes from the Cochrane Consumers and Communication Review Group 
(see http://cccrg.cochrane.org/author-resources).
Representatives of two relevant patient advocacy groups in the Netherlands agreed 
to participate in a consultation group, i.e. the Dutch Association of People with Atopic 
Dermatitis (www.vmce.nl) and the Dutch Society of Muscle Disorders (www.spierziekten.
nl). The consultation group provided feedback on the draft protocol and the draft review, 
from a consumer’s point of view. Four of the authors are clinicians with experience with 
GMAs and commented from their professional perspective. The protocol and review 
also received consumer feedback through the Cochrane Consumers and Communication 
Review Group’s editorial processes.
rEsuLts 
Description of studies 
Results of the search 
In total, we identified 5,599 unique citations from the electronic database searches 
and 273 citations from other sources. Of these, 5,764 publications were excluded after 
screening of title and abstract. We retrieved 108 potentially relevant publications in full 
text for detailed evaluation, of which 41 met our inclusion criteria, with several describing 
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the same study or study protocol. This resulted in 62 studies being excluded and 22 
being included for review. See study flow diagram Figure 6.1.
Characteristics excluded studies
Sixty-six publications, referring to 61 studies that were assessed in full text, were excluded 
due to the following reasons (See Table 6.2):
a. the study was not a randomised controlled trial (n=17, Davies 1994; Dufresne 2006; 
Collins; Firoozi 2013; Gaynor 2007; Griffin 2009; Griffiths 2009; Jessee 2012; Keller 
1997; Lin 2008; Martin 2007; Oehlke 2006; Osborn 1981; Rothwell 2012; Saysana 
2012; Sidorsky 2010; Stein 1977)
b. inappropriate study design (n=4, Escobar 2001 Masley 2001; Collins; Zazpe)
c. inappropriate patient group (n=5, Lofvenmark 2011; Kalavainen 2011; Farnam 
2014; Nova 2001; Walker 2012)
d. the GMA intervention was additional to care as usual (n= 5, Cohen 2011; Crowley 
2014; Edelman 2010; Smith 2014; Taveira 2014)
e. the intervention involved group education rather than a GMA (n=11, Abram 2007; 
Calzone 2005; Gronning 2012 ;Heller 1988; McGhan 2010; Elzen 2007; Fisker 2013; 
Lincoln 2000; Murphy 2012; Raz 1988; Rodgers 1999)
f. no GMA according to our definition (n=16, Coleman 1999; Deakin 2006; Dineen 
2013; Hederos 2005; Laakkonen 2012; Lamb 2009; Liu 2012; Mansergh 2010; Moe 
2010; Naik 2011; Primdahl 2014; Salanave 2008; Schaeffert 2013; Shaw 2003; Wade 
2003; Wagner 2001)
g. GMA was not the only intervention tested in the GMA intervention group (n=3, 
Den Hartog 2012; Sadur 1999; Visser 2011)
Characteristics of ongoing studies
We were able to identify three ongoing studies through trial registers and personal 
communication. Bruinsma 2015; Cnossen 2014; Zijlstra 2014 are trials currently being 
executed in the Netherlands, evaluating the Centering Pregnancy model and GMAs for 
pregnant women, children with constitutional eczema and children and adults with sickle 
cell disease, respectively. Allen 2013 published a study protocol and inclusion numbers 
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Figure 6.1 study flow diagram.
Records identified through database 
searching: (N=8,050)
- Medline, Embase, Psychinfo, 
Cochrane, Central, Proquest
Records after duplicates removed: 
(N=5,872)
- Database searching (N=5,599)
- Other resources (N=273)
Records excluded:
(N=2,760)
Records excluded:
(N=5,764)
Title & Abstract screened:
(N=5,872)
Full-text papers assessed 
for eligibility:
(N=108)
Full-text papers excluded, 
with reasons:
(N=66 papers & N=61 
studies)
Papers included:
(N=41)
Studies excluded:
(N=22)
Additional records identified 
through other sources: (N=273)
- Clinicaltrials.gov: (N=220)
- ISRCTN: (N=26)
- Snowball check: (N=25)
- Personal communication: 
(N=2)
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table 6.2 Table characteristics of excluded studies
Abram 2007 No GMA according to definition – educational session
Calzone 2005 Inappropriate study design – ill-defined control arm, and no GMA 
according to definition – educational session
Cohen 2011 No GMA according to definition – GMA added to usual care
Coleman 1999 No GMA according to definition – chronic care clinics, including peer 
support group
Collins 2007 Inappropriate study design - retrospective observational cohort study
Crowley 2014 Inappropriate study design – GMA added to usual care and control 
group received no active intervention
Davies 1994 Inappropriate study design – not randomised
Deakin 2006 No GMA according to definition – intervention led by peers not clinicians
Den Hartog 2012 No GMA according to definition – combined intervention
Diaz-Arriabas 2015 Inappropriate study design – control intervention is group intervention 
as well
Dineen 2013 No GMA according to definition – GMA was used as ‘booster’ and 
support session after the main intervention
Dufresne 2006 Inappropriate study design – no randomisation
Edelman 2010 No GMA according to definition – GMA added to usual care
Elzen 2007 No GMA according to definition – educational session
Escobar 2001 Inappropriate study design – control condition comprised home visits 
instead of individual appointments
Farnam 2014 Inappropriate patient group – participants experience no physical 
problems
Firoozi 2013 Inappropriate study design – not randomised
Fisker 2013 No GMA according to definition – educational session
Gaynor 2007 Inappropriate study design – clinical inquiry
Griffin 2009 Inappropriate study design – not randomised
Griffiths 2009 Inappropriate study design – qualitative study
Gronning 2012 No GMA according to definition – educational intervention
Hederos 2005 No GMA according to definition – individual consultations combined 
with group discussion
Heller 1988 No GMA according to definition – educational intervention
Jessee 2012 Inappropriate study design – not randomised
Kalavainen 2011 Inappropriate study design – ill-defined intervention, and 
inappropriate patient group – absence of physical illness (obesity)
Keller 1997 No GMA according to definition – rehabilitation programme and 
inappropriate study design – not randomised
Laakkonen 2012 No GMA according to definition – self-management programme in 
group setting
Lamb 2009 No GMA according to definition
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Lin 2008 Inappropriate study design – no randomisation
Lincoln 2000 No GMA according to definition – group-education session versus 
information leaflet
Liu 2012 No GMA according to definition – group session guided by patient
Lofvenmark 2011 Inappropriate patient group – family members, not patients
Mansergh 2010 No GMA according to definition – behavioural intervention
Martin 2007 Inappropriate study design – no randomisation
Masley 2001 Inappropriate study design – ill-defined intervention and control arm
McGhan 2010 No GMA according to definition – educational intervention
Moe 2010 No GMA according to definition – intervention combining group 
consultations and multidisciplinary care by telephone
Murphy 2012 No GMA according to definition – educational session
Naik 2011 Inappropriate study design – no control arm and no GMA according to 
definition – self-management intervention
Nova 2001 Inappropriate patient group – absence of physical illness (obesity)
Oehlke 2006 Inappropriate study design – no randomisation
Osborn 1981 Inappropriate study design – no randomisation
Primdahl 2014 No GMA according to definition – shared care intervention between 
GP and medical specialist
Raz 1988 No GMA according to definition – educational session
Rodgers 1999 No GMA according to definition – educational session
Rothwell 2012 Inappropriate study design – no randomisation
Sadur 1999 No GMA according to definition – GMA is part of multidisciplinary 
treatment setting
Salanave 2008 No GMA according to definition
Saysana 2012 Inappropriate study design – no randomisation
Schaeffert 2013 No GMA according to definition – therapy not consultation
Shaw 2003 No GMA according to definition – no group medical consultation
Sidorsky 2010 Inappropriate study design – retrospective observational cohort study
Smith 2014 No GMA according to definition
Stein 1977 Inappropriate study design – no randomisation
Taveira 2014 No GMA according to definition – GMAs added to care as usual
Visser 2011 No GMA according to definition – intervention combining GMA with 
IPad support
Wade 2003 No GMA according to definition – rehabilitation programme
Wagner 2001 No GMA according to definition – group session does not include 
consultation
Walker 2012 Inappropriate patient group – absence of physical illness (obesity)
Zazpe 2008 Inappropriate study design – no comparison of GMAs and individual 
appointments
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in clinicaltrial.gov. We were not able to contact the author or to ascertain whether this 
study was ongoing or discontinued.
Included studies 
We describe the main characteristics of the 22 studies in Table 6.3. Twenty-one were 
published in English and one was published in Italian. Thirteen were from the USA, 
four from Italy, two from the Netherlands, one from Australia, one from Sweden and 
one from Iran. No randomised studies were published in the 1980s, one was published 
in 1998, 13 between 2000–2010, and eight after 2010. The studies varied in size, with 
seven studies involving fewer than 100 patients, five involving 100–200 patients, six 
involving 200–500 patients, and four involving 500–1,000 patients. All included studies 
were RCTs. Two studies used cluster randomisation (Anderson 2013; Jafari 2010) and 
three were feasibility studies (Dorsey 2011; Gutierrez 2011; Visser 2015). We contacted 
two authors (Goldstein 2007; Schofield 2015) to obtain data after publication of a 
study protocol, with both authors responding. For more detailed information of study 
participants, in- and exclusion criteria, outcomes measured, and reasons for risk of bias 
per study, see the online version of this review.
Characteristics of the included studies
The 22 studies selected for review included 5,965 patients and 176 carers. The number of 
participants in each study varied from 52 to 815 (mean: 272). Ten studies were conducted 
in hospital-based clinics or university centres (Dorsey 2011; Ickovics 2007; Ford 2002; 
Porta 2004; Schofield 2015; Seesing 2014; Trento 2001; Trento 2005; Trento 2008; 
Visser 2015). Eight studies were conducted in primary care facilities (Beck 1997; Clancy 
2003; Clancy 2007; Coleman 2001; Gutierrez 2011; Jafari 2010; Schillinger 2009; Scott 
2004; Yehle 2009). Four studies were conducted in specialty care clinics: two veteran 
centres (Cole 2013; Goldstein 2007, an audiology clinic (Collins 2013) and a cardiology 
centre (Yehle 2009). Three studies focused specifically on care for veterans (Cole 2013; 
Collins 2013; Goldstein 2007) and one was set in an antenatal clinic (Anderson 2013). 
HRQOL (health-related quality of life) was the primary outcome measure in four studies, 
physical outcomes in five, psychological health in one, self-efficacy in three, knowledge 
in two, skills acquisition and health behaviour in two, economic outcomes in one, patient 
evaluation of care in four and feasibility in three studies.
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Characteristics of the intervention
There was considerable variation in the GMAs reported on. In this section we will describe 
the various GMAs in terms of their designs, the patients/ participants attending and 
the health professionals delivering the intervention. The largest variation was found 
in GMA design (number of GMAs, intervals between successive GMAs, duration of 
GMAs, number of patients per GMA). The variation in patient groups (patient continuity 
vs patient non-continuity, heterogeneous vs homogeneous, chronic vs non-chronic, 
children/adults/older adults) was relatively small, with all the studies we reviewed focusing 
on adults with chronic conditions in homogeneous groups, except for the studies on 
pregnant women. The majority of studies did not provide full descriptions of the GMA 
team (type of clinician(s), presence of group facilitator, training). In half of the studies it 
was the primary care physician whose appointment was substituted by the GMA. For 
more details on the characteristics of the included studies and the interventions, see 
Table 6.3.
Design
The number of GMAs offered varied from a single session (two studies: Seesing 2014, 
Visser 2015) to 20 sessions (for example Porta 2004).The multiple sessions were offered 
within a few months (Clancy 2003) up to 5 years (Porta 2004). Nineteen studies evaluated 
multiple GMAs comprising 3 to 24 sessions, with numbers being partly determined 
by the follow-up duration of the study. In twelve studies the time between successive 
GMAs was less than a month and in five studies between 2–6 months. In 16 studies the 
duration of GMAs was less than two hours, while this was more than two hours in four 
studies. Twelve studies included fewer than eight and eight studies more than eight 
patients. Anderson 2013, Ford 2002, Goldstein 2007, Gutierrez 2011 and Yehle 2009 
did not describe more than a few aspects of their GMA design. The majority of studies 
used multiple GMAs with a maximum duration of 2 hours. It was the number of GMAs 
that varied the most among the studies reviewed.
Patient group
Thirteen studies evaluated continuity groups, with the same group of patients attending 
subsequent GMAs. Only Collins 2013 studied non-continuity groups, which was partly 
due to the cross-over design of the study. The other studies either reported on a single 
GMA (2 studies) or did not describe group compositions (6 studies). Most of the studies 
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evaluated GMAs for homogeneous groups, i.e. patients with the same diagnosis, with 
the exception of two studies that included chronically ill older patients (Beck 1997, 
Coleman 2001), although chronically ill, high-utilising older patients can be considered 
more or less homogeneous in terms of impact on quality of life, psychological and 
economic outcomes. Of the 22 studies reviewed, 17 included groups of chronic patients, 
with nine studies evaluating patients with diabetes, two chronically ill older patients, 
two neurological patients, two cancer patients, one patient with hypertension, and 
one patient diagnosed with heart failure. The studies considering non-chronic groups 
concerned pregnant women (Anderson 2013; Ickovics 2007; Jafari 2010) and patients 
using hearing aids (Collins 2013). Twenty studies included adult participants and two 
older adults. None involved children. In sum, most studies focused on GMAs for 
homogeneous groups of adults with similar chronic somatic conditions.
Team 
As to the clinicians whose individual appointments were substituted by the GMAs, in 
10 studies this was the primary care physician, in four studies a nurse practitioner, in 
the other studies it was the midwife, dietician or audiologist, oncologist or neurologist. 
Nine studies explicitly mentioned the presence of a group facilitator and another nine 
describe that the team received training in how to conduct GMAs. With respect to 
the theoretical framework of the working mechanisms of the intervention, five studies 
cited the Chronic Care Model (Beck 1997; Coleman 2001; Clancy 2003; Clancy 2007; 
Schillinger 2009). Being members of the same research group, Porta 2004; Trento 2001; 
Trento 2005; Trento 2008 all evaluated GMAs for patients with type II or type I diabetes. 
Anderson 2013 and Ickovics 2007 based their group prenatal care on the Centering 
Pregnancy model originated by Rising 1998. Ickovics 2007 described Bandura’s principles 
of social cognitive theory as the basis for their GMAs (Bandura 1997). The Jafari 2010 
and Ford 2002 studies both also describe GMAs for prenatal care, and, although they 
did not specifically base their group visits on the centering pregnancy model, they 
both describe a focus on education, skills building, and self-care, mentioning the social 
cognitive theory. Two studies (Seesing 2014; Visser 2015 evaluated a single GMA for 
specific patient groups (neurological and breast-cancer patients, respectively) as a 
substitute for a regular individual appointment.
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Characteristics of the control interventions
In all studies the control interventions consisted of one or more one-to-one appointments, 
with most lasting 15–30 minutes (Coleman 2001; Dorsey 2011; Ickovics 2007; Jafari 2010; 
Seesing 2014; Trento 2005; Visser 2015; Yehle 2009), see Table 6.3. Of 13 studies we 
gathered that they provided usual care, with seven studies providing additional care 
(on top of usual care) offering educational or individual goal-setting sessions or extra 
individual appointments with professionals similar to the additional care made available 
in or alongside the GMAs (Clancy 2003; Clancy 2007; Cole 2013; Collins 2013; Trento 
2001; Trento 2005; Trento 2008). Gutierrez 2011 and Schillinger 2009 did not describe 
the control intervention.
risk of bias in included studies 
We tested each study for six main risks of bias criteria: non-random sequence generation, 
no allocation concealment, no blinding of participants and personnel, no blinding of 
outcome assessment, incomplete outcome data, selective reporting, as well as weighing 
other sources of potential bias Ryan 2013. Two studies were categorised as being at 
high risk of bias, receiving ‘high’ or ‘unclear’ ratings on sequence generation, allocation 
concealment and completeness of outcome data Ford 2002; Gutierrez 2011. The risk of 
bias of three studies was deemed ‘high’ for completeness of outcome data regarding all 
outcome measures described Anderson 2013; Goldstein 2007; Yehle 2009. Goldstein’s 
data only became available through personal communication. Thirteen of the 22 studies 
(60%) met four or more criteria for ‘low’ risk of bias Beck 1997; Clancy 2007; Cole 2013; 
Coleman 2001; Collins 2013; Ickovics 2007; Porta 2004; Schillinger 2009; Schofield 2015; 
Seesing 2014; Trento 2001; Trento 2005; Trento 2008. See Figure 6.2 and Figure 6.3.
Allocation (selection bias) 
Random sequence generation was described and adequate in all but one study: 
Anderson 2013; Beck 1997; Clancy 2003; Clancy 2007; Cole 2013; Coleman 2001; 
Collins 2013; Dorsey 2011; Ickovics 2007; Jafari 2010; Goldstein 2007; Gutierrez 2011; 
Porta 2004; Schillinger 2009; Schofield 2015; Seesing 2014; Trento 2001; Trento 2005; 
Trento 2008; Visser 2015; Yehle 2009. Ford 2002 did not report sufficient information 
to determine the risk of selection bias. For most studies randomisation was performed 
using computer-generated random-number sequencing or by using a table of random 
numbers with stratification for clinician, treatment site, language or diagnosis. Five studies 
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used blocked randomisations. The intervention assignment was concealed properly in 
eight studies: Anderson 2013; Beck 1997; Clancy 2003; Clancy 2007; Cole 2013; Collins 
2013; Dorsey 2011; Ickovics 2007; Seesing 2014. The remaining twelve studies did not 
describe the allocation concealment in sufficient detail to permit evaluation.
Blinding (performance bias and detection bias) 
Blinding of personnel and participants (performance bias)
Due to the nature of the intervention, it was not possible to blind either participants 
or staff to the intervention, rendering the risk of performance bias for all studies high.
Blinding of outcome assessment (detection bias) 
When the researcher or data analyst was blinded, we assessed the outcomes reported as 
being at low risk of detection bias, be they patient-reported or objective (e.g. biomedical 
data). Next, we will summarise the risk of detection bias per outcome category.
•	 Health-related quality of life: Of the 13 studies evaluating HRQOL, four described 
adequate blinding for the outcome assessment, Beck 1997; Coleman 2001; Seesing 
2014; Trento 2005. The remaining nine did not provide pertinent information.
Figure 6.2 risk of bias graph.
The review authors’ judgements about each risk of bias is presented as percentage across all 
included studies.
Chapter 6
138
Fi
g
ur
e 
6.
3 
r
is
k 
o
f 
b
ia
s 
su
m
m
ar
y.
Th
e 
re
vi
ew
 a
ut
ho
rs
’ j
ud
g
em
en
ts
 o
f e
ac
h 
ris
k 
of
 b
ia
s 
ite
m
 fo
r 
ea
ch
 in
cl
ud
ed
 s
tu
d
y.
139
Group medical appointments for people with physical illness
6
•	 Physical health: The nine studies reporting physical health outcomes were all assessed 
as being at low risk of bias for these measures.
•	 Other patient and/or carer outcomes: Of the 17 studies reporting other patient or 
carer outcomes, six were assessed as being at low risk of detection bias, Beck 1997; 
Ickovics 2007; Seesing 2014; Coleman 2001; Collins 2013; Seesing 2014; Trento 2005.
•	 Health economy and service use. Of the 12 studies reporting economic outcomes, 
eight were categorised as being at low and one as being at high risk of bias (Yehle 
2009). Most studies extracted health economic outcomes from medical records or 
billing systems, which provided objective data. Otherwise blinding of researchers 
was described. Three studies did not provide sufficient information to assess blinding 
for this outcome: Anderson 2013; Clancy 2007; Visser 2015.
Incomplete outcome data (attrition bias) 
We evaluated the completeness of outcome data (>75% at end of study) per outcome 
category. Anderson 2013; Visser 2015; Yehle 2009 were assessed as being at high risk 
of bias for more than one outcome.
•	 Health-related quality of life. Nine of the 13 studies evaluating HRQOL were classified 
as being at low risk of attrition bias: Coleman 2001; Collins 2013; Porta 2004; Schil-
linger 2009; Schofield 2015; Seesing 2014; Trento 2001; Trento 2005; Trento 2008.
•	 Physical health. Nine of the 14 studies evaluating physical outcomes were assessed 
as being at low risk of attrition bias: Ford 2002; Ickovics 2007; Porta 2004; Schillinger 
2009; Schofield 2015; Seesing 2014; Trento 2001; Trento 2005; Trento 2008.
•	 Other patient and/ or carer outcomes: Eight of the 17 studies evaluating patient 
outcomes were categorised as being at low risk of attrition bias: Coleman 2001; 
Collins 2013; Ickovics 2007; Porta 2004; Schillinger 2009; Seesing 2014; Trento 
2005; Trento 2008.
•	 Health economy. Seven of the 12 studies evaluating health economic outcomes 
reported a low attrition bias: Beck 1997; Coleman 2001; Collins 2013; Scott 2004; 
Seesing 2014; Trento 2001; Trento 2005.
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Selective reporting (reporting bias) 
Ten studies were classified as being at low risk of reporting bias (Beck 1997; Collins 
2013; Clancy 2007; Ickovics 2007; Porta 2004; Schillinger 2009; Schofield 2015; Seesing 
2014; Trento 2001; Visser 2015). These studies either showed no differences between 
trial registration/ protocol paper outcomes and published outcomes or were assumed 
to have no reporting bias due to their extensive descriptions of the outcomes. Four 
studies were deemed at high risk of selective reporting (Anderson 2013; Dorsey 2011; 
Goldstein 2007; Yehle 2009). For nine studies it was not possible to establish the risk 
of reporting bias due to the unavailability of a study protocol or trial registration (Cole 
2013; Coleman 2001; Ford 2002; Gutierrez 2011; Jafari 2010; Trento 2005; Trento 2008) 
or because only a summary measure of the primary outcome was provided (Clancy 
2003) or only some outcomes were described without statistical data (Coleman 2001).
Other potential sources of bias 
When studies detected baseline imbalances, these were taken into account during the 
analyses to prevent risk of bias. Comparability of cluster RCTs and individual RCTs did 
result in unit of analysis issues for two studies (Anderson 2013; Jafari 2010) as neither 
study corrected for cluster randomisation in their analyses.
Effects of interventions 
Presenting the results
This section summarises the results of the studies per outcome category: meta-analysis 
where possible complemented by narrative results where applicable (results described 
according to GRADE working group 2004; Ryan 2016). When the pooled results showed 
substantial heterogeneity, reasons for heterogeneity were explored narratively by 
investigating population, number of sessions, presence of a group facilitator and timing 
of outcome assessments. We were not able to conduct subgroup analyses as none of 
the meta-analyses contained more than ten studies (Higgins 2011). An assessment of the 
quality of evidence based on the GRADE approach is provided per outcome (GRADE 
working group 2004; Ryan 2016).Two studies with a high risk of bias were excluded 
from the analyses: Ford 2002; Gutierrez 2011.
141
Group medical appointments for people with physical illness
6
Primary outcomes
General health-related quality of life
Based on our analysis of the studies evaluating the outcome relative to one-to-one 
appointments, we conclude that the general HRQOL of patients may improve slightly by 
attending GMAs. The results of our evaluation of heterogeneity, effect size and quality 
of evidence are described below.
Eight studies assessed generic and specific HRQOL in a total of 2,102 patients diagnosed 
with various chronic diseases using different types of self-report questionnaires (Beck 
1997; Coleman 2001; Collins 2013; Dorsey 2011; Schillinger 2009; Schofield 2015; 
Seesing 2014; Visser 2015), where higher scores indicated higher QOL levels on all 
scales. Four studies were not included in our meta-analysis due to a lack of results 
(Collins 2013; Visser 2015), dichotomous outcomes (Beck 1997), and data analysed with 
a linear mixed model (Seesing 2014).
To be able to pool the results of the remaining four studies, we chose to use Schillinger’s 
SF-12 physical health summary scale as the most clinically relevant measure and 
Schofield’s EPIC-26 bowel subscale (859 participants, Coleman 2001; Dorsey 2011; 
Schillinger 2009; Schofield 2015). The EPIC-26 questionnaire consists of four subscales. 
As we were not able to determine the most clinically relevant, we ranked their effect 
sizes and selected the second effect estimate (n/2). The meta-analysis resulted in some 
statistical heterogeneity in the results from the individual studies (p=0.03; I²=66%). 
Exploring this heterogeneity descriptively by looking at population, number of sessions, 
presence of a group facilitator and timing of outcome assessments, we decided to not 
include the Coleman study in the meta-analysis as the effect size reported was larger 
than the sizes obtained in the other three studies. This difference can be explained by 
the Coleman population being older and more frail, GMAs being monthly (24 in total) 
and outcomes being assessed at two years, where the other studies all had younger 
(adult ) populations, fewer sessions and follow-up times of 6 to 12 months. The pooled 
results showed an SMD of 0.04 [-0.12, 0.21] Figure 6.4. Our narrative analyses of 
the results reported by Beck, Coleman and Seesing showed two studies in favour of 
GMAs versus one-to-one appointments and one with no evidence of effect (Appendix 
6.2). The effect sizes for this outcome did not result in clinically significant effects. 
On a scale of 0–100, all four studies showed a favourable effect lower than 5 points, 
which is described as the threshold for the general HRQOL scale SF-36 (Ware 1993). 
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Other scales, which were not all validated, showed a very small to minimal favourable 
effect.
The body of evidence for HRQOL is of low quality. Apart from a possible reporting 
bias for two of the included studies, there was no serious risk of bias. In one of the 
studies that found no evidence of effect, this could be due to a lack of power, possibly 
leaving any potential effects undetected. Pooling the results of the studies eligible for 
meta-analysis resulted in heterogeneity that may be explained by the intensity of the 
intervention and the timing of outcome assessments.
Carer HQQOL appears not to be changed by attending GMAs (Appendix 6.12). Two 
studies, by Seesing and Dorsey, evaluated the effects of GMAs on the HRQOL of the 
partners (n=176) of neurological patients using the EQ5D. Results could, however, not 
be pooled because Dorsey used the VAS scale and Seesing the Index scale. Neither 
study found evidence of effect, with the risks of bias for the Seesing study being assessed 
as not serious and as unclear for the Dorsey study. The quality of evidence for carer 
HRQOL can therefore be rated as moderate.
Diabetes-specific quality of life
Based on our analyses of the studies evaluating the outcome and relative to individual 
medical appointments, we conclude that diabetes-specific QOL may improve by 
attending GMAs. The result of the analysis of heterogeneity, effect size and quality of 
evidence is described below.
Four studies evaluating the same study group (819 participants, Porta 2004; Trento 
2001; Trento 2005; Trento 2008) used the modified Diabetes Quality of Life scale where 
higher scores indicate poorer quality of life. Unfortunately, the author we contacted was 
unable to specify the score range, rendering it impossible to reverse the scale scores 
Figure 6.4 (Analysis 1.1) Forest plot of comparison.
1 GMAs vs one-to-one appointments, outcome: 1.1 Health-Related Quality of Life.
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for pooling with the results of the other QOL scales, which is why we analysed the 
results of these studies separately. Our meta-analysis resulted in large heterogeneity 
(p<0.00001; I²=93%). See Figure 6.5. Descriptive exploration of this heterogeneity in 
terms of population, number of sessions, presence of a group facilitator and timing of 
outcome assessments did not yield an explanation, preventing pooling of the results. As 
described in Appendix 6.3, all studies were in favour of the experimental intervention, 
with effect sizes ranging between -13.40 [-22.87, -3.93] and -14.66 [-16.41, -12.91], 
except for the Trento 2001 study that reports an effect size of -45.50 [-54.86, -36.14] 
and indicates imprecision. As the scale these studies used is a modified version of the 
original questionnaire, there are no internationally agreed standards, nor did we receive 
this information from the corresponding author, rendering any judgment on the study’s 
clinical meaningfulness and effect size insecure, although the effect size seems quite 
large.
We rated the quality of evidence for diabetes-specific QOL as low given that, in the 
absence of serious risks of bias, three of the four studies did have small samples and 
heterogeneity remained unexplained. 
Physical outcomes
The second primary outcome of interest was physical health. Our narrative analysis of 
the studies that evaluated percentage of HbA1C in the blood of diabetic patients, we 
are uncertain whether attending GMAs is effective in decreasing HbA1C. Based on one 
large study including pregnant adolescents, we can conclude that attending GMAs may 
reduce the risk of preterm births. The results of the analysis, effect sizes and the quality 
of evidence are described below.
Figure 6.5 (Analysis 1.2) Forest plot of comparison.
1 GMAs vs one-to-one appointments, outcome: 1.2 HRQOL Diabetes-specific quality of life scale.
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Nine studies with a total of 2,584 patients evaluated two physical outcomes (Appendix 
6.4). Eight studies reported HBA1C% in a total of 1,474 diabetic patients (Clancy 2003; 
Clancy 2007; Cole 2013; Porta 2004; Schillinger 2009; Trento 2001; Trento 2005; Trento 
2008), where a lower percentage of HbA1C indicates better health. Clancy 2003 and 
Clancy 2007 could not be included in our meta-analysis as their longitudinal mixed-
effect models did not result in means per group at the end of the study. The meta-
analysis of six studies (Cole 2013; Porta 2004; Schillinger 2009; Trento 2001; Trento 
2005; Trento 2008) resulted in large heterogeneity (Figure 6.6, p<0.00001; I²=94%). 
Descriptive exploration of the populations, number of sessions, presence of a group 
facilitator and timing of outcome assessments did not explain the heterogeneity, which 
prevented us from pooling any of the results. As described in Appendix 6.4, six studies 
were in favour of the experimental intervention, with effect sizes ranging between -0.3 
[-0.52, -0.8] to -1.7 [-2.27, -1.13] in %HBA1C. This is -3 [-6, -1] to 19 [-25, -12] in mmol/
mol (Diabetes Fonds). Various classes of medication that reduce HbA1C levels show 
decreases between 7 to 11 mmol/mol (Dutch Association of General practitioners 2013).
Three studies (Clancy 2003, Clancy 2008 and Schillinger) found no differences between 
interventions.
Ickovics 2007 showed a risk reduction of 33% in preterm births in favour of the 
intervention in 1,047 pregnant adolescents (SMA 9.8%, standard care 13.8%, odds ratio 
0.67, 95% CI 0.44 to 0.99).
Summarising, the body of evidence for HbA1C% is of very poor quality. Pooling of 
the various results in a meta-analysis resulted in unexplained heterogeneity, while the 
narrative analysis showed both substantial (Porta 2004, Trento 2001) and no effects in 
favour of the intervention (Clancy 2003, Clancy 2008 and Schillinger). No serious risks of 
bias were detected. The evidence of preterm birth reductions was based on one large 
Figure 6.6 (Analysis 1.3) Forest plot of comparison.
1 GMAs vs one-to-one appointments, outcome: 1.3 Physical outcome: HBA1C%.
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study that had no serious risks of bias, but, indirectness occured due to the specific 
study group (pregnant adolescents). Therefore we rated this outcome as low.
Secondary outcomes
Self-efficacy and self-management
Based on our analyses of the studies evaluating self-efficacy, we conclude that attending 
GMAs may have little or no effect on this outcome, although the presence of a group 
facilitator during the intervention may improve patients’ self-efficacy slightly. The results 
of the analysis, effect sizes and the quality of evidence are described below.
Self-efficacy/self-management was measured in five studies with a total of 1,795 
participants, all with different questionnaires, while patient groups varied (Appendix 
6.5; Coleman 2001; Ickovics 2007; Schillinger 2009; Seesing 2014; Visser 2015). In all 
questionnaires higher scores indicated higher levels of self-efficacy. Coleman measured 
general self-efficacy as ‘the confidence in managing my disease’ (5-50); the remaining 
studies used individualised self-efficacy scales. Ickovics applied the Condom Use Self-
Efficacy (4-point Likert) Scale), Schillinger the Diabetes Quality Improvement Program 
diabetes self-efficacy measure (range 0–100) and Visser the Dutch Empowerment 
Questionnaire for breast cancer patients (range not available). Measuring general self-
efficacy (range 0–100), the study by Seesing could not be included in the meta-analysis 
because they used a linear mixed model, which did not result in means at the end of 
the study.
Pooling of the self-efficacy results of the remaining four studies with a total of 1,560 
participants resulted in substantial heterogeneity (p=0.03, I²=67%). Our descriptive 
exploration of heterogeneity by looking at the study populations, number of sessions, 
presence of a group facilitator and timing of outcome assessments and analysis the 
forest plots showed that imprecision and heterogeneity was partly explained by the 
presence of a group facilitator. For the two studies explicitly describing the presence 
of a group facilitator, we found a small effect of GMAs: 0.32, 95% CI 0.08 to 0.56, with 
a heterogeneity of p=0.85; I²=0%. We found no effect for the two studies (Ickovics 
2007; Coleman 2001) that did not include or mention a group facilitator: SMD -0.07, 
95% CI -0.19 to 0.04 (p=0.47; I²=0%; Figure 6.7). Although including a group mentor, 
the Seesing study showed no evidence of effect as the mean difference between study 
groups irrespective of follow-up time was: 0.0, 95% CI -0.1 to 0.1, p=0.61.
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We were unable to determine the clinical meaningfulness of the change levels due to the 
lack of international standards. Judging the clinical meaningfulness and the estimation 
of the effect sizes of standard mean differences (SMDs) was not straightforward, but we 
judged the treatment effects to be of probably small size.
The quality of evidence for self-efficacy was rated as low. There was a risk of bias due to 
the lack of outcome blinding and unclear completeness of outcome data. Inspection of 
the forest plot revealed some imprecision problems and heterogeneity between studies, 
but the latter finding was explained by the presence of a group facilitator.
The self-efficacy of the patients’ partners/carers appears not to be changed by their 
attending GMAs (Appendix 6.12) above and beyond individual visits. We found one 
study (Seesing 2014) that evaluated self-efficacy in 149 partners (Partner Generalized 
Self-efficacy Scale, range 0–100) that reported no effect. The study showed no serious 
risks of bias but since it was a single study evaluating a single SMA in neuromuscular 
patients (indicating indirectness), we rated the evidence as low.
Psychological health
Based on our analysis of the studies evaluating this outcome, we conclude that attending 
GMAs appears to have little or no effect on psychological health above and beyond 
the effects of individual visits. The results of the analyses of heterogeneity, effect size 
and quality of evidence are described below.
Psychological health was gauged in eight studies with a total of 1,876 participants with 
various diagnoses using various questionnaires (Appendix 6.6; Coleman 2001 Dorsey 
2011; Ickovics 2007; Schillinger 2009; Schofield 2015; Seesing 2014; Trento 2008; Visser 
2015). One of the studies analysed data for the SF-36 mental health subscale with a 
linear mixed model, which did not produce end-of-study means for the two intervention 
groups, rendering pooling of the results impossible (Seesing 2014).
Figure 6.7 (Analysis 1.4) Forest plot of comparison.
1 GMAs vs one-to-one appointments, outcome: 1.4 Self-efficacy and self-management.
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The results of the remaining seven studies were pooled. Psychological health was 
assessed with the following questionnaires: confidence in managing depression 
(Coleman 2001), Short Generic Depression Scale-15 (Dorsey 2011), Depression CES-D 
(Ickovics 2007), Short Form-12 Mental Health (Schillinger 2009), the Depression subscale 
of the Hospital Anxiety and Depression scale (Schofield 2015) State Anxiety (Trento 2008), 
and the Symptom Checklist-90 (Visser 2015). For most scales higher scores indicated 
lower levels of psychological health but since two scales (Confidence in managing 
Depression and Short Form-12) were reversed scales, their scores were converted. 
The results of the meta-analysis showed a moderate heterogeneity (p=0.03; I²=58%). 
Inspection of the forest plot revealed a much larger effect size for the Dorsey study 
without overlapping 95% CIs. Dorsey et al studied patients with Parkinson’s disease 
for whom one of the known non-motor symptoms is depression (Chaudhuri), which 
could explain the decrease in psychological health during follow-up as opposed to a 
null effect for the other studies. When the Dorsey study was left out of the analysis, the 
heterogeneity disappeared. The SMD analysis showed no evidence of effect: -0.08, 
95% CI -0.17 to 0.02 (Figure 6.8).
The study that could not be pooled (Seesing 2014) also showed no evidence of effect 
on the Short Form Mental Health 36 (Appendix 6.6). The outcome analysis yielded a 
null effect.
We rated the quality of evidence for psychological health as low. The main risks of 
bias were the unclear or lack of completeness of outcome data and unclear blinding 
for outcome data. Inspection of the forest plot showed some imprecision problems 
and heterogeneity among studies that was explained by the Parkinson’s disease 
population.
Figure 6.8 (Analysis 1.5) Forest plot of comparison.
1 GMAs vs one-to-one appointments, outcome: 1.5 Psychological health.
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Patient evaluation of care
Based on our analysis of the studies evaluating the outcome, we conclude that GMAs 
appear to have little or no effect on how patients rate the care they received during GMAs 
compared to one-to-one appointments. The results of the analyses of heterogeneity, 
effect sizes and quality of evidence are described below.
Ten studies with a total of 3,179 participants evaluated aspects of care from the patient’s 
perspective (Appendix 6.9; Anderson 2013; Beck 1997; Dorsey 2011; Goldstein 2007; 
Ickovics 2007; Jafari 2010; Schillinger 2009; Coleman 2001; Seesing 2014; Visser 2015). 
Except for the studies by Jafari and Dorsey, all used a general satisfaction or quality-
of-care scale. Ickovics and Goldstein used a non-specified satisfaction scale without 
describing the range. Dorsey used the GHAA consumer satisfaction scale and Schillinger 
the patient assessment of chronic illness care summary scale (0–100). Coleman used the 
patient satisfaction with overall quality of care scale (1–10 reverse scale, whose scores 
we converted). Visser and Seesing applied the QUality Of Care Through patient’s Eyes, 
QUOTE (0–4). Jafari asked after the participants’ general satisfaction with prenatal care 
(1–4). Because Beck and Anderson used dichotomous outcome measures (proportion 
of satisfied patients), their results could not be included in the meta-analysis, nor could 
the Seesing results due to their use of linear mixed model analysis and the unavailability 
of end-of-study means for the two intervention groups.
We accordingly pooled the results for seven studies including 2,034 participants 
(Coleman 2001; Dorsey 2011; Goldstein 2007; Ickovics 2007; Jafari 2010; Schillinger 
2009; Visser 2015). The pooled analysis resulted in very high statistical heterogeneity: 
(p<0.00001); I²=99%), which became acceptable when the Jafari study was excluded, 
which showed an exceptionally low SD. Trying to verify the SD, we received no reaction 
from the author. Nevertheless, the low SD may be explained by the fact that Jafari’s is 
the only study to include a non-Western population (Iran). Differences in the cultural and 
social values of Western and Iranian participants might have resulted in very positive 
evaluations with small variation in data. Leaving out the study resulted in an SMD of 
0.32 [0.16, 0.49], heterogeneity (p=0.13, I²=42%). See Figure 6.11. 
The results of the four studies that could not be pooled were inconsistent, with 
Seesing describing a negative and Beck and Jafari a favourable effect of GMAs on 
the participants’ ratings of care, while Anderson found a marginal difference between 
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intervention groups. The two studies reporting a negative effect (Seesing and Visser) 
both evaluated a single GMA with a short follow-up (6 and 3 months, respectively). 
Possibly, their participants were not able to build sufficient levels of ease, confidence 
and mutuality in the single session, negatively influencing their perceptions of the care 
received (Appendix 6.9).
We could not judge the clinical meaningfulness of the change levels due to the lack 
of international standards on general patient satisfaction scales. As a rule of thumb, 
GRADE takes an SMD of 0.5 to signify an important difference, where we found an 
SMD of 0.32 (Ryan 2016).
Because we found two main risks of bias, unclear completeness of outcome data and 
unclear blinding for outcome data, and because there was lack of consistency in the 
results, the quality of evidence is to be rated as low.
The partners/carers of participating patients may perceive the care received during 
GMAs as being of poorer quality than the care received during individual visits 
(Appendix 6.12).The Seesing trial was the only study to evaluate this outcome in 124 
partners of neuromuscular patients using the Quality of Care Through the partner’s 
Eyes questionnaire (QUOTE, 0–4). Irrespective of the time of follow-up, their linear 
mixed models showed a mean decrease in care ratings of -0.3 (95% CI -0.5 to -0.1), 
p=0.01. Because we only found one study assessing a single SMA and exclusively in 
neuromuscular patients (indicating indirectness), we rated the quality of evidence as low.
Adverse effects
None of the included studies compared intervention types with respect to adverse effects 
relating to privacy issues or time investment as described in the conceptual framework. 
Figure 6.11 (Analysis 1.8) Forest plot of comparison.
1 GMAs vs one-to-one appointments, outcome: 1.8 Patient evaluation of care.
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Still, none of the included studies described serious adverse effects in terms of symptom 
regression, emergency department visits or death.
Other outcomes
Skills acquisition and health behaviour
Based on the analysis of the studies evaluating the outcomes, we conclude that attending 
GMAs appear to have little effect on skills acquisition or health behaviour above and 
beyond individual visits. The results of the analysis of heterogeneity, effect sizes and 
quality of evidence are described below.
Eight studies with 1,884 participants evaluated skills acquisition or health behaviour 
defined as self-care skills and symptom control skills (Appendix 6.7; Porta 2004; Trento 
2001; Trento 2005; Trento 2008; Collins 2013; Goldstein 2007; Schillinger 2009; Yehle 
2009). Collins reported the number of hours hearing aids were worn daily, Schillinger 
the minutes of moderate weekly physical activity, while Yehle administered the Self-
Care Heart Failure Index, total score (66.7–300). The four studies by the Trento group 
used the Diabetes Problem-Solving Ability questionnaire (0–30). Although mentioned 
in their trial registration, the Goldstein study did not report on medication adherence.
The pooled results of the seven studies resulted in considerable statistical heterogeneity 
(Figure 6.9, p<0.00001; I²=97%). Inspection of the forest plot showed that the two 
studies without a group facilitator showed null effects (Collins 2013; Yehle 2009) where 
the other studies found small effects in favour of GMAs. Nevertheless, the presence of 
a group facilitator did not explain the statistical heterogeneity, nor did the population, 
number of sessions, or timing of outcome assessments. The effect sizes varied between 
0.33 [0.05 to 0.60] (Schillinger 2009) and 2.21 [1.67 to 2.76] (Trento 2001), increasing 
with longer follow-up times (1 year and 5 years, respectively). Determination of the 
Figure 6.9 (Analysis 1.6) Forest plot of comparison.
1 GMAs vs one-to-one appointments, outcome: 1.6 Skills acquisition and health behaviour.
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clinical meaningfulness and effect sizes of standard mean differences (SMDs) was not 
straightforward as there are no internationally agreed standards on the level at which 
change is clinically meaningful, but we judge the size of the reported treatment effects 
as small to moderate (increasing with longer follow-up times).
The quality of evidence is rated as low. Risks of bias included those due to a possible 
reporting bias (Goldstein 2007) and incomplete outcome data (Yehle 2009). Statistical 
heterogeneity remained unexplained.
Patient knowledge
As to whether GMAs improve patient knowledge more than do one-to-one appointments, 
our analysis produced uncertain results. The results of the analyses of heterogeneity, 
effect sizes and quality of evidence are described below.
Four studies with a total of 1,452 participants assessed patient knowledge (Appendix 
6.8; Ickovics 2007; Porta 2004; Trento 2001; Trento 2005). Porta 2004, Trento 2001 and 
Trento 2005 tested knowledge of diabetes with ‘GISED,’ an unvalidated questionnaire, 
while Ickovic used a Prenatal and Infant care scale, with higher scores indicating higher 
levels of knowledge.
The pooled results showed a considerable heterogeneity Figure 6.10 (p<0.00001; 
I²=91%). After excluding the prenatal care study and pooling the results of the three 
diabetes studies, a substantial unexplained statistical heterogeneity remained (p=0.02; 
I²=76%). As described in Appendix 6.8, all studies were in favour of GMAs, with effect 
sizes in the diabetes studies varying from 4.11 [0.96 to 7.26] to 9.68 [7.43 to 11.93]. 
The effect size for the prenatal and infant care study was 2.60 [1.57, 3.63]. The score 
ranges for both questionnaires were not available and we did not receive this information 
after contacting the corresponding authors, making it difficult to judge the clinical 
meaningfulness of the effect sizes.
Figure 6.10 (Analysis 1.7) Forest plot of comparison.
1 GMAs vs one-to-one appointments, outcome: 1.7 Patient knowledge.
Chapter 6
152
The body of evidence of patient knowledge was rated as very low. The main risks of 
bias were unclear selection bias and detection bias in the Trento/Porta studies. We were 
not able to retrieve information on the validity and range of the questionnaires used 
and the meta-analysis showed a considerable unexplained statistical heterogeneity.
Practical or social support 
Based on the only study investigating the outcome in 272 neuromuscular patients 
(Seesing 2014), we conclude that attending a GMA may improve social support slightly 
as compared to one-to-one appointments. Lack of social support was measured with the 
Social Support Discrepancy List (SSLD), range 0–32. The mean score for the intervention 
group showed an improvement of 1.1 scale points, irrespective of follow-up time (95% 
CI: 0.4 to 1.9). It was difficult to judge the clinical meaningfulness of this change due to 
the lack of international standards, but the effect size is likely to be small. As there is only 
one study to report on social support, the quality of evidence was rated as moderate. 
There were no serious risks of bias.
Based on the study by Seesing 2014 that also included 124 partners of the patients with 
a neuromuscular disorder, it remains uncertain whether GMAs improve their perception of 
social support because the power of the study was insufficient to evaluate the outcome 
reliably and it was the only study to do so. The quality of evidence was hence rated as 
low (Appendix 6.12).
Economic outcomes: service use and cost data
Emergency department visits
Based on the analysis of the studies reporting the number and costs of emergency 
department visits, we conclude that, compared to one-to-one appointments, GMAs 
may decrease the number of emergency department visits. The results of the analyses 
of heterogeneity, effect size and quality of evidence are described below.
Four studies with a total of 921 patients evaluated emergency department visits for 
chronically ill high-utilising older patients (Appendix 6.10; Beck 1997; Coleman 2001; 
Clancy 2003; Clancy 2007). Two studies recorded the number of visits (Beck 1997; 
Coleman 2001). The pooled analysis of these studies (Figure 6.12) showed a decrease 
in the number of visits: MD -0.34, 95% CI -0.55 to -0.13, (heterogeneity: p=0.41; I²=0%). 
Statistical heterogeneity was not detected, but this may be due to the small number 
of studies.
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Clancy examined the costs of emergency department visits in two studies. The 2003 study 
found no significant difference in these costs for GMAs and one-to-one appointments, 
whereas the 2007 study described a 50% reduction, from 121.81 USD to 61.95 USD, 
for GMAs. The latter result may be explained by the 12-month follow-up as opposed to 
the 6-month follow-up in the 2003 study. The other variables investigated showed no 
differences. The effect size appears to be clinically meaningful as emergency department 
visits are both very distressing for patients and costly, with effect sizes increasing with 
the number of sessions and longer follow-up durations.
The body of evidence was rated as moderate as there was a low risk of bias and no 
statistical heterogeneity for the pooled results. As our review aims to evaluate GMAs 
for all patients with a physical illness, there is indirectness given that the Clancy studies 
only included chronically ill, high-utilising older patients and patients with diabetes, in 
which populations emergency department visits may occur more frequently.
Hospital admissions
Based on the analysis of the studies reporting on the number and costs of hospital 
admissions, we are uncertain whether GMAs result in reductions relative to one-to-one 
visits. The results of the analyses of heterogeneity, effect size and quality of evidence 
are described below.
Five studies with a total of 980 patients evaluated the number of hospital admissions 
or the associated costs in various patient groups (Appendix 6.10; Clancy 2003; Clancy 
2007; Collins 2013; Visser 2015; Yehle 2009). Pooling of the results was not possible 
as some studies only reported the number and others the costs related to hospital 
admissions. For the 2003 Clancy study no standard deviations were available nor were 
we able to compute an SD as costs are not normally distributed. Due to the inconsistency 
Figure 6.12 (Analysis 1.9) Forest plot of comparison.
1 GMAs vs one-to-one appointments, outcome: 1.9 Economic outcome: service use and 
emergency department visits.
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in the results, we are uncertain about their effect sizes. Coleman studied the effects of 
GMAs on the number of hospital admissions in high-utilising chronic older patients, 
Yehle in heart failure patients and Clancy (both 2003 and 2007) evaluated the costs of 
inpatient stays for diabetes patients. The Yehle study did not describe the results for 
this outcome, indicating possible reporting bias, while Coleman reported a beneficial 
effect on hospital admissions (-0.38, 95% CI -0.69 to -0.07.) Clancy 2003 describes an 
increase in the costs for inpatient stays after the GMA intervention (USD 1,410 for GMA 
patients vs USD 365 for control patients, p value: 0.049). In 2007, Clancy describes the 
opposite effect, with costs for inpatient stays decreasing by more than 50% from USD 
5,577.60 for one-to-one appointments and USD 2152.78 for GMAs (p value: >0.05).
The quality of evidence was rated as very low. There was a main risk of publication bias 
for one of the studies and although the other studies showed no serious risks of bias 
for this outcome, the results were inconsistent. Indirectness occurred due to the specific 
populations, i.e. high-utilising chronically ill older patients and diabetes type II patients 
with a mean age of 54 years or over for whom hospitalisations tend to be more frequent 
than for other populations with a physical illness.
Total costs of health care use
Based on the analysis of the studies evaluating costs of healthcare use, we are 
uncertain whether GMAs lead to a reduction in expenditures compared with one-to-
one appointments. The results of the analyses of effect size and quality of evidence is 
described below.
Five studies with a total of 1,024 patients evaluated the costs of healthcare use, two 
in terms of total healthcare costs (Collins 2013 and Visser 2015) and three in terms of 
the incremental cost-effectiveness ratio (Seesing 2014, Trento 2001 and Trento 2005). 
See Appendix 6.11.
As Collins 2013 and Visser 2015 both determined GMA impact on healthcare costs, the 
results appeared fit for pooling. However, Collins provided no standard deviations (SDs) 
and we were not able to compute an SD as costs are usually not normally distributed, 
rendering pooling of the results impossible. Both studying a single GMA relative to one-
to-one appointments, Collins describes a decrease in healthcare costs of approximately 
50% with a 6-month follow-up, whereas Visser reports an increase of the same size (50%) 
after a 3-month follow-up. Although initial referrals will most probably take place in the 
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first months after an appointment, this can hardly explain the opposite directions of 
the effects. Possibly, a GMA for breast cancer patients (Visser) prompts more questions 
in the participants, resulting in an increase in healthcare use, as opposed to patients 
adapting to hearing aids for whom the prognosis and treatment is less complex and 
uncertain. The effect size is classified as small.
Three studies reported the incremental cost-effectiveness ratio of a GMA (Seesing 
2014; Trento 2001; Trento 2005), describing the costs in proportion to each incremental 
improvement in quality of life (scale scores). For the two studies evaluating effectiveness 
of multiple GMAs in diabetes patients, the ratio varied between $2.12 and € 19.42 for 
each incremental improvement on the modified diabetes-specific quality of life scale 
(DQOL/mod), which costs can be interpreted as being relatively low for the improvements 
gained. For a single GMA for neuromuscular patients, Seesing found an incremental 
cost-effectiveness ratio of €- 960 (95% CI: €- 34.600, €+36.800), where the confidence 
interval is too large to draw any firm conclusions.
One study had an unclear risk of allocation bias. The results on total healthcare costs 
following GMA(s) were inconsistent. As the studies were conducted in various countries, 
healthcare costs can be indicated as being indirect. The body of evidence is graded 
as very low.
Health professionals
None of the included studies compared health professionals’ job satisfaction and 
knowledge and understanding of patient problems.
Sensitivity analysis
The Ford 2002; Gutierrez 2011 studies were classified as having high risks of bias in 
terms of high or unclear sequence generation, allocation concealment and completeness 
of outcome data, which is why their results were not included in our analyses. The 
studies by Anderson 2013 and Yehle 2009 both were at high risk of incomplete data 
for all outcomes reported. The outcome data of the Goldstein 2007 study only became 
available after personal communication, which could indicate a publication bias. These 
incomplete data sets did not affect the results for the primary outcomes and our meta-
analysis. Their potential impact on the narrative synthesis of the secondary outcomes 
will be incorporated in the summary of the results that we provide in the discussion 
section below. 
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DiscussiON 
summary of main results 
Despite the large number of studies on group interventions for the management of 
chronic and long-term conditions that are described in the literature, a relatively small 
number concerns randomised controlled trials investigating group medical appointments 
(GMAs), defined as a series of one-to-one patient-clinician contacts in the presence of 
a group of other patients. Our systematic search resulted in 22 randomised studies that 
compared GMAs with individual outpatient appointments for adult and older patients 
with a physical illness. Two studies were categorised as being at too high a risk of 
bias and were excluded from the analysis. With this review we aimed to evaluate the 
effectiveness of GMAs from a broad perspective, which is why we included all physical 
diagnoses, eleven outcome measures and a range of different group interventions that 
all served as substitutions for of one-to-one appointments.
The strength of this review accordingly lies in its thoroughness and broad perspective. 
Still, because more than half of the 22 studies found fit for review was conducted in the 
United States and nine studies exclusively examined intervention effects in diabetes 
patients, generalisation of our results to other countries or diagnostic groups is limited. 
Additionally, despite the GMAs all being substitutions for individual visits, there was 
considerable heterogeneity in the group models used, while none of the studies 
evaluated the intervention in children.
Based on the results of our review, we conclude that the general health-related quality 
of life (HRQOL) of patients may improve slightly by attending GMAs compared to one-
to-one appointments, with GMAs with a higher intensity and longer follow-up times 
generating larger effect sizes. Analysed separately, diabetes-specific quality of life may 
also improve by attending GMAs. Our second primary outcome of interest here was 
physical health as reflected by percentage of HBA1C, but we were unable to establish 
whether GMAs were effective in decreasing this outcome compared with individual 
visits. For the secondary outcomes we found that GMAs appear to have little or no 
effect on self-efficacy, psychological health and patient evaluations of the care received, 
but the presence of a group facilitator during GMAs may improve patients’ self-efficacy 
slightly. There was no evidence of serious harm from any of the studies. See Table 6.1.
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Primary outcomes
General health-related quality of life may improve slightly by attending GMAs 
compared to one-to-one appointments. The body of evidence for general HRQOL 
is, however, of low quality. Except for a possible reporting bias, there were no serious 
risks of bias. One of the studies was underpowered, preventing it from uncovering any 
intervention effects, if present. Higher intensities and longer follow-up times appear to 
result in larger GMA effect sizes.
Diabetes-specific quality of life may improve by attending GMAs compared with 
individual medical appointments. Although there was no serious risk of bias, the quality 
of evidence for this outcome was rated as low because three of the four studies had 
small patient numbers and the statistical heterogeneity among the studies remained 
unexplained.
Physical health: it is uncertain whether attending GMAs is effective in decreasing 
HbA1C%. The differences in outcomes were not explained by characteristics of the 
intervention or the study. The quality of evidence was rated as very low due to the 
unexplained statistical heterogeneity and high level of inconsistency in the results.
Secondary outcomes 
Based on the analysis of studies evaluating self-efficacy and self-management we 
conclude that attending GMAs may have little or no effect on the participants’ self-efficacy 
or self-management abilities, while GMAs that have a group facilitator do appear to 
improve their self-efficacy slightly. The quality of evidence was rated as low. There was a 
risk of bias due to the lack of outcome blinding and unclear completeness of outcome data. 
Attending GMAs appears to have little or no effect on psychological health as compared 
with individual medical appointments. One study reported a worsening of psychological 
health, which was explained by depression as a symptom of Parkinson’s disease. The 
quality of evidence was rated as low. The main risks of bias were unclear or lack of 
completeness of outcome data and unclear blinding of outcome data.
GMAs may have little or no effect on the evaluation of care from the patients’ 
perspective as compared with one-to-one appointments. The quality of evidence was 
rated as low. The main risks of bias were the unclear completeness of outcome data and 
unclear blinding for outcome data, while there was a lack of consistency.
Chapter 6
158
There was no evidence of serious harm as none of the studies reported adverse events 
such as hospital (re)admissions, emergency department visits or deaths.
Other outcomes
Our evaluations of three additional psychological and three economic outcome measures 
led us to conclude that, compared with individual medical appointments, GMAs may 
have little effect on skills acquisition or health behaviour, but effect sizes did increase 
with longer follow-up times. Studies without a group facilitator showed null effects. 
It remained uncertain whether GMAs improve patient knowledge, while social and 
practical support may improve slightly. As to the economic outcomes, we found that 
the number of emergency department visits decreased after attending GMAs rather 
than individual visits, but whether GMAs also reduce the number of hospital admissions 
and healthcare costs remained uncertain. None of the included studies evaluated the 
effects of GMAs on job satisfaction or knowledge of patient problems for the attending 
health professionals in a randomised design.
Overall completeness and applicability of evidence 
We used a highly sensitive search strategy to identify as many papers as possible in 
this field, from all relevant databases. In an effort to capture the most contemporary 
evidence at the time of publication, the search covered studies published until July 
2015. To further increase the completeness of the search, we hand-searched reference 
lists by looking at other similar reviews in the field to identify any papers missed by the 
initial search, and by contacting authors.
The interventions delivered in the studies we reviewed showed a large variability, as did 
the study designs and outpatient treatment settings (hospitals, primary and veteran care 
centres). Unfortunately, none of the included studies compared the effects of GMAs 
on the health professionals’ job satisfaction or knowledge of patient problems with 
individual care, nor potential adverse effects of GMAs, patients’ time investment and 
privacy concerns. The body of evidence was dominated by findings on the management 
of diabetes or other chronic illnesses and prenatal care. Caution is therefore required in 
generalising from these results, particularly for clinical topics other than these patient 
groups. Moreover, applicability is influenced by patients’ and health professionals’ 
preferences. Receiving and delivering care in a group of patients requires different skills 
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from both patients and the healthcare providers. If anyone party is reluctant to speak 
freely in a group, this will influence GMA effectiveness.
Quality of the evidence 
The quality of evidence is described per outcome category in the Effects of interventions 
section and integrated in the Summary of main results.
Potential biases in the review process 
Despite the extensive search strategy in which over 7,500 records were identified, we 
may have missed some studies comparing GMAs with one-to-one appointments if they 
were not indexed in the bibliographic databases such that they could be identified by 
our search terms. We made significant efforts to contact trial authors and coordinating 
researchers as described in the online trials registries for further details of the intervention 
and possible missing data. As one of the review authors authored one of the included 
studies, she was not involved in the data extraction and rating of her own study Seesing 
2014. Another of the reviewers is the author of an ongoing study Zijlstra 2014.
While interpreting the results of this review, it is important to keep in mind that we 
analysed the effects of GMAs on thirteen different patient outcomes. In our attempt 
to include as many outcomes of importance to users of the review as possible, their 
multitude may have introduced problems of multiple comparison. As described by 
Bender, adjustments for multiple tests are not routinely used in systematic reviews and 
more research is required to develop adequate multiple comparison procedures for use 
in systematic reviews (Bender 2008).
Due to the nature of the interventions being compared, blinding of the participants and 
health professionals was not possible, which may have influenced the results. Also, the 
implementation of a new care model with a focus on self-management skills may have 
positively affected the results of both the experimental and control groups. Clinicians 
learn from patients and other attending professionals during GMAs and they may apply 
their newly gained knowledge and skills in their individual appointments as well, which 
could have prevented differences between the intervention and control groups from 
becoming more manifest.
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Risk of bias due to incomplete outcome data on all listed outcomes was detected for the 
following studies: (Anderson 2013; Goldstein 2007; Yehle 2009), while a publication bias 
was at stake for: Allen 2013; Goldstein 2007; and Schofield 2015, although Schofield 
did provide the results on all outcomes after personal communication, including both 
beneficial and inferior results, which decreased this risk. Our search of specified clinical 
trial registries did not point us to other relevant ongoing or completed trials. We did 
find one ongoing but unregistered study through personal communication (Bruinsma 
2015). Another limitation is that not all studies we reviewed reported on serious adverse 
events. The studies that did, did not record any serious or rare adverse events.
Agreements and disagreements with other studies or reviews 
In 2010, the year this Cochrane review was proposed, one qualitative review on the topic 
of GMAs had been published (Jaber 2006). Since 2010 and thus indicating the current 
interest in the subject, eight more reviews evaluating the effectiveness of GMAs were 
published (Burke 2011; Catling 2015; Edelman 2012; Housden 2014; Sheeder 2012; 
Slyer 2013; Riley 2010). Except for those by Jaber and Edelman, all reviews evaluated 
the effects of GMAs for one specific patient group, with four reviews focusing on patients 
with diabetes (Burke 2011; Edelman 2012; Housden 2014; Riley 2010), two on pregnant 
(young) adults (prenatal care) (Catling 2015; Sheeder 2012), while the Slyer 2013 review 
evaluated studies including heart failure patients. As it was our aim to compare GMAs 
and individual appointments irrespective of diagnostic groups, we feel that this particular 
Cochrane review adds valuable information to the existing reviews. It should be noted 
that, while reviews focusing on one diagnostic population often include a limited 
number of studies, rendering conclusions uncertain, they do allow a better comparison 
of the interventions and specific outcomes. Apart from evaluating GMAs for all patient 
populations, another main difference between ours and earlier systematic reviews is that 
previous reviews included several studies in which GMAs were supplemental to care as 
usual, where beneficial effects are likely to be larger than those achieved with ‘stand-
alone’ series of GMAs.
Edelman 2012 was the only review to also evaluate specified GMA characteristics. 
They developed a GMA robustness score based on GMA design and content and the 
characteristics of the team and patient group. The robustness score was not associated 
with outcomes. With our review we found a potential for beneficial effects on quality-of-
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life indices contingent on GMA intensity and follow-up time as well as for self-efficacy 
conditional on the presence of a group facilitator during the sessions.
Four reviews on physical outcomes in diabetes and prenatal care conducted meta-
analyses: (Burke 2011; Catling 2015; Edelman 2012; Housden 2014). Although the aim of 
Edelman 2012 was to review chronic medical conditions, their meta-analyses exclusively 
included diabetic patients. All four reviews describe an increase in HRQOL (Jaber 2006; 
Housden 2014; Edelman 2012; Slyer 2013), which is in line with our findings that general 
HRQOL as well as diabetes-specific QOL may improve slightly by attending GMAs.
Like us, Burke 2011; Edelman 2012; Housden 2014 performed a meta-analysis on the 
effects of GMAs on HBA1C% of patients with diabetes. Edelman 2012; Housden 2014 
reported beneficial effects of GMAs on HBA1C%, but did not account for the high 
statistical heterogeneity. Burke’s conclusion of HBA1C reductions were based on the 
meta-analysis of two studies by Trento. While not incorporating a meta-analysis, Riley 
concluded that HBA1C might decrease. Having analysed eight studies, we were unable 
to reliably determine whether GMAs indeed reduce HBA1C% due to the high statistical 
heterogeneity among studies and considerable inconsistency in the effects reported.
Catling 2015 performed a meta-analysis of studies evaluating GMAs providing prenatal 
care but did not find any beneficial effects on the percentage of preterm births where we 
did describe a possible beneficial effect for this outcome. This disparity may be explained 
by the fact that our review included a single study focusing on expecting adolescent 
mothers where Catling included three studies of which two exclusively included adult 
pregnant women. Possibly, effect sizes for support, self-management and knowledge 
of participants may be larger for pregnant adolescents.
Unlike our review, self-efficacy/self-management, psychological health, and patient 
evaluation of care were only explored narratively in other reviews. Housden reported an 
increase of self-efficacy in diabetes patients and Slyer in patients with heart-failure. Our 
pooled results showed that self-efficacy was only augmented by attending GMAs when 
a group facilitator was present. In their qualitative review, Jaber concluded that GMAs 
had no effect on depression scores, whereas we concluded that effects on psychological 
health were uncertain. Here, it needs to be noted that we pooled the results and took 
a broader perspective on psychological health. While Jaber and Riley concluded that 
patients’ evaluations of care may improve by GMAs, based on our meta-analyses we are 
uncertain about their effects on this outcome. Apart from ours, no other meta-analyses 
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were performed on patient knowledge, practical and social support, skills acquisition/
health behaviour and economic outcomes. No adverse effects were described, which 
is congruent with our findings.
AutHOrs’ cONcLusiONs 
implications for practice 
This review evaluates the results of randomised controlled trials on the effectiveness of 
group medical appointments irrespective of the medical (physical) condition, participants’ 
ages, number of appointments and models studied with respect to eleven outcome 
measures and relative to care as usual (individual visits). The included studies showed a 
large diversity in the design of the GMAs, the types of patients and clinicians involved, 
country of origin and hence health systems and cultures. Hardly any negative results 
and no serious harms or adverse effects were described, but, despite our seeking a 
broad perspective, we found that the relatively large number of studies exclusively 
focusing on patients with diabetes complicated the generalisability of the results to other 
patient populations. Moreover, since only one study evaluated the patients’ partners 
and no study included children, we were unable to draw any (firm) conclusions about 
the effectiveness of GMAs for these groups.
As described in our conceptual framework (How the intervention might work), 
we hypothesised that the direction or the size of effects would be influenced by 
characteristics of the GMA design, the type of patients attending and the composition 
of the GMA team. We found that health-related quality of life (HRQOL) may improve by 
attending GMAs as compared to one-to-one appointments, where effect sizes appear 
to increase with the number of GMAs and length of follow-up. Although the percentage 
of HBA1C in patients with diabetes was not negatively affected, the combined results 
did not allow us to determine with certainty whether GMAs are effective in reducing 
this physical outcome. Our analyses did show a positive effect on patients’ self-efficacy, 
provided the GMA team included a group facilitator. Contrary to our hypotheses, none 
of the other characteristics influenced the outcomes evaluated.
As to cost-effectiveness, we found that the number of emergency department visits 
decreased with GMAs compared to one-to-one visits, but the effect on the number of 
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hospital admissions and healthcare costs remained uncertain. Given the differences in 
national healthcare systems and political and geographical regions, we were unable to 
compare the cost data reported.
The heterogeneity of and uncertainties about the exact content of the experimental 
and control interventions and the various outcome measures necessarily imply that 
the current evidence cannot support a specific blueprint for widespread adoption. 
Nevertheless, our review does offer a comprehensive conceptual framework for GMAs 
that we hope will benefit future interventions and their evaluation. When implementing 
GMAs in practice, the results of this review may be taken into account, allowing for the 
local healthcare system and diagnostic group involved.
implications for research 
The findings of the current review suggest some beneficial effects of GMAs for 
three specific outcome measures above and beyond those reported for one-to-one 
appointments. Future research may change the current results for most of the outcomes. 
We were unable to determine which elements of this complex intervention are most 
likely to influence its effectiveness, except for two features: the presence of a group 
facilitator and the length of follow-up appears to positively affect outcomes. Further 
exploration of these and other working mechanisms through qualitative and quantitative 
studies could be helpful for clinicians considering setting up GMAs in their practice, 
where the conceptual framework described in this review might be useful to determine 
GMA objectives, procedures and providers.
This review shows that GMAs may promote the quality of life for adults with diabetes 
and older adults with other chronical somatic conditions. As with other care innovations, 
diabetes patients are a rewarding group for researchers to study due to their large 
numbers and the relatively short times needed to show the effects of the care and 
self-management interventions on biophysical markers. It is then important that future 
research is also aimed at studying GMA effectiveness in other diagnostic populations, 
more specifically children with a chronic somatic disease. As two RCTs in the ongoing 
studies of this review indeed include children, future publications will provide more 
information on this specific patient group.
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The bulk of the studies we reviewed were conducted in high-income countries. With 
the increasing numbers of welfare diseases emerging in low- and middle-income 
countries, it becomes ever more valuable to provide opportunities to set up and 
evaluate GMAs in these countries. Also, targeted randomised controlled trials are 
needed to learn more about the effects of GMAs on the partners/carers of patients, 
while non-randomised studies should evaluate their effects on the healthcare providers. 
To improve the robustness of cost-effectiveness analyses, we advise researchers to 
include relevant economic outcome measures in their future studies, where service 
use can best be compared across currencies, although here also comparability is 
complicated by differences in national healthcare system and political and geographical 
characteristics.
Since this review was limited to studies in which GMAs were compared to individual 
appointments, we excluded studies in which GMAs were an add-on to individual 
consultations or care as usual (Cohen 2011; Crowley 2014; Edelman 2010; Taveira 
2014). It would be interesting, though, to compare the outcomes of these studies 
with the findings of this review, where one would expect larger effect sizes for patient 
outcomes and negative results for economic outcomes, while a review evaluating GMAs 
as add-on interventions versus care as usual would provide more information about the 
effectiveness of combining individual and group appointments.
From a still broader perspective, it would be interesting to compare the effectiveness 
of GMAs with other group meetings such as educational groups and to study which 
factors contribute most to the effects. One could then verify whether the intensity of 
group interactions is related to intervention gains and which conversational techniques 
promote such interactions.
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DiFFErENcEs bEtWEEN PrOtOcOL AND rEViEW 
In our protocol paper we described that we would first be assessing clinical heterogeneity 
and then statistical heterogeneity in case of meta-analyses. This resulted in a very 
small number of studies deemed sufficiently homogeneous to pool results. The main 
objective of our review was to evaluate the effectiveness of GMAs irrespective of patient 
groups and the specific characteristics of the intervention. In order to enable us to draw 
meaningful conclusions in line with this objective, we decided to deem the interventions 
of all studies as sufficiently similar to pool results. See Assessment of heterogeneity.
It was not possible to perform subgroup analyses to explore reasons for statistical 
heterogeneity as the number of studies included in the meta-analyses was too small. 
Reasons for heterogeneity were hence explored narratively, as described in the section 
Assessment of heterogeneity.
Ideally, outcomes to be included in the SOF table should be identified at the protocol 
stage. During the analysis phase of the review and following discussion with the CCCRG 
and based on the requirements of the Cochrane handbook, we decided to restrict the 
number of main outcomes to a maximum of seven. The selection of these outcomes was 
based on their relevance for patients, clinicians and decision makers without knowledge 
of the results on the outcomes. The primary outcomes remained the same. 
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APPENDicEs 
1 MEDLiNE search strategy 
1. “appointments and schedules”/
2. office visits/
3. “referral and consultation”/
4. (visit? or consult* or appointment* or clinic?).tw.
5. disease management/
6. exp practice management/
7. physicians practice patterns/
8. or/1-7
9. group processes/
10. (group adj (based or basis or approach or education*)).tw.
11. or/9-10
12. 8 and 11
13. (shared adj (visit? or consult* or session* or appointment* or setting* or care)).tw.
14. ((group or cluster) adj (visit? or consult* or appointment* or setting* or care or 
clinic?)).tw.
15. ((shared or group or cluster) adj (medical or patient or outpatient or office or 
education*) adj (visit? or consult* or session? or appointment* or setting* or 
discussion* or clinic? or approach* or care or basis or model*)).tw.
16. ((shared or group or cluster) adj2 (visit? or consult* or appointment*)).tw.
17. (cooperative health* adj2 clinic?).tw.
18. (cooperative adj3 care clinic?).tw.
19. (chronic adj3 care clinic?).tw.
20. or/12-19
21. randomized controlled trial.pt.
22. controlled clinical trial.pt.
23. randomized.ab.
24. placebo.ab.
25. drug therapy.fs.
26. randomly.ab.
27. trial.ab.
28. groups.ab.
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29. or/21-28
30. exp animals/not humans.sh.
31. 29 not 30
32. 20 and 31
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Introduction
This thesis presents a comprehensive study of the effectiveness and cost-effectiveness 
of a novel care model, shared medical appointments (SMAs). A large randomised 
controlled trial (RCT) was conducted to evaluate the effects of single, stand-alone SMAs 
in neuromuscular patients and their partners relative to the effects for single individual 
visits. To enable us to reliably assess the effects on the patients’ quality of life, the 
individualised neuromuscular quality-of-life questionnaire (INQoL) was translated into 
Dutch and validated. Finally, to gain insight into the model’s broader application, we 
performed a systematic review of all RCTs investigating SMA outcomes in other physical 
illnesses up to 2015. This chapter provides a discussion of the main findings as well 
as a glimpse into future perspectives, including the preconditions for successful SMA 
implementation in clinical practice. 
Discussion of the ﬁ ndings described in this thesis 
The effectiveness of SMAs for neuromuscular patients 
In our RCT we compared the effects of a single, stand-alone, neurologist-led SMA 
with the effects of an individual appointment with a neurologist and found small but 
significant improvements on two subscales (general health and social functioning) of 
our patient-reported primary outcome measure, the SF36, indicating improved health-
related quality of life. Also two secondary outcome measures, the fatigue subscale of the 
INQoL and the perceived social support scale, showed significant treatment effects of 
the SMA. The positive effects obtained during the trial were even larger when one takes 
into account that the participating clinicians gained new knowledge and insight during 
the SMAs, which enabled them to target their treatment better during the individual 
appointments. We accordingly venture that SMAs have potential for both the patients 
and the consulting clinicians. 
Self-efficacy, an outcome we had hypothesised to be influenced strongly by SMAs, did 
not show significant differences when compared to an individual appointment. In the 
next sections we will discuss three potential explanations for this lack of intervention 
effect in neuromuscular patients: the choice of self-efficacy measure, single versus 
multiple SMAs, and SMA content.
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General vs individualised self-efﬁ cacy measures
In the general introduction of this thesis we defined self-efficacy as the extent to which 
an individual has confidence in being able to execute specific behaviour. The degree 
of self-efficacy then predicts actual behavioural change and is often used to evaluate 
self-management interventions (1-4). Self-efficacy is typically facilitated by increased 
knowledge, social support and successful past experiences of oneself or others to whom 
one can relate (2, 5-7), all more readily available during an SMA than during one-to-one 
appointments. We accordingly hypothesised that any positive effects of a single SMA 
were likely to be mediated by improved self-efficacy through augmented social support 
and new knowledge gained from positive past experiences of peers. At the time of our 
trial, no neuromuscular disease-specific scale was available, which is why we opted for 
Schwarzer et al.’s general self-efficacy questionnaire4 that assesses general beliefs that 
successful outcomes depend on one’s actions. Unfortunately, we failed to find statistically 
significant improvements with this generalised scale. This lack of effect also contrasted 
starkly with the scores we obtained with two SF36 subscales gauging perceived social 
support and social functioning, which showed that after having attended an SMA our 
neuromuscular patients did experience more social support. Arguably, had we used a 
disease-specific self-efficacy measure, we might have uncovered differences between 
our two intervention groups. According to Bandura, a general self-efficacy scale has 
little predictive value, which is why a specific questionnaire should be made for every 
patient group (3, 5). Previous SMA studies reporting improvement in self-efficacy indeed 
all used disease-specific scales (89). 
Single vs multiple SMAs
As described in Chapter 4, in all but two of the previous randomised studies that 
evaluated series of SMAs it was consistently suggested that effectiveness was related to 
the number of SMAs the patients had attended (9-14). We argued that it was the focus 
on sharing and learning from the experiences of fellow patients that accounted for the 
effectiveness of the single SMAs evaluated during our trial. Results of the Cochrane 
review (Chapter 6) did confirm the conclusions of earlier studies that larger effect sizes 
for SMAs were associated with a higher number of visits and longer follow-up times. 
Potentially, if neuromuscular patients are offered multiple SMAs during a longer period 
of time, effect sizes may increase.
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Content of the shared medical appointment
In our trial, the content of each single SMA was dictated by the patients’ current needs 
and demands, which implies that the topics discussed and time devoted to interactions 
among patients will necessarily have varied. If more attention can be paid to successful 
earlier experiences of fellow patients and more time spent on eliciting social support 
during consecutive SMAs, this is likely to increase effect size of self-efficacy as well. Here 
it needs to be noted that the results of the Cochrane review (Chapter 6) indicate that 
the presence of a group facilitator during the SMA may have a beneficial influence on 
self-efficacy. The group facilitator could very well be the team member who, more so 
than the more medically oriented clinician, facilitates topics and exchanges relating to 
self-efficacy. From an implementation point of view, the content and organisation of an 
SMA would have to be flexible, allowing for the type, composition and both individual 
and communal needs of the patient group. Still, a blueprint for effective SMA delivery, 
detailing methodologies promoting social support and the exchange of experiences, 
would be welcome. 
All things considered, we posit that the use of a general rather than disease-specific 
self-efficacy questionnaire is the most plausible explanation for the lack of effect on 
this outcome during our trial. The fact that the Cochrane review (Chapter 6) describes a 
possible beneficial effect on self-efficacy when a group facilitator is part of the SMA team, 
which was the case in our trial, appears to underscore this supposition. It is also in line 
with our conclusions on the value of disease-specific questionnaires in Chapter 3. Here, 
we claimed that a quality-of-life questionnaire specifically designed for neuromuscular 
patients (INQoL) will provide the most relevant information in care and intervention 
evaluations without adding undue burden to patients. 
Lack of effectiveness for partners
As opposed to what we hypothesised at the start of our study, we did not find any 
improvements in the quality of life and self-efficacy of the patients’ partners that had 
participated in the SMAs. On the contrary, we found that the partners reported being 
less satisfied with the SMA and having experienced less social support than they had 
during individual visits. Although the effect size was small and fewer partners than 
patients attended the group visit, this nevertheless was an unexpected result.
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Although several studies called attention to the impact a chronic disease has on a 
partner’s life, also when this concerns a neuromuscular disorder (15-18), the current 
body of evidence is limited and does not suggest beneficial effects of SMAs (19, 20). 
Randomised studies evaluating interventions for the partners of patients are limited 
because, due to practical and financial reasons, healthcare typically almost exclusively 
revolves around patients. 
The lack of positive and in part even negative outcomes for the attending partners 
could be explained by the time constraints that have to be respected during an SMA. 
As all patients receive a full neurological consultation, this may leave too little time 
for the partners’ needs. Alternatively, when partners do not experience any specific 
quality-of-life or social-support issues (18), attending an SMA may be a time-consuming, 
ineffective enterprise. 
To determine which aspects of an SMA negatively affect the partner’s satisfaction with 
the care model, it might be interesting to organise a partner focus group. This may 
reveal that, to address their individual needs, separate group visits for partners scheduled 
alongside the SMAs for the patients are preferred. Here, the group meetings offered 
by the Dutch Society of Muscle Disorders may also be useful for partners seeking 
social support and wishing to learn from the experiences of others. Based on the single 
appointments we evaluated in our RCT, we cannot but conclude that SMAs have no 
added value for the partners of patients with a chronic neuromuscular disorder.
Economic aspects of SMAs for chronic neuromuscular populations
One of the appealing principles of SMAs for our patient population was that the model 
allows for good care services aimed at fostering the patients’ quality of life as well as 
the optimal use of healthcare resources. In this way, SMAs fit in well with the “work 
smarter, not harder” approach (21) to improving healthcare quality. We hypothesised 
that SMAs would contribute to the efficiency of healthcare in two ways: 1. as consulting 
time is used more efficiently, physicians would be able to see more patients within the 
same time frame, and 2. resource utilisation would be reduced due to patients (and 
partners) being better informed. 
After discussing our findings regarding these hypotheses, we will contemplate on current 
reimbursement procedures for SMAs in the Netherlands.
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Seeing more patients within the same time frame
Depending on the number of patients attending, SMAs can be an instrument to help 
meet healthcare staffing challenges. For cost-efficiency purposes and to facilitate the 
necessary interaction among patients, SMAs should have a minimum of six patients (22, 
23). During our trial, the mean number per group visit was 5.2, and thus lower than our 
intended eight. This is explained by two aspects of our study. First, our trial included 
ten different rare diagnostic groups, for which in 50% the number of available patients 
randomized to the SMA group was lower than the desired minimum of eight. Second, 
patients with myotonic dystrophy type 1, the largest diagnostic group, experience severe 
cognitive and psychosocial barriers to everyday activities and social participation, which 
resulted in a relatively large number of no-shows (17, 24). We accordingly recommend 
inviting at least one or two patients more than the targeted number to guarantee a 
sufficiently large group size for adequate interactions and cost-effectiveness.
Decrease of service use
In Chapter 5 of this thesis, we describe that we were unable to detect a significant 
decrease in the use of resources in the six months following the single SMAs as 
compared to individual visits. Possibly, a reduction in service use will only become 
visible after a larger number of SMAs and longer follow-up times. This assumption is 
underscored by our Cochrane review in which we did record a decrease in emergency 
department visits with regular SMAs, particularly in high-utilisation groups (9, 14, 25, 
26). Another explanation for the lack of a resource-use reduction may be explained 
by our diagnostic groups. Due to the multisystemic, chronic and progressive nature of 
their disorders, people with NMDs commonly use a wide array of resources and do so 
for many years rather than months. As opposed to the SMAs for patients with diabetes 
or heart failure reported on in previous studies, for patients with a rare neuromuscular 
disease a 90-minute group appointment with a neuromuscular neurologist and six to 
eight peers is likely to provide them with a wider variety of information and expertise, 
giving rise to more rather than fewer initial referrals. Clearly, SMAs make specialised 
care available to more patients, which is of specific importance for people with relatively 
rare diseases such as NMDs. 
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210
Which conditions contribute to the cost-effectiveness of SMAs?
We found that total costs were significantly higher for patients who were not seen by 
their own neurologist during the trial, regardless of the type of appointment (group 
or individual visit). Interestingly, this aligned with our clinical experiences during the 
study period. The percentage of patients who were seen by another than their treating 
neurologist was higher during the trial than is typical in daily clinical practice. During 
the study, patients who were normally in the care of general neurologists, were now 
seen by one of two neurologists specialised in neuromuscular disorders. Arguably, those 
patients that were normally seen by a general neurologist had, up until the trial, not 
been aware of the symptomatic treatment possibilities available to them due to the rarity 
of their disease, explaining the initial increase in resource use. A sensitivity analysis in 
which we included the group size of the SMA and the attending neurologist (treating 
consultant yes/no) showed that if an SMA comprised six or more patients and 75% of 
them was seen by their treating neurologist, a single SMA was more cost-effective than 
an individual appointment. Although descriptive papers and handbooks do stress the 
need for a minimum number of patients per group visit for efficiency and interactive 
purposes (22, 27, 28), we are the first to describe the prerequisites for successful group 
visits in more detail. 
Reimbursement of SMAs in the Netherlands
The results of our study suggest that SMAs can be an efficient care model for patients with 
neuromuscular diseases , but for implementation on a wider scale proper reimbursement 
procedures need to be in place, which may differ from context to context. In the 
Netherlands, a complex healthcare system has evolved with both public and private 
elements. All adult citizens of the Netherlands are obliged by law to take out a healthcare 
insurance with a private company, with each insurer having to accept every citizen. The 
content of the basic healthcare coverage is laid down by law. The National Appraisal 
Committee acts as an advisory body to the Ministry of Health on reimbursement issues, 
while our National Health Authority decides on the actual reimbursement rates that 
healthcare providers are allowed to claim from insurers.
At the time of writing, no separate reimbursement arrangement exists for SMAs as part 
of hospital care services in the Netherlands. With the growing evidence supporting 
SMAs as an efficient means of providing healthcare, the Dutch Health Authority has 
agreed to create a separate billing code for SMAs. Initially, the code will merely serve 
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as a registration code, in that during a two-year period it will be recorded by and for 
whom the code is used. On the basis of these data, the National Health Authority will 
decide whether the code will progress to become an actual billing code and, if so, what 
the formal reimbursement rate for SMAs will be. In the meantime, healthcare providers 
are expected to cover the costs themselves (e.g., from government research funding 
in case of university hospitals) or negotiate reimbursement from healthcare insurers.
Future perspectives
In this section we aim to provide a glimpse into the future of SMAs, addressing their 
possible working mechanisms, their relevance in the context of patient empowerment, 
as well as implications for clinical practice. Finally, future research questions will be 
discussed. 
Possible working mechanisms
Today, randomised controlled trials are the gold standard for the evaluation of healthcare 
interventions, with the main goal being to compare two (or more) alternatives on a 
prespecified outcome measure. Comparisons of the effectiveness of SMAs and individual 
appointments does not by and of itself provide us with information on SMA working 
mechanisms. Moreover, apart from the potential benefits of a group facilitator, the 
large variety in SMAs complicates the identification of common mechanisms, as we 
described in chapter 6 (29), even though this knowledge is highly relevant if the group 
care model is to be more widely implemented. Based on existing theoretical frameworks 
on group processes, previous qualitative studies, and our own clinical experiences, we 
propose a framework that may be used in future research to uncover which mechanisms 
contribute to the effectiveness of SMAs (see Figure 7.1). We have classified four potential 
mechanisms: patient-patient interaction, patient-clinician interaction, clinician skills, and 
patient time (2, 22, 30-32). 
1. Patient-patient interaction
Although SMAs are not synonymous with group therapy, the working mechanisms of 
group psychotherapy provide an interesting insight into how ‘the wisdom of crowds’ 
can lead to interpersonal effects that do not occur during an individual consultation 
with a clinician (30, 33). The social comparison theory states that we determine our 
personal worth by comparing ourselves with others (34). This can take two perspectives: 
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a negative angle, when we compare ourselves with people who appear less fortunate, 
and a positive angle, when we contrast ourselves to peers who are doing better. Negative 
comparison is a strong predictor of patient well-being as patients will put their own 
situation into perspective and gain confidence in their ability to manage their own 
health, while a certain competition between or among patients may trigger change of 
behaviour. Positive social comparison elicits two-directional peer support and feelings 
of universality, among other processes, and induces patients to observe others, which 
may also enhance personal well-being (2, 3). Patients may thus be motivated to ask 
questions they may be reluctant to pose during individual appointments. With regard 
to gaining knowledge and information, due to the presence of peer patients, a wider 
variety of information will be exchanged than will be the case during individual visits 
as different perspectives are being suggested and more time can be spent on the 
psychosocial aspects of care (35).
2. Patient-clinician interaction 
During a group visit, patients are provided access to care, information and medication 
changes by a provider with special expertise in the common condition or by a team of 
providers with synergistic knowledge (22). During an SMA participants witness teamwork 
in progress, which can make care delivery even more team-based (36-38). The potential 
hierarchical difference between patients and clinicians may be moderated by the fact 
that patients outnumber the care providers. This will help empower patients and make 
them less dependent of the health professional(s), while the presence of fellow patients 
will enable them to function as ‘expert-patients’ for their peers. 
3. Clinician skills
All team members will have to be transparent in the way they communicate and deliver 
care during an SMA as they have an audience of ‘expert patients’ who can question their 
decisions and actions. Team members need to truly work as a team, while the presence 
of multiple patients also prompts each to skilfully apply psychosocial techniques. As the 
responsibility for disease management shifts from clinician to patient, this can contribute 
to improving the participants’ self-management abilities (39, 40).
Not in the last place, we found the SMAs an energising way of providing care that 
promoted job satisfaction, thus indirectly contributing to the effectiveness of this care 
model.
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4. Patient time
Among other organisational aspects, the increased length of time and prolonged 
attention the clinician can pay to each patient is crucial to the success of SMAs. It 
enables him/her to inform patients more extensively and still have time to address 
psychosocial aspects, which often is not the case during the typically problem-focused, 
medically oriented one-to-one appointments. The benefit of the longer consultation 
times is mentioned as one of the main advantages of SMAs in most papers evaluating 
group visits (20, 22, 32, 41).
SMAs as part of a patient empowerment approach 
In this section, we wish to reflect on the relevance of SMAs in the context of patient 
empowerment. The notable 1967 paper of Mac Keith on the tyranny of the idea of 
cure seems more topical now than ever (42). Growing numbers of chronic patients and 
an increasing pressure on healthcare budgets force us to think differently about the 
future of healthcare. Half a century after Mac Keith’s paper we are still not able to cure 
all diseases, underscoring the importance of the other two duties of a physician – to 
alleviate and to support (43). The ideas Mac Keith committed to paper correspond 
directly to the newly proposed definition of health by Huber et al who describe health 
as the ability to self-manage and adapt. This new definition aims to be the successor of 
the WHO definition of health dating from 1948, which described health as the absence 
of disease, a definition well on its way to becoming unsustainable and unworkable (44).
But how can health professionals help “alleviate and support” patients with a chronic 
disease? One of the possibilities is by improving the self-management skills of 
patients. This can be done through various methods, of which SMAs is one (45, 46), 
where we assume that SMAs augment the patients’ self-management skills through 
a less hierarchical, more bi-directional relationship between patient and clinician, 
the information exchanges and support to and from peer patients and negative as 
well as positive social comparison. Other patient empowering innovations described 
in the literature are shared decision making, experienced-based co-design, the 
upcoming online patient communities and the reinforced role of patient associations 
(47-49). Together with clinicians from our rehabilitation department, empowerment of 
neuromuscular patients with chronic fatigue is boosted by offering them both physical 
training and training in self-management techniques within a group programme, which 
is currently being evaluated (50). Finally, all patients of the Radboud University Medical 
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Center have online access to their medical record (51). The outcomes of the SMAs 
described in this thesis are promising , which is why we feel that, when implemented on 
a wider scale, this care model can become a valuable part of the patient empowerment 
approach to care. 
Implications for clinical practice
Based on our clinical experiences and empirical findings with SMAs reported in this 
thesis, we see tentative possibilities for their wider dissemination and implementation. 
Although further research is necessary, the effectiveness of SMAs does not appear to 
be dependent on the characteristics of the group visit model as such (Chapter 6). The 
decision to introduce group visits does need to be carefully weighed for each specific 
patient population, care providers and national health system, and made contingent 
on the goals of the care process. When these factors are taken into account, we think 
several patient groups and healthcare providers stand to gain from this care model. 
Below, we will suggest possibilities for SMA dissemination in the context of the Dutch 
healthcare system. For the benefit of interested healthcare professionals, in the appendix 
we describe in brief the necessary preparations for and design of an SMA, based on 
the Dutch manual on SMAs (31). 
Dissemination of SMAs in the Netherlands 
In the Netherlands, SMAs are currently mainly being delivered in specialised outpatient 
settings. However, the possibilities for primary care, with delivery by the general 
practitioner or a practice nurse, are emerging and abundant, where patients with 
diabetes, cardiovascular risk or chronically ill elderly patients come to mind. As an 
example, to improve referrals to and cooperation with primary care providers, the first 
SMA jointly delivered by a GP and a consultant physician has been piloted and is currently 
being evaluated. Also in well-baby care (introduced by Stein 30 years ago) group visits 
are quite conceivable. The well-defined timeframe and high frequency of visits, together 
with the need for peer support and peer experiences in this population make SMAs 
highly suitable for this target group. Also, in prenatal care an increased use of group visits 
is expected; their effectiveness is currently being evaluated in a multicentre trial (52). 
The dissemination and embedding of SMAs are subject to appropriate reimbursement 
regulations as well as an enhanced awareness among and support from healthcare 
providers. The development of an e-health learning module and an SMA platform that 
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helps bring research and clinical practice together may further foster the dissemination 
and implementation of this care model.
Future research questions
The results of the studies reported on in this thesis are encouraging although further 
research is needed to check the robustness of the effects we obtained and study the 
underlying mechanisms that may account for SMA effectiveness.
The robustness of the effects we found need to be substantiated by trials with various 
patient groups in diverse settings. More data is needed to improve the quality of the 
evidence. We also recommend to systematically evaluate various economic aspects in 
all future studies to further determine SMA cost-effectiveness.
Comparing the effects of a single, stand-alone SMAs for neuromuscular patients with 
those of individual visits and evaluating the findings of existing trials in other populations, 
we were, unfortunately, not able to determine which elements of this complex 
intervention are most likely to influence its effectiveness. The Cochrane review (Chapter 
6) tentatively points to the beneficial effects of the presence of a group facilitator, but, 
for successful implementation in clinical practice, also other SMA working mechanisms 
need to be explored further. Starting points from which to explore core elements for 
effective SMAs may then be the characteristics of the target population, the goals and 
organisation of the group visit, and the composition of the attending team. 
Important additional topics that future research on SMAs for individuals with 
neuromuscular or other chronic somatic conditions should address are their effects on 
the healthcare professionals, their role in their live education, as well as the potential 
gains and obstacles for the patient’s partners or primary carers. Preferably, studies should 
analyse the experiences and satisfaction with the care model through separate patient 
and partner focus groups. In the Netherlands, such focus groups have recently been 
organised for patients with cardiovascular risk who have been referred back to primary 
care; their experiences with SMAs are currently being evaluated. 
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Final conclusion
With the studies described in this thesis we found shared medical appointments (SMAs) 
to be equally effective and, with respect to certain outcomes such as health-related 
quality of life (HRQOL), even superior to individual appointments with a clinician for 
patients with a chronic neuromuscular disorder. These results expand the possibilities of 
medical care to optimise patient self-management, where future trials are instrumental 
to further test and refine the care model. The results presented in this thesis may then 
serve as a source for future research and the model’s dissemination and implementation.
Chapter 7
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Summary
This thesis presents a comprehensive study of the effects and cost-effectiveness of a 
novel care model: shared medical appointments (SMAs). The presented randomised 
controlled trial (RCT) focused on group visits for chronic neuromuscular patients, while 
the review of the literature covered trials in patients with a physical illness in general. 
An SMA is an outpatient visit lasting between 90 and 120 minutes during which five 
to twelve patients (and, if preferred, their spouses or principal informal caregivers) 
are seen by a physician or team of health professionals. An SMA generally substitutes 
individual follow-up visits, with the consulting physician remaining responsible for each 
patient’s treatment plan, addressing the same topics (s)he tends to address during 
regular individual visits. 
In the General introduction (Chapter 1) possible advantages are described from the 
perspectives of patients, healthcare professionals and (cost-)efficiency, as well as potential 
downsides of seeing multiple patients simultaneously. The scope of current practical 
applications and the body of evidence on the topic are discussed. The main motive for 
this study was to optimise the care for chronic neuromuscular patients in the absence of 
curative care. Most of these typically progressive disorders have a large impact on the 
patients’ lives as well as on the lives of their partners and families, specifically in terms 
of quality of life. Many consulting neurologists and allied health professionals find it 
difficult to fulfill the complex needs of their patients in the usually brief, problem-focused 
one-to-one visits that leave little room for the patients’ and partners’ psychosocial needs, 
their education or empowerment. The studies described in this thesis investigate the 
potential of and evidence on the effectiveness of SMAs as an alternative care model in 
the management of chronic neuromuscular disorders and other chronic somatic illnesses.
Part I, Chapter 2 describes the study protocol of an RCT with a follow-up of six months 
to compare a single, stand-alone SMAs with an individual outpatient appointment for 
chronic neuromuscular patients and their partners at the Radboud University Medical 
Center. The aim was to include 300 patients. The primary outcome was health-related 
quality of life (HRQOL). Although generic HRQoL scales facilitate the comparison with 
other studies, they do not allow the detection of changes in specific muscle symptoms. 
To help us do so, we translated the Individualised Neuromuscular Quality of Life (INQoL) 
questionnaire into Dutch and performed a validation study, which is described in Part 
II, Chapter 3. After backward and forward translation, the psychometric properties of 
the questionnaire in terms of reliability and validity were determined. Reliability, known 
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group validity for severity and age, item-total correlation for overall QoL and concurrent 
validity with the SF-36 and EQ-5D were all satisfactory or good. The instrument was 
accordingly deemed to be appropiate for quality-of-life assessments in Dutch-speaking 
populations diagnosed with a wide variety of neuromuscular disorders. 
Part III details the clinical and economic outcomes of the RCT. Chapter 4 describes the 
clinical results with respect to HRQOL, the primary outcome measure, and the secondary 
outcome measures self-efficacy, social support, patient and partner satisfaction with the 
SMA and time available per patient. In total, 272 patients and 149 partners were randomly 
allocated to an SMA or an individual appointment. In the patients who had attended an 
SMA, the improvement in HRQoL was greater but patient satisfaction lower. The other 
secondary outcome measures showed no significant differences between the intervention 
arms. Outcome comparisons did not reveal any differences for the patients’ partners, 
except for satisfaction, which was again lower for SMAs. The results thus showed that 
SMAs can improve aspects of the QoL of patients with a chronic neuromuscular disorder, 
underscoring the care model’s potential as an alternative for individual appointments. 
While healthcare expenditures continue to rise worldwide, we, as clinician-researchers, 
are of the opinion that, before implementing an alternative care model on a wider scale, 
a thorough analysis of the costs and effects of the intervention is imperative. In Chapter 5 
the results of a cost-effectiveness analysis – executed alongside the RCT – are presented. 
The data on resource utilisation and quality of life were collected prospectively, using 
a healthcare perspective. Factors critical to the incremental cost-effectiveness of SMAs 
were explored in sensitivity analyses. As to cost-effectiveness in terms of costs per quality-
adjusted life year (QALY), differences between SMAs and individual appointments were 
not statistically significant according to the probabilistic decision model. However, the 
sensitivity analyses showed that, if SMAs have a minimum of six patients attending and 
if 75% of these patients are seen by their treating neurologist, SMAs do qualify as a 
cost-effective alternative. SMAs can thus serve as a means to increase the productivity 
of the physician without compromising quality of care. 
To gain more information on the effectiveness and characteristics of SMAs irrespective 
of the diagnostic target group, a systematic review of previous trials was performed, 
the results of which are presented in Part IV, Chapter 6. Literature databases were 
searched from their start date up until July 2015 for RCTs comparing SMAs with one-to-
one appointments in juvenile and (older) adult patients with a physical illness. Twenty-
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two studies qualified for review involving a total of 6,436 adults with diabetes, another 
chronic somatic illness or neurological condition, cancer, or hypertension, pregnant 
(young) women and people with hearing aids. The results of the meta-analyses and 
supplementary narrative syntheses showed that HRQOL and diabetes-specific QoL 
may improve slightly as a result of SMAs; results for HBA1C reduction in participants 
with diabetes were inconclusive. For the secondary outcomes self-efficacy and self-
management, psychological health and patient evaluation of care, the review showed 
that attending SMAs has little or no effect above and beyond the effects reported for 
individual patient visits. The analyses did show a trend towards a positive effect on self-
efficacy for SMAs that have a group facilitator. The incompleteness of the outcome data 
may have prevented clear differences between the intervention types from emerging. 
None of the included studies described serious adverse effects. The results of the 
review are limited by generalisation issues. Additional research is needed to inspect 
the robustness of the results in diverse settings and patient groups. 
The findings of the studies described in this thesis are summarised and put into context 
in the General discussion (Chapter 7). Challenging the main hypothesis of our RCT for 
neuromuscular patients, the lack of effect on self-efficacy is discussed first, followed by a 
discussion of the economic aspects of SMAs and the topical situation on reimbursement 
of SMAs in the Netherlands. In short, in the first part of the general discussion the 
relative impact and value of generic and disease-specific quality-of-life inventories is 
discussed, while in the second part suggestions are made that may guide future SMAs 
and their evaluation. First, an overview of their possible working mechanisms is provided, 
followed by a description of the role SMAs can play in the current patient empowerment 
approach to care. Next, suggestions on how to set up SMAs in clinical practice are 
given. Finally, recommendations for future research are provided. It is advised to verify 
the robustness of the effects reported so far and to study underlying mechanisms that 
account for the effectiveness of SMAs. It is concluded that SMAs for patients with a 
(progressive) neuromuscular disorder or any other chronic physical condition are equally 
effective and for specific outcomes such as HRQOL better than individual appointments 
with a physician or other healthcare providers. These promising results expand the 
possibilities of medical care, where SMAs can be seen as instrumental to optimising 
the self-management abilities of people for whom no curative treatment exists. The 
findings and suggestions described in this thesis can be used as a source for further 
research and wider implementation.
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Dit proefschrift beschrijft een studie naar de effecten en kosteneffectiviteit van een nieuw 
zorgmodel: gezamenlijke medische consulten (GMC’s). De effecten zijn geëvalueerd voor 
chronische neuromusculaire patiënten en voor patiënten met een fysieke aandoening 
in het algemeen. 
Tijdens een GMC ziet een zorgverlener 5–12 patiënten en hun eventuele partners of 
mantelzorgers tijdens een 90–12 minuten durend groepsconsult. Over het algemeen 
beoogt een GMC het gehele individuele consult te vervangen, waarbij de zorgverlener 
verantwoordelijk blijft voor het behandelplan van elke patiënt en hij of zij dezelfde 
onderwerpen bespreekt als tijdens reguliere individuele consulten. 
In de Algemene inleiding (hoofdstuk 1) worden de voor- en nadelen van het simultaan 
zien van meerdere patiënten besproken vanuit het perspectief van de patiënt, zorg-
verlener en efficiëntiedoelstellingen, gevolgd door de huidige praktische toepassing 
en stand van zaken van wetenschappelijk onderzoek. Onze belangrijkste motivatie om 
deze studie op te zetten was het bieden van optimale zorg aan patiënten met een 
chronische neuromusculaire aandoening, voor wie op dit moment (nog) geen curatieve 
behandeling mogelijk is. De meeste van deze progressieve spierziekten hebben een 
grote invloed op het leven van de patiënt evenals op dat van hun partner en gezin, 
vooral in termen van kwaliteit van leven. Veel neurologen en paramedici betrokken bij de 
zorg voor deze patiëntengroep vinden het moeilijk om aan de complexe behoeften van 
hun patiënten te voldoen tijdens de, meestal korte, probleemgeoriënteerde individuele 
consulten. Er blijft vaak weinig ruimte over voor de psychosociale behoeften, educatie 
en empowerment van de patiënt. De studies die worden beschreven in dit proefschrift 
onderzoeken of GMC’s van toegevoegde waarde kunnen zijn voor het huidige zorgaan-
bod voor chronische neuromusculaire patiënten en evalueren de effectiviteit van GMC’s 
voor patiënten met een fysieke aandoening in het algemeen. 
Deel I, hoofdstuk 2 beschrijft het studieprotocol van een gerandomiseerde, gecon-
troleerde studie met een follow-up van 6 maanden, waarbij een individueel consult 
met de neuroloog vergeleken wordt met een GMC voor chronische neuromusculaire 
patiënten en hun partners in het Radboud Universitair Medisch Centrum. Ons doel 
was om 300 patiënten te includeren. De primaire uitkomstmaat was aan gezondheid 
gerelateerde kwaliteit van leven. Alhoewel algemene vragenlijsten die kwaliteit van leven 
beoordelen ervoor zorgen dat de uitkomsten vergeleken kunnen worden met andere 
studies, beperken zij de mogelijkheden om verschillen in de specifieke symptomen van 
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onderscheiden spierziekten te achterhalen. Aangezien wij ook de kwaliteit van leven 
specifiek voor neuromusculaire patiënten wilden meten, hebben we de Engelstalige 
Individualised Neuromuscular Quality of Life (INQoL) vertaald naar het Nederlands. 
Vervolgens hebben we de eigenschappen van deze vertaalde vragenlijst gevalideerd 
door deze te vergelijken met de uitkomsten van de algemene vragenlijsten die kwaliteit 
van leven vaststellen, welke wij voor onze gerandomiseerde studie hebben gebruikt. 
Deze studie is beschreven in Deel II, hoofdstuk 3. Klinische collega’s hebben de 
vragenlijst naar het Nederlands vertaald en vervolgens hebben twee anderen deze 
terugvertaald in het Engels waarna we de verschillen in interpretatie besproken 
hebben. Daarna hebben we de psychometrische kwaliteiten beoordeeld op basis van 
validiteit (meet de vragenlijst wat deze beoogt te meten) en betrouwbaarheid (geeft 
de vragenlijst bij herhaalde afname dezelfde uitkomst). We hebben aangetoond dat 
betrouwbaarheid, concurrerende validiteit voor SF-36 en EQ-5D, known group validiteit 
en item-total correlatie voor ‘overall’ kwaliteit van leven allen voldoende of goed 
waren.
Dit resulteerde in een vragenlijst die geschikt is om de kwaliteit van leven te meten in 
Nederlands sprekende populaties met uiteenlopende neuromusculaire aandoeningen. 
Deel III bespreekt de resultaten van de eerder genoemde gerandomiseerde GMC-studie 
voor neuromusculaire patiënten, zowel vanuit klinisch als vanuit economisch perspectief. 
In hoofdstuk 4 worden de resultaten van neuromusculaire patiënten en partners die aan 
één GMC met een neuroloog hebben deelgenomen vergeleken met die van patiënten 
en partners na hun jaarlijkse individuele controleconsult met de eigen neuroloog. De 
primaire uitkomstmaat van deze studie was aan gezondheid gerelateerde kwaliteit van 
leven. Daarnaast zijn als secundaire uitkomstmaten de volgende aspecten gemeten: 
self-efficacy (het vertrouwen in eigen kunnen), ervaren sociale steun, tevredenheid 
met de afspraak van zowel patiënt als partner en de beschikbare tijd per patiënt. 272 
patiënten uit 10 verschillende diagnosegroepen en 149 partners zijn willekeurig (at 
random) toegewezen aan een GMC of een individueel consult. Voor de patiënten waren 
de belangrijkste uitkomsten een verbeterde kwaliteit van leven voor deelnemers aan een 
groepsconsult, maar een lagere patiënttevredenheid. Voor de overige uitkomstmaten zijn 
geen significante verschillen gevonden. Bij de partners van de patiënten vonden we geen 
verschillen tussen groepsconsult en individueel consult, behalve voor tevredenheid met 
het consult, dat ook bij hen iets lager was voor de groepsconsulten. Onze belangrijkste 
conclusie was dat een GMC aspecten van kwaliteit van leven van patiënten met een 
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neuromusculaire aandoening kan verbeteren, waarmee het groepsconsult een effectief 
alternatief kan zijn voor individuele consulten met de neuroloog. 
Met de voortdurende stijging van de zorguitgaven wereldwijd zijn we van mening dat, 
voorafgaand aan de bredere implementatie van een nieuw zorgmodel, een grondige 
analyse van zowel de effecten als de kosten noodzakelijk is. Hieruit volgde een grondige 
analyse van de kosteneffectiviteit, waarvan de resultaten zijn beschreven in hoofdstuk 
5. Deze analyse hebben we uitgevoerd met data die we tijdens de gerandomiseerde 
studie hebben verzameld. Gegevens over gebruik van zorg en kwaliteit van leven 
hebben we vanuit het gezondheidszorgperspectief beschouwd. Daarnaast hebben 
we bekeken welke factoren bijdragen aan de kosteneffectiviteit van een GMC met 
behulp van sensitiviteitsanalyses. De kosteneffectiviteit van GMC’s verschilde niet 
significant met die van individuele consulten in termen van kosten per extra levensjaar 
in goede gezondheid (QALY). De sensitiviteitsanalyses lieten echter zien dat wanneer 
minimaal zes patiënten deelnemen aan het groepsconsult en voor minimaal 75% van 
de aanwezige patiënten de betrokken neuroloog hun eigen behandelend arts is, een 
GMC een kosteneffectief alternatief kan zijn voor een individueel consult. Dit impliceert 
dat GMC’s een manier kunnen zijn om de productiviteit van de arts te verhogen met 
behoud van kwaliteit van zorg. 
Om meer informatie te verkrijgen over de effectiviteit en kenmerken van GMC’s onge-
acht het ziektebeeld van de deelnemers, hebben we een systematische evaluatie 
van alle gerandomiseerde studies uitgevoerd, waarvan de resultaten in Deel IV, 
hoofdstuk 6 worden beschreven. We hebben in een brede selectie van databanken 
van wetenschappelijke literatuur gezocht naar gerandomiseerde studies waarin GMC’s 
zijn vergeleken met individuele afspraken voor patiënten – zowel volwassenen als 
kinderen – met een primair lichamelijke aandoening. Hierbij hebben we gezocht vanaf 
de start van de databases tot juli 2015. De uitkomsten die we geanalyseerd hebben zijn 
aan gezondheid gerelateerde kwaliteit van leven, fysieke gezondheid, psychologische 
gezondheid, self-efficacy en zelfmanagement en patiëntevaluaties van zorg en eventueel 
deelnemende partners of verzorgers. We hebben 22 studies geïncludeerd waar in totaal 
6436 volwassen patiënten aan deel hebben genomen. Deze 22 studies hebben GMC’s 
geëvalueerd voor diabetespatiënten, chronisch zieke oudere patiënten, neurologische 
patiënten, patiënten met kanker, patiënten met hoge bloeddruk, zwangeren, en 
patiënten met een hoorapparaat. De resultaten van onze overzichtsstudie – gebaseerd 
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op meta-analyses aangevuld met beschrijvende analyses – lieten zien dat GMC’s een 
kleine verbetering in de aan gezondheid gerelateerde kwaliteit van leven en kwaliteit 
van leven van patiënten met diabetes kunnen bewerkstelligen. De resultaten lieten geen 
verbetering zien in de fysieke gezondheid (percentage HBA1C) van diabetespatiënten. 
Voor de secundaire uitkomstmaten psychologische gezondheid, zelfmanagement 
en patiëntevaluatie van de zorg hebben we niet kunnen aantonen dat GMC’s 
betere uitkomsten opleveren dan individuele consulten. Hierbij dient wel te worden 
aangetekend dat de aanwezigheid van een groepsbegeleider tijdens het groepsconsult 
ertoe kan bijdragen dat de self-efficacy van patiënten toeneemt. Van de 22 studies 
waren er maar twee studies die de effecten op partners en/of verzorgers van patiënten 
op systematische wijze hebben geëvalueerd; de navenant beperkte hoeveelheid data 
lieten geen overstijgende conclusies toe. Ook heeft geen enkele studie de effecten 
op zorgverleners systematisch onderzocht. Geen van de studies beschrijft serieuze 
negatieve gevolgen van groepsconsulten. De generaliseerbaarheid van de resultaten 
van de geëvalueerde studies wordt beperkt door de grote variatie in ziektebeelden en 
kenmerken van de groepsconsulten. Aanvullend onderzoek is nodig om de robuustheid 
van de conclusies in verschillende patiëntengroepen en zorgomgevingen te evalueren. 
De bevindingen van dit proefschrift worden bediscussieerd in de Algemene discussie 
(hoofdstuk 7). Als eerste bespreken we het onverwachte gebrek aan effect op self-
efficacy dat we vonden in onze gerandomiseerde studie voor neuromusculaire patiënten. 
Dit was anders dan onze hypothese. Daarna volgt een reflectie op de economische 
aspecten en de actuele situatie omtrent financiering van GMC’s in Nederland. Vervolgens 
wordt kort bediscussieerd waarom we geen effecten voor partners van patiënten 
hebben gevonden en beschrijven we alternatieven om partners te ondersteunen. Het 
tweede deel van de algemene discussie beschrijft toekomstige perspectieven voor vier 
verschillende aspecten van GMC’s:
1. Mogelijke werkingsmechanismen;
2. De rol van GMC’s in de huidige patiënt-empowermentbenadering van 
zorg;
3. Suggesties voor de implementatie van GMC’s in de klinische praktijk; 
4. Aanbevelingen voor toekomstig onderzoek waarin we adviseren de 
robuustheid van de effecten te verifiëren, leemtes in de uitkomsten 
op te vullen en onderliggende mechanismen te onderzoeken welke 
bijdragen aan de effectiviteit.
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Tot slot concluderen we dat voor patiënten met een neuromusculaire of andere (chronische) 
somatische aandoening GMC’s minimaal even effectief en voor specifieke uitkomstmaten 
zoals kwaliteit van leven zelfs doeltreffender kunnen zijn dan individuele consulten met 
een behandelaar of andere zorgverlener. Deze hoopgevende resultaten vergroten de 
mogelijkheden van de medische zorg en kunnen de zelfmanagementcapaciteiten van 
patiënten helpen optimaliseren. Daarnaast beoogt dit proefschrift een bron te zijn voor 
verder onderzoek naar GMC’s en een opstap te bieden naar de implementatie van deze 
zorgvorm in de praktijk.
Adapted from:
Gezamenlijk medisch consult. Een praktische handleiding. 
ISBN9789031372430, Bohn Stafleu van Loghum; 2009.
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Preconditions for SMA implementation in clinical practice
There are fundamental differences between seeing multiple patients within the context 
of an SMA and seeing a patient in the privacy of an examination room. Making sound 
preparations, utilising practical tools, and staging a try-out are important steps to 
guarantee a confident and effective delivery. Dedicated training is not required but can 
be helpful. For clinicians to become familiar with and confident in this care model, one 
must allow for a learning curve of three to five group visits. The preparations and design 
of a group visit are described in brief in the following sections as well as an overview 
of the structure of the SMAs conducted during our RCT.  
Preparations 
Any new implementation of an SMA depends on good groundwork. Table A.1 describes 
the timeframe and specifies all relevant preparatory steps. Clinical experience has shown 
that one needs to book a suitable venue well in advance as most healthcare organisations 
are not equipped to host group visits. It is also imperative that patients are informed 
timely and in a clear, empathetic and convincing way, especially when patients are not 
familiar with this care model. Examples of invitation letters and information leaflets can 
be obtained from various printed manuals and online facilities (27, 28, 31).
Table A.1 Preparation of shared medical appointments
Timeframe Action
Eight weeks before first SMA Determine targeted patient group
Compose fitting SMA team
Determine goals of SMA
Finalise the design of the SMA (patient group, frequency, 
number of participants; See Table A.2)
Book a suitable group visit room
Compose patient information package
Four weeks before first SMA Plan date for first SMA and subsequent group visits
Agree on how to guarantee patient privacy with the board of 
the organisation / legal department
Agree on SMA cost-reporting and billing system with the board 
of the organisation / finance department
Send out patient invitations for first SMA
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Design
When designing an SMA it is important to keep in mind that a group visit should be a full 
substitute for an individual consultation with that specific healthcare professional. Based 
on our experiences, we think this is a precondition for SMAs to become a sustainable 
healthcare intervention. One also needs to consider that group visits are subject to 
various interpretations and the literature frequently describes a predominant group 
education focus rather than a clinician-guided visit with the opportunity for medication 
adjustment and reconciliation. Table A.2 gives an overview of the topics that should 
be covered and settled during the design stage. Where each has to be adjusted to the 
characteristics of the specific patient group and allow for the needs of the attending team 
of clinicians and organisation. From an implementation point-of-view, one should always 
be focused on possibilities for improvement of the design and schedule time to evaluate 
newly developed SMAs. In Chapter 4 of this thesis we recommend to include a minimum 
of six patients to guarantee effective group interactions as well as cost-effectiveness, in 
which case one should account for the standard no-show rate at the department. Group 
size is also dependent on the typical duration of individual appointments. One might 
then determine minimum group size by multiplying the number of patients that can 
be seen in one-to-one visits within 90 or 120 minutes by two (27). The team members 
involved in SMA delivery further need to reach agreement on their specific roles during 
Table A.2 Design of a shared medical appointment
Department
Specification patient group
Name/position clinician whose medical appointment is to be substituted by the SMA
Name/position group facilitator
Names/positions other team members and their roles
Specification patient carers / relatives invited to participate in the SMA
Number of participating patients that are seen weekly/monthly/yearly
Mean duration of an individual appointment
Minimum group size for the SMA
Intended frequency of SMAs
Need for physical examinations before or during SMA
Chart noting during SMA
Issuing / scheduling prescriptions, referrals and follow-up appointments during SMA
241
Appendix
the group visit. Roles and techniques to encourage interaction among SMA participants 
can be practiced during a try-out session in which colleagues play the role of patients. 
These ‘mock’ SMAs staged prior to the first actual group visit tend to be very illustrative 
and can help build team confidence.
Structure and content of a shared medical appointment
This section gives an overview of the structure of the SMAs conducted during our RCT. 
• Welcome and introductions: The group mentor explains SMA rationale 
and procedure
• Patients and partners or primary caregivers are invited to sign a privacy 
statement 
• The clinician addresses the first patient and his/her partner, discusses the 
patient’s medical needs and questions, after which they jointly formulate 
a disease-management plan and medication regimen 
• The group mentor checks whether fellow patients have comparable 
experiences or questions they want to share
• The clinician concludes the consultation with the first patient and 
completes the chart notes
• The clinician turns to the next patient and so on, until all patients have 
been attended to.
• The group mentor verifies with the participants whether all questions 
have been satisfactorily addressed and, if so, concludes the SMA. 
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Dankwoord
Acht jaar geleden had ik mijn eerste gesprek met Baziel en GertJan in Nijmegen. Ik zou 
hen gaan vertellen dat promoveren niets voor mij is, ook al was ik erg geïnteresseerd in 
het onderwerp. Op de terugweg voelde ik zoveel energie dat ik dacht, ik begin gewoon 
en we zien wel waar het schip strandt. Maar zoals één van mijn vriendinnen een paar 
jaar later zei: je was even vergeten dat als jij aan iets begint, je het dan ook afmaakt. 
Nu ligt er een boekje waar ik erg trots op ben. Dit had niet gekund zonder de hulp en 
steun van veel mensen, waarvoor mijn dank!
Als eerste natuurlijk dank aan de patiënten en hun partners die bereid waren mee te 
doen aan ons onderzoek én alle vragenlijsten ingevuld hebben. Zonder jullie inzet en 
vertrouwen is er geen klinisch onderzoek mogelijk.
Dank aan Baziel als promotor, voor de deur die altijd open staat, je optimistische kijk en je 
helikopterview om uit de resultaten de meest interessante informatie te halen. En niet te 
vergeten het samen doen van de groepsconsulten. Dank ook aan GertJan als promotor, 
voor je kritische blik, focus op kwaliteit en het plaatsen van ons onderzoek in een breder 
perspectief. Gea, dank voor je betrokkenheid als co-promotor, je enthousiasme en 
meelevendheid. Het samen doen van de groepsconsulten was bijzonder en je luisterend 
oor heb ik erg gewaardeerd. Hans, wij hebben heel wat uurtjes doorgebracht achter 
jouw pc, naast praten over nachtvlinders heb ik veel van jou geleerd over statistiek. 
Waarvan het belangrijkste misschien wel was: de eerste grove analyses laten meestal 
de omvang en richting van de resultaten al zien, die moet je alleen bevestigen met de 
juiste modellen en aanvullende analyses. 
Een grote klinische trial kan onmogelijk uitgevoerd worden zonder de nodige onder-
steuning. Dank aan de betrokken studentassistentes en stagiares: Eline, Nadine en 
Lisanne. Daarnaast ook dank aan Anneke Pelgröm voor haar ondersteuning en gezel-
ligheid tijdens de trial.
Mijn paranimfen. Willemijn: mooier dan jij hebt verwoord kan het ik niet doen… 8 jaar, 
6 kinderen, 2 promoties en een vriendschap later… jij hoort hier vandaag naast mij te 
staan als paranimf en daar ben ik trots op. Wieneke: maar goed dat we bij aanvang 
niet wisten waar we aan begonnen. Onze Cochrane review heeft veel discussies en 
doorzettingsvermogen gevergd. Maar daarmee ook genoeg S2M-tijd voor lekkere 
koffie van Thomas mét een koek en kletsen. Dank voor de fijne samenwerking en op 
naar jouw promotie!
Dankwoord
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Leden van de manuscriptcommmissie, prof. van Dulmen, prof. Kremer en prof. 
Verschuuren. Dank voor jullie tijd en moeite om dit proefschrift te beoordelen.
Collega’s RadboudUMC. Tijdens mijn onderzoek heb ik weinig directe collega’s gehad 
betrokken bij mijn onderzoek, maar des te meer collega-onderzoekers van de afdeling 
neurologie. Ondanks mijn wisselende aanwezigheid heb ik mij altijd zeer welkom gevoeld 
en heb ik alle uitwisselingen van ervaringen over onderzoek én prive-zaken gewaardeerd. 
Dank Nicol, Charlotte, Maarten, Lars, Anke, Susanne, Loes, Pauline, Saskia, Karlien, 
Noortje, Renate, Michiel, Nienke, Bas, Tim, Merel, Elske en Judith.
Naast mijn onderzoek heb ik ook veel andere meelevende collega’s gehad op verschil-
lende plekken. Collega’s CBO. Het startpunt voor het introduceren van groepsconsul-
ten in Nederland lag hier. Het CBO bestaat jammer genoeg niet meer, maar de daar 
opgedane ervaring, kennis en contacten met collega’s blijven als een rode draad door 
mijn werkende leven lopen.
Collega’s Raedelijn. In de flexibele schil van jullie organisatie heb ik veel mooie projecten 
mogen doen en op jullie kantoor heb ik ook aardig wat uurtjes besteed aan het afronden 
van mijn promotie. Dank voor jullie gastvrijheid en interesse.
Collega’s Zorgdragers. Een groep heel verschillende mensen met een gezamenlijke 
passie: de zorg beter maken en één ‘lonely nut’ die hiervan een geheel weet te smeden. 
Dat belooft nog veel moois.
Lieve vrienden, in deze fase van mijn leven lukt het niet altijd om zoveel tijd met jullie 
door te brengen als ik af en toe zou willen. Maar dank voor alle keren dat ik mijn hart 
mocht luchten en voor alle leuke momenten samen. Many more to come!
Medusa-meiden, ook na (bijna) twintig jaar haal ik nog steeds veel energie uit onze 
gezamenlijke afspraken en niet te vergeten vakanties. Op het moment van schrijven 
tel ik de dagen…
Familie. Lieve paps en mams, dank voor jullie onvoorwaardelijke steun en ook praktische 
hulp waar nodig. Onmisbaar en zo fijn. Lieve Gerda, ook jij staat altijd voor ons klaar 
en dat is heel waardevol. Lieve Lobke, Daan, Arjan en Dianne, wat wij samen hebben 
is heel bijzonder, het voelt als thuis en er altijd voor elkaar zijn. Ik verheug me op alle 
mooie momenten samen met de kleintjes.
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Waar alles om draait. Hoe lastig ik onderzoek doen soms ook vond, bij thuiskomst 
bestormd worden door drie kleine muppets relativeert alles. Lieve F, Ph en Q, dank voor 
jullie onvoorwaardelijke liefde & tomeloze energie, ik geniet elke dag van jullie. En last 
but not least Björn, mijn grote liefde. Wat ben ik dankbaar voor alle mooie momenten 
samen. Dank voor een geduldig luisterend oor en jouw rotsvaste vertrouwen in mij. Zin 
in ons volgende avontuur!
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